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 Summary 
 Cutaneous melanoma is the most aggressive form of skin cancer. The aggressive nature 
of this disease is manifested by the fact that lesions of barely 2 mm in depth already bear a 
high potential for metastasis. High throughput analyses have identified recurrent alterations 
in oncogenic pathways (i.e involving BRAF, NRAS, PI3K>AKT, NF1 or NOTCH, among 
others) that have paved the way for the development of molecularly-targeted therapies. 
However, melanoma is also a prime example of how a complex (epi)genome can activate 
compensatory protective responses (also against recently-approved immune checkpoint 
blockers). A rather unexplored strategy to search for putative tumor drivers is to focus on 
lineage-specific oncogenic dependencies rather on common cancer hallmarks conserved 
with other malignancies. In melanoma, these lineage-specific oncogenes have been 
traditionally linked to melanosome and pigmentation pathways. However, our group has 
recently identified new signalling cascades distinctively enriched in melanoma cells. These 
include specific RNA binding proteins (CPEB4, UNR), as well as over 30 endolysosomal 
factors. Analysis of autophagy, another lyososmal-associated process also revealed 
selective heterozygous loses in ATG5 as a feature favouring poor patient prognosis.  
 p62/SQSTM1 (sequestosome 1) was an attractive candidate to pursue for its known links 
in autophagy and as a signaling hub for multiple protein-protein complexes.  Importantly, 
although p62 has been found accumulated in a broad spectrum of tumor types, there is no 
clear consensus on whether it acts as a tumor promoting or tumor suppressive agent, 
particularly in the context of metastasis. 
 Here we present a comprehensive analysis of p62 expression and functional requirement 
in melanoma cells, clinical biopsies and newly generated genetically engineered mouse 
models. This strategy was used to assess key pending questions in this field such as: (i) 
what is the relative impact of p62 copy number in the stroma vs benign and malignant 
melanocytic lesions, particularly in the context of metastasis; (ii) does p62 share autophagy 
and non-autophagy roles with other tumor types, or (iii) does it act in a tumor-specific 
manner?, and if so, (iv) what are the underlying mechanisms. To this end, particular 
attention was dedicated to genome-wide analyses of the p62 interactome and its global 
impact on the transcriptome and proteome of melanoma cells. Computational analyses, 
studies in GEMM and proteomic analyses were also performed in comparison to ATG5. In 
addition, targeted gene depletion was exploited to assess best known functions of p62 as a 
signaling hub. Together, this integrated approach revealed a distinct impact of p62 in the 
control of melanoma-enriched gene networks. Finding an unexpected role of p62 opposing 
mRNA decay of FERMT2 and other pro-metastatic factors, our data ultimately revealed a 
new function of p62 as a hub of RNA binding proteins. Together, the results of this PhD 
thesis offer a platform for tumor-type specific functions of p62 in cancer. 
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    Resumen 
  El melanoma cutáneo es la forma más agresiva y letal de cáncer de piel, tanto es así, que 
lesiones de menos de 2 mm de grosor ya poseen una gran capacidad metastásica. A través 
del desarrollo de múltiples análisis a gran escala se ha se han podido identificar una serie 
de alteraciones recurrentes en diversas rutas de señalización oncogénicas (BRAF, NRAS, 
PI3K >AKT, NF1 y/o NOTCH entre otros), lo que ha facilitado el desarrollo de terapias 
genéticamente dirigidas. A pesar de ello, el melanoma es  uno de los mejores ejemplos de 
cómo un (epi) genoma tan complejo y con tal número de alteraciones, puede resultar en la 
activación de mecanismos compensatorios de adaptación y protección frente a los 
tratamientos vigentes. Una estrategia aún poco explorada en la identificación de nuevas 
dianas pro-oncogénicas es el estudio restringido de las dependencias oncogénicas 
asociadas a linaje, en lugar de perseguir alteraciones comunes a otros tipos de tumores. En 
melanoma estos oncogenes específicos de linaje se han asociado clásicamente a rutas de 
pigmentación y producción de melanosomas. Sin embargo nuestro grupo ha identificado 
nuevas rutas de señalización selectivamente enriquecidas en melanoma. Entre sus 
componentes se han encontrado proteínas de unión a RNA (CPEB4, UNR) y más de 30 
proteínas endolisosomales. Por otro lado, estudios previos de nuestro grupo sobre 
autofagia, un proceso asociado a los lisosomas, muestran que la pérdida selectiva de una 
copia del gen que codifica para la proteína ATG5 se encuentra asociada a un pronóstico 
desfavorable en pacientes. Por todo lo anteriormente mencionado, p62/SQSTM1 
(sequestosoma 1) se presenta como un candidato atractivo en melanoma, tanto por su 
relevante función en autofagia, como por funcionar como plataforma de señalización en 
numerosos tipos tumorales. Sin embargo, aunque se ha observado que p62 se encuentra 
sobre-expresado en múltiples tipos de cáncer, aún no existe un consenso sobre su papel 
como promotor o supresor tumoral, particularmente en metástasis.  Por todo ello, esta tesis 
se planteó con los siguientes objetivos: (i) determinar del impacto en el número de copias de 
p62, tanto en el estroma tumoral como en lesiones melanocíticas (benignas y malignas), y 
particularmente en melanoma metastásico; (ii) definir si las funciones de p62, en autofagia y 
otros procesos celulares, son específicos en melanoma o comunes a otros tumores (iii), y 
por último, (iv) caracterizar el mecanismo de acción específico en melanoma. Para 
responder a estas cuestiones se ha realizado un exhaustivo análisis de la función de p62 en 
líneas celulares de melanoma, biopsias clínicas y modelos animales modificados 
genéticamente. A su vez, se ha dedicado especial énfasis al interactoma de p62 y al 
impacto que esta proteína tiene en el transcriptoma y proteoma celular. En paralelo, se ha 
analizado mediante estudios de proteómica y computacionales el papel de p62 y ATG5 en 
animales modificados genéticamente para ambos genes. Y por último, mediante ensayos de 
pérdida de función, se ha caracterizado la función de p62 como plataforma de señalización. 
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Integrando las aproximaciones anteriormente descritas, se ha descubierto que p62 tiene un 
papel protector en la estabilidad del mRNA de FERMT2 y otros factores pro-metastásicos, 
por lo que se describe por primera vez la función de p62 como plataforma de señalización a 
través de proteínas de unión a RNA (RBPs). En conjunto, estos resultados revelan nuevas 
funciones de p62 y determinan su especificidad en melanoma. 
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3.1 Melanocyte: the cell of origin of melanoma 
Melanocytic neoplasms range from benign lesions 
(melanocytic nevi), to malignant ones, termed melanomas. 
All originate from melanocytes, which are neural crest-
derived cells1. Although melanocytes are located in 
mucosas, leptomeninges and uveal sites, these cells 
reside primarily in the skin2-5. Consequently, most 
melanomas are of cutaneous origin, accounting for ~90% 
of deaths from skin cancer6 due to the high aggressive 
capacity to metastasize7-10.  
The melanocyte lineage is derived from the neural crest, which has its origins in the 
neural tube. Following its formation, neural crest cells delaminate from the dorsal-most 
aspect of the neural tube by a process of epithelial-to-mesenchymal transition. These cells 
are highly migratory and form many specialised structures in the developing embryo by 
migration, proliferation and differentiation11. Melanoblasts, the melanocytes precursors, 
migrate during embryonic development mostly to the basal layer of the skin (Figure 1), 
where melanocyte:keratinocyte number ratio is typically of 1:1012,13. Keratinocytes, together 
with surrounding cells like dermal fibroblasts sustain melanocyte function and survival in 
response to environmental signals such as UV radiation14. There are approximately 1,500 
melanocytes per square millimetre of human epidermis, corresponding to nearly 3 billion 
cutaneous melanocytes in the skin of an average human15. Melanocytes represent a minority 
cell population within the basal epidermis, and divide infrequently, less than twice a year16 
and mainly provide melanin pigment to their neighbouring keratinocytes17. Melanin is a 
complex macromolecule that scatters and absorbs UV radiation, and epidermal 
keratinocytes use it to protect their nucleus from UV radiation-induced DNA damage18. The 
pigments are synthesized within specialized organelles called melanosomes. 
Mechanistically, the proliferation and pigment production of melanocytes is stimulated by UV 
radiation-induced DNA damage to keratinocytes, which subsequently secrete α-melanocyte 
stimulating hormone (αMSH) in a p53-dependent manner19. αMSH binds to the melanocortin 
1 receptor (MC1R), which is expressed on melanocytes activates the cAMP/protein kinase A 
(PKA)/CREB signaling pathway and enhances the level of the microphthalmia-associated 
transcription factor (MITF). MITF promotes the synthesis of melanin, which melanocytes 
deliver to keratinocytes20. A reduction in its activity is coupled to reduce melanin synthesis 
and pigmentation21. MITF also regulates melanosome biogenesis22,23 and trafficking24.  
In addition to MITF, during embryogenesis, the survival and migration of melanocytes rely 
on other signaling pathways such as Wingless signaling (Wnt)/𝛽-catenin, the endothelin B 
Figure 1: Skin structure. Typical skin 
structure with the outer epidermis 
and the inner dermis and on top 
pointing the melanocytes. Source: 
www.cancer-cure-secrets.com. 
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receptor and its ligand endothelin-3, the receptor tyrosine kinase KIT and its ligand KIT-
ligand/SCF (stem cell factor), NOTCH25,26, paired box gene 3 (PAX3), SRY-box10 (SOX10), 
hairy/enhancer of split (HES1)27-31. Outside the skin, melanocytes are present in 
considerable numbers in the uveal tract of the eye and at lower densities in other tissues, 
such as the meninges and the anogenital tract. However, the melanocytic neoplasms that 
originate from these melanocytes are distinctly different in their histopathological and genetic 
status from cutaneous melanomas5,32-34.  
The treatment landscape for advanced-stage, unresectable or metastatic melanoma has 
shifted dramatically over a short period of time. From a devastating disease with poor sur-
vival (~9 months) the discovery of FDA approved targeted agents and immunotherapeutic 
antibodies (Table S1, appendix) has led to a tremendous improvement of the response rates 
and the increase in overall survival with the simultaneous reduction of the adverse effects35.   
 
3.2 Classification of melanocytic lesions 
3.2.1 Bening melanocytic nevi 
Melanocytic nevi are benign proliferations of melanocytes with theoretically a low 
likelihood of progressing to melanoma. Nevertheless, their high prevalence makes them 
contributors to a considerable portion of melanomas36-38. Congenital nevi are presented at 
birth or shortly after, while acquired nevi tend to appear with more than six months of age 
and are accumulated during life time32. Acquired nevi can exhibit a lentiginous growth 
pattern or a congenital growth pattern. The latter category does not necessarily imply that 
the nevi was present at birth as in bona fide congenital nevi, but indicates that it has a similar 
growth pattern. Lentiginous and congenital pattern nevi can be stratified as i.  junctional, in 
which melanocytes appear at the dermo-epidermal junction; ii. dermal, depending on 
whether melanocytes appear on the dermis; and iii. compound, when melanocytes appear 
in both places, respectively39-41. Spitz nevi are another type of melanocytic neoplasm 
characterized by a predominance of large polygonal (epithelioid) or spindled melanocytes 
with enlarged nuclei and often multinucleated cells42,43. Blue nevi are characterized by the 
proliferation of dendritic, spindled, ovoid, or epithelioid melanocytes in tissues without any 
significant epithelial involvement. While the majority involve the skin, they can be 
encountered in many other organs39,44. A long-standing debate and controversial category of 
benign lesions is termed as intermediate melanocytic neoplasm. This grey zone of 
neoplasms contains lesions with overlapping benign and malignant histopathological 
features. The overall mutation burden is higher than those of unequivocally benign lesions. 
This category also contains the contentious category of lesions known as dysplastic nevi45-
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47. There is clear evidence that individuals with multiple dysplastic nevi are at increased risk 
of developing melanoma over their lifetime48,49.  
The mutational status of oncogenes in benign nevi such as NRAS in congenital nevi50, 
HRAS in spitz nevi43, and later BRAF in acquired nevi51, GNAQ or GNA11 in blue nevi34,52 
came as a surprise as many of them are common in melanomas. After acquiring an initiating 
mutation, a melanocyte will undergo limited proliferation to form a nevus, before entering a 
state that has been described as “senescence-like”53,54. However, several observations 
indicate that at least some melanocytes within a nevus retain the ability to proliferate55,56.  
3.2.2 Malignant melanoma 
Classification by anatomical site 
 Melanoma has been classified in several 
ways taking into account various variables 
such as histopathological type, vertical 
growth, whether it has spread to nearby lymph 
nodes or any other organ, among other 
factors. The traditional clinical and 
pathological classification scheme for 
melanoma includes four subtypes based on 
the pioneering work of Wallace Clark, more 
than forty years ago60, and has been included 
to the current World Health Organisation 
(WHO) classification61. The 4 categories are 
briefly described below with representative 
images and the most common mutated genes 
depicted in Figure 257-59. 
I. Superficial Spreading Melanoma (SSM) is the most common subtype, comprising 
approximately 75% of all malignant melanomas. A quarter of this type of melanoma are 
originate from with a pre-existing nevi, while most develop de novo62. SSM is usually flat with 
an intra-epidermal component and is linked to episodes of severe sunburn63-65.  
II. Nodular Melanoma (NM) represents 15 to 30% of all melanomas. They progress to 
invasiveness more quickly than any other type of melanoma. Although it is an aggressive 
lesion, the prognosis for a patient with a NM is the same as for any other subtype65,66.  
III. Acral Lentigious Melanoma (ALM) is the least common variant, representing 2% to 8% 
of all melanomas in white people and 29% to 72% in dark skin population. ALM commonly 
develops in palmar regions, plantar regions, and occasionally subungual surfaces65,67 
Figure 2: Traditional melanoma subtypes and their 
most frequently mutated oncogenes. Source: 
Refs.
57-59
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SSM
BRAF 59-78%
NRAS 3-22%
LMM
BRAF 40-60%
NRAS 15-29%
KIT 16-28%
ALM
BRAF 12-23%
NRAS 8-15%
KIT 9-36%
NM
BRAF 43-68%
NRAS 12-31%
UM
GNAQ 46-50%
KIT 1-76%
MM
BRAF 3-11%
NRAS 5-13%
KIT 15-39%
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IV. Lentigo Malignant Melanoma (LMM) accounts for 4% to 15% of melanomas. LMM 
represents in situ melanoma that 5% to 8% of the cases may progresses to invasive lentigo 
malignant melanoma. Transformation is slow and the lesion can be present for 10 to 50 
years before undergoing vertical growth68,69.  
 Furthermore, other rare forms of melanoma such as uveal melanoma (UM) and 
mucosal melanoma (MM) belong to the category of non-cutaneous melanoma. UM, 
account for approximately 5% of all melanomas in the US with a 10-year survival rates at 
50% and is among the most lethal presentations of melanoma70,71. MM, account for 1% of all 
melanomas and primarily involves the mucosa of the anogenital region, nasal cavity, and 
paranasal sinuses, but can occur in all mucosal sites72.   
Classification by clinicopathological criteria (Clark model-linear evolution) 
Cancer progression has been conceptualized as a multistep process whereby normal 
cells accumulate genetic alterations that enable tumor growth and metastatic 
dissemination73. Classically, the different steps of melanoma progression are characterized 
by different histologic lesions according to the Clark modeI8,74,75. Melanoma is thought to 
arise in one of two ways: (1) with no visible precursor lesion or (2) in association with a 
benign melanocytic proliferation (nevus or mole). Five distinct stages have been proposed in 
the evolution of melanoma on the basis of such histological criteria (Figure 3): 
I. Benign nevi. This first step refers to the proliferation of structurally normal melanocytes 
leading to the benign nevi. The absence of progression is probably due to Oncogene-
Induced Senescence (OIS), in which growth that is stimulated by the activation of 
oncogenic pathways is limited76. Hotspot mutations in BRAF (up-to 82% of acquired nevi51) 
or NRAS genes (up-to 81% of congenital nevi77) lead to the MAPK pathway activation which 
triggers a stress response leading to permanent G1 arrest78,79. However, these features 
cannot be used as markers of benign melanocytic tumors since malignant melanoma cells 
may also display similar phenotypic and molecular signatures80-84. It has been reported that 
senescence-like phenotypes can be induced genetically in metastatic melanoma cells 
suggesting that induction of senescence could be a novel therapeutic approach to treat 
melanoma85-87. 
II. Dysplastic nevi. They may arise from pre-existing benign nevi or as new lesions. 
Genetically, in 25-40% of cases of familial melanoma, a genetic defect inactivates CDKN2A, 
a single gene that encodes two tumor suppressor proteins, p16INK4A and p19ARF88-90; in 25-
50% of non-familial melanoma, a different tumor-suppressor gene, phosphatase and tensin 
homologue (PTEN), is inactivated by mutation91-93. CDKN2A or PTEN mutations are not 
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enough to the development of melanoma, but it is unclear precisely when such mutations 
occur8. 
III. Radial Growth Phase (RGP). RGP consist in the intraepidermal proliferation of 
melanoma cells, which can be confined to the epidermis forming an in situ melanoma or 
penetrate the papillary dermis growing as small nests94. Multiple pathogenic alterations are 
accumulated over a considerable period of time, as reflected by their relatively late age of 
onset and slow development. This is more notable for neurofibromin 1 (NF1) mutant 
neoplasms, which affect older patients95-98. Melanoma in situ lesions are more common on 
chronically sun-exposed anatomical sites and tend to have a high mutation39,95,99. 
IV. Vertical Growth Phase (VGP). The invasiveness begins once the melanoma cells 
leave the epithelium of the epidermis and enter the subjacent mesenchymal tissue100. In the 
VGP melanoma cells inherit driver mutations that activate the MAPK pathway, as well as 
TERT and members of the SWI/SNF chromatin-remodelling complex45. A small fraction of 
melanomas appear suddenly as nodular growths indicating that either accumulating 
mutations were in rapid succession, or perhaps more likely, they come directly from 
melanocytes that already harboured the secondary and/or the tertiary genetic alterations39,45. 
There seems to be no further substantial increase in the burden of point mutations from RGP 
to VGP45,101,102. In the molecular level, secretion of soluble factors and extracellular matrix 
proteins enable melanoma cells to communicate with their microenvironment cells103-106. 
V. Metastatic Melanoma. Once melanoma cells have disseminated beyond the local site 
they are termed as metastatic, which generally appear first in the lymph nodes of the 
draining area of the primary tumour. Apart from lymph nodes; brain, liver, bone and intestine 
are the sites that are most frequently colonized by metastatic melanoma cells107. Sentinel 
lymph node resection does not experience an extension of life expectancy in patients108,109. 
Moreover, circulating tumour cells are commonly found in patients who present with only 
regional metastasis, or even no metastases at all110-112. Metastatic melanoma tends to have 
the highest proliferative index of all stages of melanoma. Mutations that confer resistance to 
targeted therapies can also lead to simultaneous emergence of resistant clones at many 
separate body sites113. The last decade, studies showed that melanoma cells secrete signals 
(exovesicles) from the very early stages of progression; and these signals “educate” the 
organs and prepare the so-called “pre-metastatic niche” to be metastasized for the 
colonization of melanoma cells to come114-117. 
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Classification by clinicopathological criteria (AJCC-non linear evolution) 
 For years, Clark classification has been 
known to have prognostic significance, and 
has served as a criterion in several melanoma 
staging systems. However, only 20–30% of 
melanomas arise in association with a nevus 
precursor119,120. Several investigators have 
demonstrated that the level of invasion is less 
reproducible among pathologists, and is less 
accurate in providing prognostic information 
compared to tumor thickness121,122. As there 
are many routes to primary tumor formation, 
there are likely also many routes to the 
establishment of clinically meaningful 
metastatic disease (Figure 3). This prompted 
the definition of a revised model for melanoma progression which also theorizes melanoma 
as developing de novo. In the new staging system, Clark’s level has far less importance. The 
TNM (Tumor, Node, Metastasis) classification and stage grouping of melanoma patients is 
based on clinical and histopathological prognostic factors, endorsed by AJCC database 
(American Joint Committee on Cancer Melanoma Staging)100. The T category is based on 
the thickness (or depth) of the primary melanoma and is further subcategorized to include 
the presence or absence of ulceration and mitotic rate- two very important prognostic 
features of a primary melanoma. The N category is determined by the presence and extent 
of regional lymph node involvement, and is further subcategorized according to number of 
involved lymph nodes and whether the metastases were macroscopic or microscopic 
(palpable or determined by sentinel-node evaluation, respectively). In-transit and satellite 
metastases are also included in the N staging. The M category is determined by the 
presence or absence of distant metastases (including skin), by site of disease, and serum 
LDH level100. The new revised AJCC (8th) classification includes molecular markers and 
newly acquired insights into the molecular underpinnings of cancer. This edition features 12 
entirely new staging systems and a refined emphasis on a personalized-medicine 
approach123. 
 
Classification by genetic alterations 
Due to melanoma complexity, integration of molecular data with relevant clinical and 
histopathological information are likely to be an important interim step before research 
Figure 3: Linear and non-linear melanoma 
progression model. Individual steps in primary 
melanoma are colored in blue and individual steps 
in metastasis are colored in green. Source:Ref.
118
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advances to a level permitting a mechanism-based classification. Detailed genetic studies 
using massively parallel sequencing have clarified the prevalence of driver oncogenes and 
have identified unique genetically-defined subpopulations of melanoma. Melanoma exhibits 
the highest rate of genetic alterations among cancer type124 and whole-genome sequencing 
studies have confirmed that 80% of those changes are related with UV mutagenesis125. 
However, the above (and additional) studies have either focused on single high-throughput 
platforms of large sample sets or multi-platform analyses of fewer samples126,127. The Cancer 
Genome Atlas (TCGA) is the largest systematic multi-platform characterization of 333 
cutaneous melanomas at the DNA, RNA, and protein levels to create a catalogue of somatic 
alterations and describe their potential biological and clinical significance (Figure 4)95. 
From this study a framework for genomic classification into four subtypes based on the 
pattern of the most prevalent significantly mutated genes (SMGs) was established: i. BRAF 
mutant, ii. RAS mutant, iii. NF1 mutant, iv. and Triple-WT (wild-type). The largest 
genomic subtype was defined by the presence of BRAF hot-spot mutations. Of the 318, 
52% (n=166) harboured BRAF somatic mutations. Of those, 145 targeted the well 
documented V600 amino acid residue: V600E (n=124), V600K (n=18), and V600R (n=3). 
The second major subtype is defined by the presence of RAS hot-spot mutations, 
including known amino acid changes with functional consequences, in all three RAS family 
members (N-, K- and H-RAS). Overall, 28% had NRAS somatic mutations. The third most 
frequently observed SMG in the MAPK pathway was NF1, which was mutated in 14% of 
samples. More than half of its mutations were predicted to be loss-of-function (LoF) events 
Figure 4: Landscape of driver mutations in melanoma. Total number of mutations, age at melanoma accession, 
and mutation subtypes are indicated for each sample. Color-coded matrix of individual mutations (specific BRAF 
and NRAS mutations indicated) (middle), type of melanoma specimen (primary or metastasis), and mutation 
spectra for all samples (bottom) are indicated. Source:Ref.
95
. 
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(as an alternative way to activate the canonical MAPK pathway). The Triple-WT subtype 
(n=46) was defined as a heterogeneous subgroup characterized by a lack of hot-spot BRAF, 
N/H/KRAS, or NF1 mutations95. The above SMGs, and additional that were found mutated in 
lower fraction samples, are components of the MAPK and the PI(3)K (Phosphatidylinositol-
4,5-bisphosphate 3-Kinase) pathways and were also confirmed to be activated.  
 
3.4 “Classical” versus “Lineage-Specific” oncogenes in melanoma 
 As shown in Figure 4 and in Table S2 (Appendix) the majority of melanoma oncogenes 
signal through the MAPK and/or PI3K pathways. Other examples of initiating oncogenic 
events are the amplification of the cell cycle regulators CCND1 or CDK4128. These 
oncogenic mutations are accompanied by alterations in tumor suppressor genes such as 
CDKN2A129,130, PTEN128,129, TP53131 and RB1132, among others. These factors suffer 
activating genetic aberrations which are frequently shared among different tumor types and 
have been termed “classical oncogenes”133. 
 Besides these aberrantly activated/deactivated genes which are shared among different 
types of cancer, there seems to be a lineage-specific element to certain pathways that are 
able to transform melanocytes and that contribute to the robust metastatic potential of 
melanoma. The best characterized lineage specific gene in melanoma is MITF134. MITF has 
been defined as the master regulator of melanocyte development, differentiation and 
pigmentation135. Amplification of MITF has been identified in approximately 15% of 
melanomas134. Loss-of-function mutations of MITF result in the complete absence of the 
melanocytic lineage136. Loss of MITF expression is lethal to most melanoma cell lines in vitro 
(by inducing cell cycle arrest136 or DNA damage137). Intriguingly, MITF depleted melanoma 
cells are also highly invasive138. These contradictions have led to a proposed rheostat 
model where low MITF is a hallmark of stem-like cells (invasive pheonotype), whereas 
MITF-positive cells either proliferate or differentiate depending on the expression levels or 
post-translational modifications. As MITF levels and activity are strongly influenced by the 
microenvironment, the effect of MITF expression on melanoma cell identity is dynamic139-141. 
Importantly, our group recently identified the endolysosomal GTPase RAB7 as an MITF-
independent mechanism of lineage-regulation in melanoma142. 
 
3.5 Non-Oncogene Addiction in melanoma 
 Cancer cells are addicted to “classical” or to “Lineage-Specific” oncogenes in order to 
sustain hyper-activated signaling pathways and progress. However, there are many genes 
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that are unable to directly promote tumor formation but whose reduction in activity can 
become rate-limiting to the pathway. By this rationale, cancer cells are addicted to both 
oncogenes and non-oncogenes. To describe this addiction of cancer cells to the functions of 
non-oncogenes, this phenomenon was termed as “non-oncogene addiction”143,144. One 
cellular process in melanoma proposed to be mediated by oncogenic and non-oncogenic 
mediators is autophagy. 
3.5.1 Autophagy 
 Autophagy is the major 
intracellular degradation 
process by which cytoplasmic 
materials are delivered to and 
degraded in the lysosome. 
However, the purpose of 
autophagy is not the simple 
elimination of materials; but 
instead, serves as a dynamic 
recycling system that produces 
new building blocks and energy 
for cellular renovation and 
homeostasis. The term was 
introduced in 1966 by de Duve, 
derived from the Greek words 
“auto” and “phagy” meaning “self” and “eating”, to describe the occurrence of distinct 
intracellular, membranous vesicles that contained degraded cytoplasmic material146.  
 Autophagy is classified as microautophagy, chaperone-mediated autophagy and 
macroautophagy147. In microautophagy, the lysosome itself engulfs small components of 
the cytoplasm by inward invagination of the lysosomal membrane. Membrane dynamics 
during microautophagy may be quite similar to that of endosomal sorting complex required 
for transport (ESCRT)-dependent multivesicular body (MVB) formation, which occurs in the 
late endosome148. The chaperone-mediated autophagy does not involve membrane 
reorganization; instead, proteins directly translocate across the lysosomal membrane during 
chaperone-mediated autophagy149. Macroautophagy (herein will be referred as 
‘‘autophagy’’) is thought to be the major type of autophagy, and it has been studied most 
extensively compared to other categories. Although autophagy was initially considered a non 
selective cellular process, the specific catabolism of cellular organelles like mitochondria, 
Figure 5: Main steps of (macro)autophagy. Schematic 
representation of key regulatory proteins involved in the formation 
and maturation of autophagosomes. Shown also are 
pharmacological inhibitors and small interfering RNAs (red 
blocking arrows). Source: Ref.
145
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peroxisomes, endoplasmic reticulum, and ribosomes has been discovered and is termed 
“mitophagy”150,151, “pexophagy”152,153, “ERphagy/reticulophagy”154, and “ribophagy”155, 
respectively. In general, the role of autophagy to maintain cellular homeostasis requires the 
versatility to recognize a diverse range of substrates and stimuli156. Autophagy is 
orchestrated by a number of highly conserved AuTophaGy-related genes (ATGs), which 
were originally identified in yeast, with many of these genes having orthologues in 
mammalian cells157,158. The main steps and the core components of this process are 
highlighted in Figure 5 and in Table S3 in the Appendix. Briefly, double-membrane-bound 
autophagosomes develop in a multi-step process starting by the engulfment of cytoplasmic 
material by the phagophore159. This process involves the de-repression of the mTOR 
Ser/Thr kinase which inhibits autophagy by phosphorylating the Atg13 (step 1). This leads to 
the dissociation of Atg13 from a protein complex that contains Atg1 kinase (the fly 
orthologue of ULK1) and Atg17. When mTOR is inhibited, re-association of Atg13 with Atg1 
induces autophagy160,161. Among the initial steps of vesicle nucleation is the activation of 
mammalian Vps34 (a class III PI3K) to generate phosphatidylinositol-3-phosphate 
(PtdIns3P) (step 2). Activation of Vps34 depends on the formation of a complex in which 
beclin-1 (Becn1; the mammalian orthologue of Atg6), UVRAG (UV irradiation resistance-
associated tumour suppressor gene) and a myristylated kinase (Vps15, or p150 in humans) 
participate. Two ubiquitin-like conjugation systems are part of the vesicle elongation process 
(step 3). One pathway involves the covalent conjugation of Atg12 to Atg5, with the help of 
the E1‑like enzyme Atg7 and the E2‑like enzyme Atg10. The second involves the 
conjugation of phosphatidylethanolamine (PE) to LC3/Atg8 (LC3 is one of the mammalian 
homologues of Atg8). Lipid conjugation leads to the conversion of the soluble form of LC3 
(named LC3-I) to the autophagic vesicle-associated form (LC3-II)162,163. LC3-II is used as a 
marker of autophagy because its lipidation and specific recruitment to autophagosomes 
provides a shift from diffuse to punctate staining of the protein164. The mechanism of retrieval 
in which the Atg9 complex participates is poorly studied (step 4). Autophagosomes undergo 
maturation by fusion with lysosomes to create autolysosomes (steps 5 and 6). In the 
autolysosomes, the inner membrane and the cargo are degraded by lysosomal enzymes 
that act optimally within this acidic compartment145,165-167. In the phagosome formation, 
autophagy related proteins participate in the orchestrated fusion of Golgi-, endosome- and 
plasma-membrane-derived membranes168-171. 
3.5.2 Autophagy: A “double-edged” sword in cancer 
 Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells, 
such a homeostatic activity constitutes a robust barrier against malignant transformation. In 
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cancer, autophagy can be tumor-suppressive172,173 or tumor promoting174,175 in different 
contexts176. Large-scale analyses from TCGA indicate that the core autophagy machinery 
largely escapes genomic mutation in human cancers177. Autophagy impacts cellular 
metabolism, the proteome, and organelle numbers and quality, which alter cell functions in 
diverse ways. Additionally, autophagy can promote a cross-talk between the tumor and the 
stroma, which can support tumor growth. Thus, the role of autophagy is determined by 
nutrient availability, microenvironment stress, and the presence of an immune system178.  
Autophagy as a tumor suppressor 
 Autophagy was initially 
thought to be a tumor-
suppression mechanism. 
This concept derived from 
early reports that the 
essential autophagy gene 
ATG6/BECN1 (part of the 
class III PI3K complex) was 
monoallelically lost in 40% 
to 75% in various cancer 
types. Becn1+/- mice 
(Becn1-/- are not viable) 
spontaneously develop 
various malignancies, 
including lymphomas as 
well as lung and liver 
carcinomas179-183. However, 
in human tumors, to assess 
the possibility that BECN1 
is acting as a tumour 
suppressor is complicated because of the close proximity of the BECN1 gene and the potent 
tumor suppressor BRCA1184. Mutations in BRCA1 are known drivers in human breast and 
ovarian cancers. This makes difficult to rule out the possibility that in human tumors, it is loss 
of BRCA1 rather than BECN1 that is important. Indeed, TCGA data shows there is no 
significant loss of BECN1 independent of BRCA1 loss185.  
 The mosaic deletion of Atg5 in mice or Atg7 in mouse livers produces only benign 
hepatomas, suggesting that complete and specific autophagy deficiency promotes liver 
Figure 6: Tumor suppressive roles of autophagy in malignant 
transformation. Several mechanisms have been proposed such as: the 
preservation of genetic/genomic stability; the disposal of endogenous 
sources of potentially mutagenic reactive oxygen species (ROS); the 
maintenance of normal bioenergetic functions; the degradation of 
oncogenic proteins; the optimal activation of oncogene-induced 
senescence (OIS) and oncogene-induced cell death (OICD); the 
maintenance of a normal stem cell compartment. Source: Ref.
176
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tumor initiation but restricts progression to malignant disease186. Similarly, loss of Atg5 or 
Atg7 in the mouse pancreas promotes benign pancreatic intraepithelial neoplasia (PanIN) 
formation but prevents progression to malignant disease187,188. Autophagy loss in the liver 
and pancreas causes oxidative stress, chronic tissue damage, and inflammation, all factors 
that are well known to promote tumor initiation189. This chronic state of tissue damage, cell 
death, and inflammation promotes compensatory proliferation, producing cells vulnerable to 
mutation and oncogenic transformation. Atg7 deletion increased oxidative stress and 
enhanced tumor growth at early stages, but promoted abnormal mitochondria accumulation, 
proliferation defects, a decrease in tumor burden, and increased survival of animals in more 
advanced stages of tumorigenesis190. Similarly, deletion of Atg7 in mice expressing an 
activating mutation of B-Raf (Braf+/V600E) promotes early tumor development in the lung but 
also inhibits the progression to a more malignant phenotype and increases mouse 
survival191. An additional autophagy-promoting factor that has tumor suppressor functions is 
Atg4C, where its deletion in mice leads to the development of fibrosarcomas192. Finally, it 
has been proposed that autophagy contributes to oncogene induced cell death or oncogene-
induced senescence, two oncosuppressive mechanisms. The activation of various 
oncogenes imposes a significant stress on healthy cells, a situation that is normally aborted 
through the execution of a cell death program193,194, or cell senescence195. 
 The above studies, and other, have shown that autophagy deficiency causes oxidative 
stress, mitochondrial defects, activation of the DNA damage response, genome instability 
and other features that are highlighted in Figure 6. It remains unclear if these premalignant 
tumors in autophagy-deficient mice are in a “benign” state that requires additional genetic 
alterations to promote malignant transformation (e.g. p53 mutation), or if autophagy inhibition 
can only promote premalignant/benign tumor formation but somehow protects cells from 
advancing to malignant cancers189,196-199. 
 Autophagy as a tumor promoter 
 In established tumor cells, autophagy is hijacked to serve as a cell survival mechanism 
that plays a vital role in facilitating tumor cell growth. Several potential mechanisms in cancer 
have been suggested and are depicted in Figure 7. The notion that autophagy represents a 
mechanism that promotes tumor growth is based on the need of tumor cells to adapt to an 
environment that is hypoxic, as well as growth factor and nutrient deprived. Furthermore, 
tumor cells generally have high proliferation rates, which translate into higher bioenergetic 
and biosynthetic needs compared to non-transformed cells. These requirements can be 
fulfilled by increasing autophagy as a mechanism that permits obtaining both ATP and 
metabolic intermediates190. Importantly, for tumor cells in which the oncogene Ras is 
activated, high levels of basal autophagy and dependence on this mechanism for survival 
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are observed. For these 
reasons, autophagy is 
thought to promote tumor 
cell survival by increasing 
stress tolerance and 
providing a pathway that 
permits obtaining the 
nutrients necessary to 
meet the enhanced 
energetic requirements of 
these cells187,200. A first 
indication that autophagy 
may promote cancer came 
from the observations that 
autophagy is up-regulated 
in hypoxic tumor regions, 
suppresses tumor-induced 
inflammation, and 
promotes tumor cell 
survival201.  
 In GEMM for lung cancer, sporadic activation of an oncogenic allele of Kras (KrasG12D) 
results in tumor initiation and gradual progression to adenomas and adenocarcinomas upon 
acquisition of TP53 mutations. Deletion of Atg7 dramatically alters the progression of these 
tumors, producing the accumulation of defective mitochondria, accelerated induction of p53, 
and proliferative arrest. ATG7 loss promotes the formation of oncocytomas instead of 
adenomas and carcinomas, proliferation is suppressed, and tumor burden is reduced. 
Surprisingly, mice with Atg7+/+ tumors die from cancer, whereas mice with Atg7−/− tumors die 
from inflammatory pneumonia, demonstrating that Atg7-deficient lung tumors trigger an 
immune response202. 
 In pancreatic adenocarcinoma, KRASG12D-driven cells enter a state of dormancy in 
response to oncogene ablation and exhibit activated autophagy to efficiently counteract 
metabolic stress. Interestingly, these cells (characterized as cancer stem cells) have the 
ability to efficiently form tumors in vivo,and this relies on autophagy203-205. 
  FIP200 (key component of autophagosome) deficiency in mammary cancer suppresses 
tumor growth and prolongs mouse survivalvia the disruption of autophagy machinery206,207. 
FIP200 loss in mammary tumors activates an immune response and T-cell depletion partly 
restores the growth of FIP200-deficient tumors. This suggests that targeting FIP200 or other 
Figure 7: Tumor-supporting functions of autophagy in malignant 
transformation. Such tumor supporting functions reflects the ability of 
autophagy to: improve the resistance of cancer cells to endogenous 
conditions that normally provoke cell death, render transformed cells less 
sensitive to therapy-induced cell death, sustain the survival of cancer cells 
that enter a state of dormancy or senescence in response to therapy and 
ensure the maintenance of the cancer stem cell compartment. Source: 
Ref.
176
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components of the autophagy initiation complex may suppress breast cancer by activating 
innate and adaptive anti-tumor immune responses208.  
 In glioblastoma it is demonstrated that autophagy is crucial for both glioma initiation and 
sustained growth in a Kras-driven mouse model where shRNAs against Ulk1, Atg7, or Atg13 
promote senescence and extended mouse survival209.  
 Epithelial to Mesenchymal Transition (EMT) is one of the leading biological processes of 
metastasis during cancer210,211. Several works show that EMT requires autophagy to support 
viability of potentially metastatic cancer cells174,212-214. 
 Autophagy is an evolutionarily conserved mechanism and its role in cancer depends on 
many factors like tissue type, tumor stage, and the type of oncogenic mutation involved215.  
 
3.5.3 Autophagy in melanoma 
 Melanomas have a high level of basal autophagosomes suggestive of increased 
autophagy. Melanoma patients with with higher levels of autophagosomes have decreased 
survival216. BRAF targeted therapy results in a transient response in some patients with 
BRAF mutant melanoma, only to relapse shortly thereafter. In a GEMM of melanoma 
(BrafV600E/Pten-/-), Atg7 deficiency prevents melanoma initiation and proliferation and 
prolongs survival. Although the mechanism is not firmly established, Atg7 prevents oxidative 
stress, apoptosis, fibrosis, and, notably, senescence, a known barrier to melanoma growth 
and progression217. Moreover, autophagy in Braf-resistant melanoma cells either by ATG5 
knockdown or pharmaceutically was not sufficient in restoring sensitivity to Vemurafenib 
(BrafV600E inhibitor) treatment; however, combinational treatment increased melanoma cell 
death218. 
On the other hand, two autophagy markers, ATG5 and LC3, were found significantly 
decreased in patients with early-stage cutaneous melanoma as compared with those with 
benign nevi219. Importantly, studies in our lab using GEMM, in vitro studies and data from 
TCGA database revealed that specific heterozygous loss of ATG5 favors melanoma 
metastasis and it’s a poor indicator of survival (Figure 8). Of note, the tumors in the ATG5 
heterozygous mice were more resistant to targeted therapy with a BrafV600E inhibitor 
(Dabrafenib)220. Although mechanistically was not characterized how the specific loss 
triggers metastasis, it is speculated that the expression levels of autophagy proteins  should 
be fine tuned in order to regulate downstream factors that favor invasion.  
Whether other proteins of autophagy machinery behave in the same manner is poorly 
characterized. 
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3.6 Cargo receptors in autophagy 
 As was mentioned above, the turnover of 
damaged organelles, removal of protein 
aggregates, and elimination of intracellular 
pathogens, are highly selective and tightly 
regulated processes that require selective 
sequestration of the specific cargo into 
autophagosomal membranes221,222. An autophagy 
receptor is defined by its ability to bridge cargo 
and autophagosomal membrane, leading to the 
engulfment of cargo by the autophagic vesicle. 
Selectivity is achieved through autophagy 
receptors. The interaction of cargo receptors with 
LC3/GABARAP relies on the formation of an 
intermolecular β-sheet to which the cargo receptor 
contributes a single strand, the so-called LC3-
interacting region (LIR). LIR motifs in general 
interact with autophagy modifier proteins of the 
LC3/GABARAP family223. In mammalian cells, more than two dozen autophagy receptors 
were identified by the yeast two-hybrid system and proteomic approaches224. There is an 
additional class of proteins autophagy adaptors that also bind to members of the 
LC3/GABARAP family (Figure 9). However, they do not facilitate engulfment and 
Figure 8: ATG5 heterozygous loss favors melanoma metastasis. A. Graphical representation of the 
percentage of cases with the indicated alterations in the Atg5 gene in specimens with clinical annotations in 
the TCGA melanoma database. Amp and del stand for amplifications and deletions, respectively. B. Overall 
survival for melanoma patients with diploid, partial losses or deep deletions of the ATG5 locus (TCGA 
database). C. Higher metastatic potential of Atg5
+/Δ
 melanomas determined by macroscopic examinations of 
lungs. Source: Ref.
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Figure 9: Cargo receptors. Proteins with the 
interacting domains involved in selective 
autophagy and their domain organization. 
Source: Ref.
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subsequent degradation of cargo, but serve as anchor points for the autophagy machinery 
and regulate initiation, conjugation, transport and fusion of autophagosomes225.  
 One of the most characterized cargo receptors in the higher organisms is p62 also known 
as Sequestosome-1 (SQSTM1). Unexpectedly, p62 localizes to the phagophore even in the 
absence of LC3 interaction226. Self-oligomerization of p62 rather than binding to LC3 is 
critical for the translocation of p62 to the autophagosomal membrane227. 
  
3.7 p62 as an autophagy adaptor and a signaling hub 
p62 was first identified as a 62 kDa protein which binds lymphocyte-specific protein 
tyrosine kinase (Lck), a Src family member228. Later, p62 was also reported to be a binding 
partner of atypical protein kinase C (aPKC)229,230. Since its initial discovery, p62 through the 
well-defined structural elements has been characterized to act as an autophagy adaptor 
and also as a signaling hub due to its ability to interact with key signaling proteins. 
 
3.7.1 Structure of p62 
p62 is ubiquitously expressed in various cell types, mainly in the cytoplasm, and is also 
present in the nucleus, autophagosomes, and lysosomes231-233. It contains multiple major 
domains (Figure 9) such as the  PB1 (Phox1 and Bem1p regions, aa 20–102), the ZZ (ZZ-
type zinc finger, aa 122-166), the TB (TRAF6 binding, aa 225-250) and the KIR (Keap1-
interacting region, aa 346–359) that confer the ability to interact with key components 
involved in essential signaling pathways234,235. Two other domains, UBA (Ubiquitin-
associated domain, aa 391–436) and the LIR (LC3-interacting region, aa 337-343) domains, 
cause p62 to function as an adaptor between autophagy and ubiquitinated proteins236. 
The UBA domain of p62 can bind both K48-linked and K63-linked Ub chains237-239. 
Exposure to proteasome inhibitors or expression of polyglutamine-expanded huntingtin, UBA 
is phosphorylated in Ser407 by ULK1 kinase, which is required during the early steps of 
autophagosome biogenesis. This phosphorylation destabilizes the UBA dimer interface. 
Subsequently, Ser403 of the UBA domain is phosphorylated by casein kinase 2 or TANK-
binding kinase 1 to increase the binding affinity of p62 for ubiquitin chains240. The UBA is 
frequently mutated in Paget’s disease. This pathology is characterized by an increase in the 
number and the activity of osteoclasts, leading to bone architecture abnormalities241,242.  
The LIR domain, via an 11 amino-acid portion located in the 332-343 region, is 
responsible for the association of p62 with all isoforms of the LC3 protein and consequently 
the targeting in the autophagic machinery243. There are a series of salt bridges and hydrogen 
bonds between p62 and LC3. The hydrophobic (Trp340–Leu343) and acidic cluster 
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(Asp337–Asp339) of p62 are very important for LC3 binding, and these motifs are conserved 
across species. Disruption of the interaction is sufficient to impair the degradation of p62, 
resulting in the formation of ubiquitin- and p62-positive inclusions244. 
The KIR domain interacts with Keap1, a Cullin3-ubiquitin E3 ligase complex adaptor 
protein. In turn, Keap1-promoted polyubiquitinylation and subsequent proteasomal 
degradation of the transcription factor Nrf2 are inhibited. As a consequence, the expression 
of cytoprotective, antioxidant Nrf2 target genes is increased199,245. Moreover, the p62 gene 
itself is a target for Nrf2; thus, the appropriate oxidative stress response is supported by a 
positive feedback regulation between p62 and Nrf2246.Autophagy has a strong impact on 
Nrf2 activation, since p62 not only disrupts Keap1-Nrf2 interaction but also removes Keap1 
from the cytosol via selective autophagy247. 
The ZZ domain is related to NF-kB signaling and glucose regulation. This domain could 
associate with RIPK1. Recently, some studies reveal that the ZZ domain of SQSTM1 may 
links autophagy to N-end rule pathway248,249. 
The TB domain of p62 interacts with TRAF6, an E3 ubiquitin ligase that regulates 
mTORC1 activity by K63-ubiquitination in a p62-interaction dependent manner. Through this 
TB domain, p62 could function as a crucial mediator for mTORC1 activity regulation233. 
The PB1 domain was characterized initially by its ability to bind atypical protein kinase C 
(PKC ζ and ι)229,250. Heterodimerization of p62 with atypical PKC is crucial for the regulation 
of the NFκB pathway. Indeed, following binding of the RANK ligand to its cognate receptor 
RANK in osteoclasts, the association of p62 with either atypical PKC (or with TRAF6 via TB 
domain) contributes to the activation of IKK (Ik-B Kinase) and to the nuclear translocation of 
NFκB. p62 binds and inhibits ERK1, which is crucial for the negative regulation of 
adipogenesis and obesity and the ensuing inflammation251. The PB1 domain plays a role in 
p62 self and hetero-oligomerization with other PB1 domain containing proteins, such as 
NBR1252. Finally, PB1-mediated p62 self-oligomerization is essential for its localization to the 
autophagosome formation site, a process that is independent of LC3 localization227.  
Figure 10: Domain structure of p62 and its interacting partners. There are six main domains in the p62 protein, 
necessary for its interaction with the autophagic machinery and with signaling pathways. The N-terminal PB1 
domain is involved in the self-oligomerization of p62 or in heterodimerization. The ZZ domain and the TB interact 
with the RIP and TRAF6 proteins, respectively, to regulate the NF-κB pathway. Through LIR and the UBA, p62 
links the autophagic machinery to ubiquitinylated protein substrates to promote the selective degradation. Finally, 
KIR binds Keap1 leading to stabilization and nuclear translocation of the transcription factor Nrf2. 
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3.7.2 Transcriptional regulation of p62 
 One of the main modes of transcriptional regulation of p62 is dependent on the NRF2 
transcription factor245. NRF2 binds to the antioxidant-responsive element (ARE motif) located 
in the p62 promoter to promote the expression of p62 mRNA. In the absence of oxidative 
stress, NRF2 is maintained as an inactive protein in the cytoplasm through its interaction 
with the KEAP1. In addition to its specific regulation by NRF2, p62 can interact directly with 
KEAP1 via its KIR domain and is able to dissociate NRF2 from KEAP1, thus promoting the 
activation and nuclear translocation of NRF2199,253. Additionally, the constitutive activity of the 
Ras/MEK/ERK1/23,254 and the JNK/c-Jun255,256 pathways regulates p62 at transcriptional 
level in different systems. Finally, other stimuli including phorbol 12-myristate 13- acetate 
(PMA), calcium and IL-3, drastically increase the expression of p62 mRNA in a very short 
time257.  
3.7.3 p62 in cancer progression and metastasis 
 As mentioned above, p62 expression is elevated in response to a variety of cellular 
stresses, especially those that result in impaired autophagic flux. p62 is overexpressed in 
many human cancers. Studies have shown that p62 is overexpressed in hepatocellular 
carcinoma (HCC)189,258-263, intrahepatic cholangiocarcinoma264, pancreatic cancer265, lung 
cancer262,266,267, oral, head and neck cancer268,269, esophageal cancer270, gastric cancer265,271, 
colon cancer262,272, breast cancer273-278, prostate cancer278-284, melanoma285, endometrial 
cancer286, ovarian cancer287, glioblastoma multiforme288 and kidney cancer289, as well as 
chronic liver diseases, such as alcoholic and non-alcoholic steatohepatitis (ASH, NASH) that 
increase HCC risk259,290-293. In the Table S4 (Appendix) are listed the main functions of p62 
in different pathological diseases and mainly in different types of cancer.  
p62 autophagy dependent roles in cancer 
 p62 has been identified as one of the many autophagy receptors and may promote 
autophagic degradation of cargos through at least three mechanisms. First, p62 is directly 
associated with early autophagosome formation by recruiting Atg proteins to the 
autophagosome formation site through its PB1 domain independent of its LIR227. Second, 
p62 binds to ubiquitinated proteins to form protein aggregates via its UBA domain. Third, p62 
also directly interacts with LC3 via its LIR motif (Figure 10)236,243. Along with its PB1 partner, 
NBR1 (Neighbor of BRCA1 gene 1), it has been proposed to regulate the packing and 
delivery of polyubiquitinated, misfolded, aggregated proteins and dysfunctional organelles for 
their clearance through autophagy in mammalian cells and in the fruit fly Drosophila243,294,295.  
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 Defects in autophagy promote a failure of protein and organelle quality control in cells, 
which leads to p62 accumulation, resulting in perturbation of gene expression, increased 
genome damage and tumorigenesis189. Importantly, in autophagy deficient and apoptosis-
incompetent tumor cells, metabolic stress leads to the accumulation of p62, elevated 
expression of endoplasmic reticulum (ER) chaperones, damaged mitochondria, and reactive 
oxygen species (ROS). This increase in p62 levels is critical for tumorigenesis, as 
overexpression of p62 in this cell model leads to increased tumor volume in mouse xenograft 
experiments189,296. 
 A relevant in vivo study described that complete inhibition of autophagy in hepatocytes; 
induced by deletion of the essential autophagy genes, Atg5 or Atg7; causes spontaneous 
liver injury, hepatomegaly, and appearance of liver tumors186. These tumors, however, are 
benign adenomas297. Liver adenomas in liver-specific Atg7-/- mice show strong accumulation 
of p62 and subsequent NRF2 activation due to autophagy inhibition, and both tumor growth 
and liver injury are markedly suppressed by p62 loss186,298. Liver injury is alleviated by NRF2 
ablation and exacerbated by Keap1 deletion in liver-specific Atg7-/- mice199. This indicates 
that p62 may also be a central element in a quality-control mechanism for the disposal of 
toxic aggregates.  
 p62 has been proposed as a critical regulator of the EMT factor, Twist1. Insufficient 
autophagy causes accumulation of p62 and promotes cell proliferation and migration through 
stabilization of the oncogenic transcription factor Twist1299. 
In established breast tumors FIP200-mediated autophagy is required for maintaining 
tumor growth in vivo and the accumulated p62 upon autophagy blockage stimulated the 
growth of autophagy-deficient tumors. These results revealed a rather synergistic 
mechanism of p62 signaling and autophagy in the promotion of cancer growth207.  Of note, 
recent studies found that p62 is not only required for the proper elimination of ubiquitinated 
proteins but also participates in the autophagic clearance of non-ubiquitinated substrates300.    
Several studies highlight that although p62 usually recruits ubiquitinated cargos, loss of 
p62 has little effect on selective autophagy. This lack of phenotypic impact might be 
explained by the presence of other autophagy receptors including NBR1, NDP52 (Nuclear 
Dot Protein 52 kDa) and Optineurin236,301,302. 
p62 as a signaling hub in cancer 
 Unlike other autophagy adaptors, with the exception of NBR1, p62 is also a central hub 
due to its ability to interact with key signaling proteins through well-defined structural 
elements. Therefore, it is possible that autophagy only intervenes as a facilitator or an 
inhibitor of the prooncogenic action of p62296,303. 
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 In ductal pancreatic adenocarcinoma, the constitutive activation of Ras activates the NF-
κB pathway to trigger increased p62 synthesis, and this newly synthesized p62, in turn, 
interacts with TRAF6 to amplify Ras signaling in a positive feedback loop304. The same 
observations arise from studies on lung cancer in which Ras activation stimulates the 
TRAF6-p62-NF-κB complex that is necessary to inhibit deleterious ROS production253. In 
glioblastoma multiforme, p62 is strongly overexpressed harboring a mesenchymal oncogenic 
signature and this overexpression is concomitant with MAPK activation288. 
 mTORC1 is sensitive to inhibition by rapamycin and senses multiple cellular and 
environmental cues including nutrient availability, energy levels, protein misfoldingand 
growth signals. p62 can promote mTORC1 activation by directly interacting with Raptor, a 
key component of mTORC1. In response to stimulation with amino acids, deletion of p62 
results in reduced mTORC1 activity. Conversely, overexpression of p62 enhanced mTORC1 
activation. Moreover, p62 serves as a docking site and is required for mTORC1 localization 
to the lysosomal membrane in response to amino acid stimulation. Therefore, p62-mTORC1 
signaling may also establish another line of feedback regulating p62 levels.282.  
 The positive regulation of p62 and c-Myc was also addressed in breast cancer stem cells 
by delaying the degradation of MYC mRNA through the repression of let-7a and let-7b, thus 
promoting MYC mRNA stabilization at the post-transcriptional level277. 
 Interestingly, chronic p62 accumulation occurs in human pancreatitis and most liver 
degenerative diseases305. High p62 levels promote the activation of NRF2 that results in the 
transcriptional activation of the p62 gene making a feed-forward loop that promotes cancer 
initiation199,245,306. Although p62 inactivation in liver parenchymal cells abrogates the 
expression of the NRF2-dependent anti-oxidant response, it also results in the 
disappearance of hepatocytes that accumulate ROS, which presumably serve as HCC-
initiating cells. The loss of these cells is most likely due to inactivation of the NRF2-mediated 
protective response as well as inhibition of mTORC1 activation and c-Myc expression 
(Figure 11). These studies demonstrate that p62 accumulation in a chronically damaged 
liver is one of the most important factors that lead to HCC development. The proof of 
principle that p62 is an oncogenic protein is that its overexpression in vivo is sufficient to 
induce HCC. This effect of p62 is independent of autophagy because overexpression of a 
p62 variant lacking the UBA domain, and therefore stripped of its autophagy adaptor 
function, was also sufficient to drive HCC260,307. In contrast, a recent study revealed that p62 
is downregulated in stellate cells (another type of cells in the liver) acting as a suppressor of 
HCC development. More specifically, it was shown that p62 is a negative regulator of liver 
inflammation and fibrosis through its ability to promote Vitamin D Receptor signaling (i.e. 
VDR:RXR heterodimerization) in HSCs, whose activation supports HCC308.  The high 
  III.INTRODUCTION 
47 
 
complexity of the liver clearly demonstrates that p62 may exert different levels of expression 
and opposing roles in cell populations even in the same cancer type.  
 Tumor-suppressive functions of p62 were also found during mitosis. During the early 
mitotic phase p62 is phosphorylated by CDK1 allowing the cells to properly progress through 
mitosis. Cancer cells expressing a non phosphorylatable p62 mutant display higher 
tumorigenic properties in vivo and in vitro309.  
 Apart from cancer cells, many tumors display reduced levels of p62 in their stroma, 
especially in cancer-associated fibroblasts (CAFs) (Figure 11). p62-deficient stromal 
fibroblasts exhibit increased production of IL-6, which is critical for TGF-β synthesis that 
converts CAFs into activated myofibroblasts that promote tumor progression. This 
downregulation of p62 in CAFs is needed for acquiring their tumor-promoting function. 
Decreased mTORC1 activity due to the downregulation of p62 results in reduced c-Myc 
levels and the concomitant increase in ROS levels under conditions of autophagy 
competence. Interestingly, the increased oxidative stress in these stromal cells translated 
into higher levels of IL-6 that promoted TGF-β synthesis, being both required for CAF 
activation in p62-deficient prostate cancer stroma278. 
 The above results can explain why genetic inactivation of p62 at an organism level is 
associated with increased tumor progression278, whereas the selective inactivation of p62 in 
cancer epithelial cells restrains cancer initiation260,307. 
Figure 10: p62 key functions in cancer. Role of p62 in the tumor epithelium during cancer initiation (left) and p62 
negative expression in the tumor stroma in metabolic reprogramming and inflammation (right). Source: Ref.
307
 
 
 
Tumor epithelium Tumor stromal 
fibroblasts
Cancer 
initiation
Cancer 
progression
  
 
 
 
 
 
 
 
 
 
 
 
IV.OBJECTIVES 
  IV. OBJECTIVES 
 
51 
 
 This PhD thesis stemmed from our interest in the identification of melanoma drivers, with 
a particular interest in lineage-specific or lineage-enriched metastatic pathways that may 
represent new prognostic factors and putative targets for drug development. 
 The adaptor protein p62/SQSTM1 (sequestosome 1) was selected for its previously 
reported functions at the crossroads of autophagy189,300 and lysosomal-associated pathways, 
both with melanoma-selective features. Moreover, p62 can also function as a signaling 
hub260,282, although there is no clear consensus on whether it acts as a tumor promoting253,260 
or tumor suppressive agent278,308. For example, while p62 is an indisputable autolysosome 
cargo186,227,236, other roles as a hub for multiple protein-protein complexes can be highly cell 
type dependent (mTOR, KEAP1-NRF2 pathway, MYC metabolism)260,282,299,308. These 
pleiotropic functions of p62 illustrate the need for integrated expression and functional 
studies in physiologically-relevant systems. 
 The main goal of this PhD thesis was to dissect the expression and functional contribution 
of p62 to melanoma progression. To this end, we integrated a comprehensive analysis in 
melanoma cell lines, tissue specimens and newly-generated mouse models. In addition an 
integrated –omic strategy (transcriptome/proteome/interactome studies) was performed.  
 
 Therefore, the main goal was pursued in the following specific objectives: 
 
1. THE CHARACTERIZATION OF THE PATHOPHYSIOLOGICAL ROLES OF P62 IN 
VIVO BY GENERATING MELANOMA MOUSE MODELS HARBOURING ALLELIC LOSS 
FOR P62. 
 
2. THE FUNCTIONAL CHARACTERIZATION OF P62 IN MELANOMA BY AN -OMIC 
COMPREHENSIVE ANALYSES.  
 
3. THE DISSECTION OF THE MOLECULAR MECHANISMS OF P62 IN MELANOMA. 
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5.1 Cell Culture 
The human melanoma cell lines SK-Mel-5, SK-Mel-19, SK-Mel-28, SK-Mel-103, UACC-
62, WM-115, WM-164, WM-209 and LU-1205, were selected for their genetic background, 
recapitulating the most frequent genetic alterations in this disease (see Table 1). B16-F10 
(ATCC) mouse melanoma cells were used for subcutaneous injections in mice. All these 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Lonza, cat. No. BE12-
604F/U1) supplemented with 10% fetal bovine serum (FBS, Lonza, cat. No. DE14-801F) and 
100 μg/mL Penicillin/Streptomycin (Invitrogen, cat. No. 15070-063). Primary human 
melanocytes, keratinocytes and fibroblasts were isolated as described before310 from 
neonatal foreskins obtained from the Hospital Niño Jesús, Madrid, Spain. Melanocytes were 
cultured in Medium 254 (Invitrogen, cat. No. M-254CF-500) supplemented with 1% 
melanocyte growth factors (HMGS, Invitrogen, cat. No. S-002-5), 0.2 mM CaCl2 and 100 
μg/mL Penicillin/Streptomycin; keratinocytes were cultured in Epilife Medium (Invitrogen, cat. 
no. M-Epi-500) supplemented with 1% human keratinocyte growth factors (HKGS, 
Invitrogen, cat. No. S-001-5), 0.2 mM CaCl2 and 100 μg/mL Penicillin/Streptomycin and 
fibroblasts were cultured in DMEM, supplemented with 10% FBS, and 100 μg/mL 
Penicillin/Streptomycin. 
 
Table 1: Human melanoma cell lines used in this PhD thesis study. 
CELL LINE STAGE BRAF NRAS PTEN* p62* 
SK-Mel-5 LN met V600E WT + ++ 
SK-Mel-19 Primary Melanoma V600E WT + ++ 
SK-Mel-28 LN met V600E WT + +++ 
SK-Mel-103 Primary Melanoma WT Q61R + + 
UACC-62 Primary Melanoma V600E WT - +++ 
WM-115 Primary Melanoma V600E ND - ++ 
WM-164 LN met V600E WT + ++ 
WM-209 met WT G12A ND + 
LU-1205 Lung met V600E WT - ++ 
                           *: protein levels; WT: wild type; ND: not determined 
 
5.2 Protein Immunobloting 
Cells were harvested and total cell lysates were obtained using 1x Laemmli buffer (62.5 
mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol and 5% β-mercaptoethanol) and boiled at 95°C 
for 5 minutes or RIPA buffer [50mM Tris-HCl pH 8, 150 mM NaCl, 1% Nonidet P-40 (NP-
40), 0.5 % Sodium Deoxycholate, 0.1% SDS, 1mM EDTA pH 7.4 and supplemented 
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protease (Roche Diagnostics, cat. No. 11836170001) and phosphatase inhibitors (Santa 
Cruz, cat, No. sc-45045). Protein concentrations were determined using the Bio-Rad Protein 
Assay (Bio-Rad Laboratories) according to manufacturer’s protocol. Protein immunoblots 
were performed by standard SDS-PAGE electrophoresis in polyacrylamide gels and 
subsequently transferred to Immobilon-P membranes (Millipore, cat. No. IPVH00010) using 
Mini Trans-Blot Cell system (Bio-Rad Laboratories). Transfer was performed at 100V during 
1 hour at 4°C. Membranes were blocked with 5% milk in tris-buffered saline with 0.05% 
Tween-20 (TBS-T) for 1 hour at RT. Primary antibodies (Table 2) were diluted in 5% milk or 
5% BSA in TBS-T and incubated overnight at 4°C or 1 hour at RT. Secondary antibodies 
were diluted in 5% milk TBS-T or in PBS and incubated for 1 hour at RT (Table 3).  
 
Table 2: Primary Antibodies used in this PhD thesis. 
Primary antibody Company Cat. Number Isotype 
Atg5 Cell Signaling Technology 2630 Rabbit 
Atg7 Cell Signaling Technology 2631 Rabbit 
Beta-Actin (AC-15) Sigma-Aldrich A5441 Mouse 
GAPDH Monoclonal core unit (CNIO) - Mouse 
Histone 3 Abcam ab1791 Rabbit 
HMGA2 Cell Signaling Technology 8179 Rabbit 
IgG Sigma-Aldrich I5006 Rabbit 
IGF2BP1 /IGF2BP1 MBL  Ribonomics RN007P Rabbit 
KEAP1 Proteintech Group 10503-2-AP Rabbit 
Kindlin-2/FERMT2 Millipore MAB2617 Mouse 
Kindlin-2/FERMT2 Abcam ab74030 Rabbit 
LC3B Cell Signaling Technology 2775 Rabbit 
Myc Millipore 06-340 Rabbit 
NBR1 Abnova H00004077-M01 Mouse 
NQO1 Abcam ab28947 Mouse 
p62 BD Biosciences 610832 Mouse 
p62 Abcam ab101266 Rabbit 
p62 Novus Biologicals NBP1-49956 Rabbit 
p65 Santa Cruz Biotechnology, Inc. sc-372 Rabbit 
phospho-NF-kB p65 Cell Signaling Technology 3037 Rabbit 
phospho-S6 (Ser240/244) Cell Signaling Technology 2215 Rabbit 
S6 (5G10) Cell Signaling Technology 2217 Rabbit 
Tubulin Sigma-Aldrich T 9026 Mouse 
 
Table 3: Secondary Antibodies used in this PhD thesis. 
Secondary antibody Company Cat. Number Isotype 
TrueBlot Rabbit IgG-HRP Rockland antibodies 18-8816-31 mouse 
TrueBlot Mouse IgG-HRP Rockland antibodies 18-8817-33 rat monoclonal 
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Secondary antibody Company Cat. Number Isotype 
Rabbit IgG-HRP GE Healthcare NA934 donkey 
Mouse IgG-HRP GE Healthcare NA9310 donkey 
 
5.3 RNA extraction, PCR and qPCR 
Total RNA was extracted and purified from cell pellets using RNeasy Mini-Kit (QIAGEN, 
cat. No. 74104) following the manufacturer’s instructions. RNA concentration was 
determined by NanoDrop Spectrophotometer ND-100 (NanoDrop Biotechnologies). 1-2μg 
total RNA was reverse-transcribed into cDNA using the high capacity cDNA reverse 
transcriptase kit (Applied Biosystems, cat. No. 4368814), according to manufacturer´s 
protocol. 20ng of the total cDNA were subjected to real-time quantitative polymerase chain 
reaction (RT-qPCR - 60°C annealing temperature) using Power SYBR® Green PCR Master 
Mix (Applied Biosystems, cat. No. 4367659). Assays were run in triplicates on the 7900HT 
Fast Real-Time PCR system (Applied Biosystems) or QuantStudio™ 6 Flex Real-Time PCR 
System (Applied Biosystems). The primer sequences and annealing temperatures listed on 
Table 4. GAPDH and β-actin were used as loading control to normalize mRNA expression. 
 
Table 4: Primers used in this PhD thesis. 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) °C 
CD2AP GGTGGCTGGAAGGAGAACTA GTTTGATGGGCAAACTGTCA 60 
EHMT2 GGAGGAAGCTGAACTCAGGAGG GACTGAAGTCATCACCCACCAC 60 
FERMT2 GATGCTAAGCTTCAGTTCACC GGGTGTCTGATATTAAAAGTCTTAC 60 
FLOT1 CCCATCTCAGTCACTGGCATT CCGCCAACAT CTCCTTGTTC 60 
GAPDH GAAGGCTGGGGCTCATTTGC CCAGGGGTGCTAAGCAGTTG 60 
HMGA2 GAAGCAGCAGCAAGAACCAAC GCTTCTGCTTTCTTTTGAGCTG 60 
NCEH1 TGGACAACAGTTTACTCAAGA GATCATTGCCTGCACAAAGT 60 
OGFOD1 CCCTGGACCTGTACAGCATT GACCATGAAACCAGCCACTT 60 
p62 TAGCGCTACCGGTCGCCA CCGGAATTTCGAGCGGCCAA 60 
TOP2A ACAAGACATCAAAGTGAAGTAAAGCC GCAGACTCAAAACACAGACAAAGC 60 
β-actin GGCACCACACCTTCTACAATG GTGGTGGTGAAGCTGTAGCC 60 
 
 
5.4 Cloning of genes into lentiviral constructs 
The primers that were used in the cloning of p62 and FERMT2 are indicated in the Table 
5. A Kozak sequence was added in the forward sequence. For p62 cloning amplified 
fragments and empty FG12-CMV-GFP-Puro vector were digested by NheI (NEB Inc, cat. no. 
R0131S) and XhoI (NEB Inc, cat. No. R0146S). For FERMT2 cloning amplified fragments 
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and empty pLV-CMV-SV40-Puro vector were digested by XhoI (NEB Inc, cat. No. R0146S) 
and NheI (NEB Inc, cat. no. R0131S).The products were digested at 37oC for 3 hours in the 
presence of NEBuffer Cutsmart (NEB Inc, cat. No. B7204S) and BSA (NEB Inc, cat. No. 
B9001). Digested PCR products were purified by PCR purification kit following manufacturer 
instructions (QIAquick PCR Purification Kit, cat. No. 28104). Ligation was performed (3:1, 
insert:vector molar ratio) with T4 DNA Ligase (NEB Inc, cat. No. M0202). For bacterial 
transformation Stbl3 cells were used (Thermo Scientific, cat. No. C737303). Plasmid 
isolation was performed following manufacturer instructions (QIAGEN-tip 500, cat. No. 
10063).  Insertion was checked by DNA sequencing. 
 
Table 5: Primers for cloning used in this PhD thesis. 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) °C 
p62 
TTAACGCTAGCGGAGCCATGGCGTCGCTCAC
CGTG 
GTTAACTCGAGTCACAACGGCGGGGGATG
C 
62 
FERMT2 
TTAACCTCGAGGGAGCCATGGCTCTGGACGG
GATAA 
GTTAAGCTAGCTCACACCCAACCACTGGT
AAGTT 
59 
 
 
5.5 Gene Silencing and ectopic expression via lentiviral transduction of 
 shRNAs 
Lentiviral supernatants were generated using HEK 293FT cells transfected via standard 
protocols of calcium phosphate precipitation: 500µL of HBS solution (280 mM NaCl, 10 mM 
KCl, 1.5 mM Na2HPO4.2H2O, 12 mM dextrose and 50 mM HEPES), 250 nM of CaCl2, 4 μg of 
vector plasmid, and 4 μg of each of the lentiviral packaging constructs (pRSV-REV, 
pMDLg/pRRE and the VSV-G expression plasmid pHCMVG). Media was changed 8 hours 
after transfection and the viral supernatants were collected 24 hours later. Cells were 
infected with the viral supernatants and 4 μg/mL of Polybreen (Sigma-Aldrich). Infected cells 
were selected with 1 μg/mL of Puromycin (Sigma-Aldrich). 
For genetic inactivation of p62, FERMT2 and NBR1, melanoma cells were infected with 
short hairpin RNAs purchased from Sigma-Aldrich (Table 6). 
For ectopic expression of p62 and FERMT2, melanoma cells were stably infected with the 
lentiviral constructs, pLV-CMV-p62-mcherry-Puro and pLV-CMV-FERMT2-SV40-Puro in 
parallel with the corresponding empty vectors. 
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Table 6: short haiprin RNAs used in this PhD thesis 
Gene TRC number Sequence region 
shcon SHC001 CAACAAGATGAAGAGCACCAA - 
p62 TRCN0000007237 
CCGGCCTCTGGGCATTGAAGTTGATCTCGAGATCAACTTCAATGCCC
AGAGGTTTTT 
CDS 
FERMT2 TRCN0000128058 
CCGGGCGGACAGTTCTTACAACTTACTCGAGTAAGTTGTAAGAACTG
TCCGCTTTTTTG 
CDS 
FERMT2 TRCN0000128511 
CCGGCCGAAGAACTTTCTCTCTTAACTCGAGTTAAGAGAGAAAGTTCT
TCGGTTTTTTG 
CDS 
NBR1 TRCN0000123159 
CCGGGCTTCATAGTTATTTGGCATTCTCGAGAATGCCAAATAACTATG
AAGCTTTTTG 
3-UTR 
NBR1 TRCN0000123160 
CCGGGCAGCATTTGTGGATGAGAATCTCGAGATTCTCATCCACAAAT
GCTGCTTTTTG 
CDS 
 
 
5.6 siRNA-mediated transient genetic inactivation of p62  
Cells were transfected with specific short interfering RNA (siRNA) molecules using 
Lipofectamine 2000 Transfection Reagent (Invitrogen, cat. No. 11668027) according to 
manufacturer´s protocol. Specifically, for genetic silencing of p62 pool of siRNAs 
(Dharmacon, cat. No. L-010230-00-0005) was used at a final concentration of 100nM. 
Expression analyses were performed at 72h post‐transfection, by protein immunbloting 
and/or RT‐PCR. 
5.7 p62 gene targeting in cells using CRISPR/Cas9. 
 Gene-specific sgRNA oligos were cloned into the lentiCRISPR_v2 expression vector 
(Addgene, cat. No. 52961), which bicistronically expresses sgRNA and Cas9 nuclease. The 
sgRNA sequence was determined by the CRISPR Design Tool (http://crispr.mit.edu/) 
targeting the first exon of all p62 isoforms. The designed sgRNAs were 
sgp62_1:CACCGCACCGTGAAGGCCTACCTTC and sgp62_2: 
CACCGCGCTACACAAGTCGTAGTCT. Lentiviruses were produced in 293FT cells and 
infections were performed as previously described311. Gene silencing efficiency was 
determined by immunoblotting. 
5.8 Clonogenic capacity of cells (Colony Formation) 
Low confluency colony formation assays were performed by seeding 1x103 (SK-Mel-103) 
or 5x103 (SK-Mel-28, UACC-62) cells per well onto 6-well plates. Cells were allowed to grow 
for 10-14 days, followed by fixation with cold methanol for 10 minutes. Colonies were stained 
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with 0.4g/L crystal violet (Sigma). The number of colonies was quantified from micrographs 
of the plates using the ImageJ software.  
5.9 Matrigel invasion assays 
The invasive activity of melanoma cells was determined by matrigel transwell invasion 
assays using Boyden chambers (0.8 μm BD BioCoat™ Matrigel™ Invasion Chambers; from 
BD Biosciences, cat. No. 354480), according to the manufacturer’s guidelines. Briefly, 105 
cells were serum‐starved overnight and were seeded in serum‐free DMEM onto the upper 
chamber. DMEM containing 10% FBS was placed in the lower chamber. After incubation for 
the indicated time intervals, invading and non‐invading cells were first fixed with 4% 
paraformaldehyde and then stained with DAPI. Single cells were visualized by confocal 
detection of DAPI‐stained nuclei through the 40x objective of a TCS‐SP5‐WLL (AOBS‐UV) 
spectral microscope (Leica Mycrosystems, Wetzlar, Germany). The transwell membrane 
was also visualized by laser reflection. LAS AF Matrix screening Software was used for an 
automated high-throughput acquisition across the total width of the matrigel membrane in 9 
different fields per experimental condition. IMARIS 6.3 Software was used to quantify the % 
of invading cells (normalized to the total cell number per field). Data are presented as means 
± SEMs of three independent experiments performed in triplicates. 
 
5.10 Drug treatments in vitro 
To assess the autophagic flux in melanoma, cells were treated with autophagy activator 
Rapamycin at 25nM (Selleckchem, cat. No S1039) and autophagome-lysosome inhibitor 
Chloroquine used at 20μM (Sigma Aldrich, cat. No. C6628) at indicated times. Cells were 
fixed or collected for further Immunofluorescence and Immunoblotting assays. 
 
5.11 RNA stability assay (Actinomycin D treatment) 
p62 genetic silenced cells and cells with non-targeting shRNA were seeded on day 4 after 
infection (250000 cells/6cm plate). Cells were treated with Actinomycin D (Sigma Aldrich, 
cat. No. A9415) at 5 μg/ml concentration. After treatment, cells were washed with ice cold 
PBS and collected via scraping at indicated time points (0, 1, 2, 4 and 6 hours). RNA 
extraction, quantification, reverse transcription and qPCR were performed as described 
above. 
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5.12 Isobaric Tag for Relative and Absolute Quantitation (ITRAQ) 
Melanoma cell pellets from two melanoma cell lines (SK-Mel-103 and UACC62) were 
extracted 3 days upon p62 or ATG5 genetic inactivation and proteins were subjected to 
proteome analysis by iTRAQ. 
 
(I) Sample Preparation 
Cell pellets were washed 3 times with cold PBS containing protease inhibitors (Mini 
Complete, Roche) and then resuspended in 500 μL of ice-cold RIPA lysis buffer (150 mM 
NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 50 
mM Tris, pH 8.0 plus protease inhibitors) and 0.1% Benzonase Nuclease (Novagen, 
Darmstadt, Germany). Samples were vortexed, sonicated and clarified by centrifugation at 4 
°C and 16,100 × g for 15 min. The supernatants containing the protein fraction were 
collected and cleaned up by acetone precipitation with 6 volumes of ice-cold acetone. Pellets 
were dissolved in 7M urea 2M tiourea. The protein concentration of the samples was 
determined according to the Bradford assay using BSA as standard (Protein Assay Kit, Bio-
Rad, Hercules, CA). 
 
(II) Protein Digestion and labeling with ITRAQ reagents 
Samples were digested using the filter aided sample preparation (FASP) method as 
described above. Briefly, 100 ug of each sample dissolved in 7M urea 2M tiourea was 
loaded on the filter, reduced with 10 mM DTT 1 h at 37ºC and alkylated using 50 mM 
iodoacetamide for 20 min in the dark. The excess of reduction and alkylation reagents was 
washed. The proteins were digested overnight using endoproteinase Lys-C from 
Acromobacter lyticus M497-1 (Wako Pure Chemical Industries, Osaka, Japan) with 1:50 
enzyme to protein ratio. Finally, trypsin (Promega, Madison, WI) was added and samples 
were subjected to a second digestion for 6 h. Each tryptic digest was labeled according to 
the manufacturer's instructions (AB Sciex, Framingham, MA) with one isobaric amine-
reactive tag as follows: Tag114; Tag116; Tag115; Tag117. After one hour incubation, 
labeled samples were pooled, and evaporated to dryness in a vacuum centrifuge. The 
iTRAQ sample was cleaned up using a Sep-Pak C18 cartridge for SPE (Waters Corp., 
Milford, MA)312. Eluted peptides were vacuum-dried and reconstituted in OFFGEL solution 
(5% glycerol, 1% ampholytes pH 3-10) prior to electrofocusing. 
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(III) OFFGEL Fractionation 
For pI-based peptide separation, we used the 3100 OFFGEL Fractionator system (Agilent 
Technologies, Böblingen, Germany) with a 24-well set-up. The IPG gel strips of 24 cm-long 
(GE Healthcare, München, Germany) with a 3–10 linear pH range were rehydrated for 15 
min with the Peptide IPG Strip Rehydratation Solution according to the protocol of the 
manufacturer. Subsequently, 150 μL of sample was loaded in each well. Electrofocusing of 
the peptides was performed at 20°C and 50 μA until the 50 kVh level was reached. After 
focusing, the 24 peptide fractions were withdrawn and the wells rinsed with 100 μL of a 
solution of 0.1%TFA. Rinsing solutions were pooled with their corresponding peptide 
fraction. All fractions were evaporated by centrifugation under vacuum. Solid phase 
extraction and salt removal was performed with home–made columns based on Stage Tips 
with C8 Empore Disks (3M, Minneapolis, MN)313 filled with Poros Oligo R3 resin (Life 
Technologies). Eluates were evaporated to dryness and maintained at 4°C. Just prior nano-
LC, the fractions were resuspended in H2O with 0.1% (v/v) formic acid (FA). 
 
(IV) Peptide analysis by nanoLC-MS/MS 
Digested samples were separated by on-line reversed-phase nanoscale capillary LC and 
analyzed by electrospray MS/MS. The experiments were performed on an Eksigent nano LC 
system (Eksigent) coupled to an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, 
Bremen, Germany) equipped with a nanoelectrospray ion source (Proxeon Biosystems, 
Odense, Denmark). Peptides were resuspended in 0.1% FA and loaded from a cooled 
nanoLC AS-2 autosampler (Eksigent). In order to pre-concentrate and desalt the samples 
before switching the pre-column in line with the separation column, 5 μL from each sample 
was loaded onto a reversed-phase ReproSil Pur C18-Aq 5 µm 0.3 x 10 mm trapping 
cartridge (SGE Analytical, Australia), and washed for 15 min at 2.5 μL/min with loading 
buffer (0.1% FA). The peptides were eluted from a RP ReproSil Pur C18-AQ 3 µm 200 x 
0.075 mm (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) by application of a binary 
gradient consisting of 2% ACN in 0.1% FA (buffer A) and 100% ACN in 0.1%FA (buffer B), 
with a flow rate of 300 nL/min. Peptides were separated using the following gradient: 0-5 min 
2% B, 5-150 min 40% B and 150-165 min 98% B. The column was operated at a constant 
temperature of 30ºC.  The LTQ Orbitrap Velos was operated in positive ionization mode. The 
MS survey scan was performed in the FT analyzer scanning a window between 250 and 
1750 m/z. The resolution was set to 60 000 FWHM at m/z 400. The m/z values triggering 
MS/MS with a repeat count of 1 were put on an exclusion list for 60 s. The minimum MS 
signal for triggering MS/MS was set to 1000 counts. In all cases, one microscan was 
recorded. The lock mass option was enabled for both MS and MS/MS mode and the 
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polydimethylcyclosiloxane ions (PDMS, protonated (Si(CH3)2O))6; m/z 445.120025) were 
used for internal recalibration of the mass spectra314. For the HCD, up to the 15 most 
abundant isotope patterns with charge ≥2 from the survey scan were selected with an 
isolation window of 2 m/z fragmented in the C-trap collision cell. Normalized collision energy 
was set to 42%, the Q value to 0.25 and an activation time to 0.10 ms. Waveform filter was 
activated. The resulting fragments were detected in the Orbitrap system with a resolution of 
7500 FWHM at m/z 400. The maximum ion injection times for the survey scan and the 
MS/MS scans were 500 ms and 250 ms respectively and the ion target values were set to 
1E6 and 2E4, respectively for each scan mode. 
 
(V) Data analysis 
The raw files were processed using the Proteome Discoverer 1.3.0.339 software suite 
(Thermo Scientific). The fragmentation spectra were searched against the concatenated 
SwissProt Human database (release date: March 21, 2012; 20329 entries) using 
MASCOT315 as the search engine (v 2.2) with the precursor and fragment mass tolerances 
set to 10 ppm and 0.075 Da, respectively, and with up to two missed cleavages. Lysine and 
peptide N-termini labeling with iTRAQ-4plex reagent as well as carbamidomethylation of 
cysteine were considered as fixed modifications, while oxidation of methionine was chosen 
as variable modification for database searching. Minimal peptide length was set to 6 amino 
acids and Mascot ion score > 20. Peptide identification false discovery rate (FDR) was less 
than 1%. In case that identified peptides were shared by two or more proteins (homologs or 
isoforms), they were reported by Proteome Discoverer as one protein group. The results 
were then exported into Excel for manual data interpretation. Although relative quantification 
and some statistical data were provided by the Proteome Discoverer software, an additional 
1.3-fold change cutoff for all iTRAQ ratios (ratio <0.77 or >1.3) was selected to classify 
proteins as up- or down-regulated316-318. Proteins with iTRAQ ratios below the low range 
(0.77) were considered to be under-expressed, while those above the high range (1.3) were 
considered overexpressed. Protein classification (biological process and protein class) was 
performed by Ingenuity Pathway Analysis (IPA) software, using the entire list of identified 
proteins as the reference data set to analyze the regulated proteins. 
 
5.13 Co-Immunoprecipitation assay followed by Mass Spectrometry  
 
5.13.1 Subcellular Fractionation followed by Co-Immunoprecitation assay 
Cells at 80% confluency were washed twice with ice cold PBS and collected by scraping 
with PBS. Cells were lysed first on ice for 5min in cytoplasmic extraction buffer (Tris/HCl 
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pH=8 50mM, EDTA pH=8 2mM, NP-40 0.1%, Glycerol 10%). Samples were centrifuged at 
3000 rpm for 5min. Pellets were washed once with cytoplasmic extract buffer then 
resuspended in high-salt NP-40 buffer (50 mM Tris pH=8, 150 mM NaCl, 5mM EDTA, 1% 
nonionic detergent NP40). The buffers were supplemented with protease (Applied 
Biosystems, cat. No. 88266) and RNase inhibitors (Applied Biosystems, cat. No. N8080119). 
Extracts were incubated for 20 minutes at 4oC under rotation and sonicated in a Bioruptor 
Standard (Diagenode) for 10 minutes at medium amplitude. The extracts were centrifuged at 
maximum speed and the supernatant was collected.  After preclearing by protein A 
Dynabeads (Invitrogen, cat No. 10001D) for 30 minutes at 4°C, protein concentrations were 
determined and 2mg of total protein extract per condition was subjected to 
immunoprecipitation  using p62 antibody (Abcam, ab101266) or rabbit IgG (Sigma-Aldrich, 
I5006) as a negative control coupled to protein A Dynabeads  for 3h at 4°C. 
Immunoprecipitates were washed extensively, 4-6 times with the corresponding lysis 
bufffers. For Mass Spectrometry Analysis two sequential elutions with 100μl of urea 8M each 
step (Tris-HCl 0,1M + protease inhibitor) at 37oC for 15 min under high agitation. The two 
elution products were combined for Mass Spectrometry injection. For validation of protein-
protein interactions independent co-IP experiments were performed and the 
immunoprecipitates were eluted in NP-40 buffer mixed with loading dye, boiled at 95°C for 5 
minutes and supernatant were collected for immunobloting assays. 
 
5.13.2 Mass Spectrometry  
 
(I) Sample Preparation  
Eluted proteins were subjected to label free proteome analysis. Samples were digested 
by means of the standard FASP protocol319. Briefly, samples were eluted with UT buffer (8M 
urea in 100 Mm Tris-HCl, pH=8.01) with continuous mixing at 37ºC and transfer to a filter 
unit. Proteins were then reduced with 10 mM DTT, alkylated using 50 mM iodoacetamide for 
20 min in the dark and the excess of reagents was washed out with UA twice. Proteins were 
digested with endoproteinase Lys-C (Wako) during 6 hours in a wet chamber (1:50 enzyme 
to substrate ratio). Finally, samples were diluted in 50 mM ammonium bicarbonate to reduce 
the urea concentration to 1M and subsequently digested with Trypsin Gold (Promega) 
overnight at 37 °C. Resulting peptides were further desalted and concentrated using 
homemade reversed phase micro-columns filled with Poros Oligo R3 beads (Life 
Technologies). The samples were dried using the Speed-Vac and dissolved in 30 µL of 0.1% 
formic acid (FA). 
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(II)  LC-MS/MS analysis 
Desalted peptides were separated by reversed-phase chromatography using a nanoLC 
Ultra system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo 
Fisher Scientific) via nanoelectrospray source (ProxeonBiosystem). Peptides were loaded 
onto the column (Dr. Maisch, Reprosil-Pur C18 GmbH 3 μm, 200x0.075 mm), with a 
previous trapping column step (Prot Trap Column 0.3 x 10 mm, ReproSil C18-AQ, 5 µm, 
120Å, SGE), during 10 min with a flow rate of 2.5 μl/min of loading buffer (0.1% FA). Elution 
from the column was made with a 90 min linear gradient (buffer A: 2% ACN, 0.1%FA; buffer 
B: 100% ACN, 0.1%FA) at 300 nL/min. The peptides were directly electrosprayed into the 
mass spectrometer using a PicoTip emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) 
a 1.4 kV spray voltage with a heated capillary temperature of 325°C and S-Lens of 60%. 
Mass spectra were acquired in a data-dependent manner, with an automatic switch between 
MS and MS/MS scans using a top 20 method with a threshold signal of 800 counts. MS 
spectra were acquired with a resolution of 60000 (FWHM) at 400 m/z in the Orbitrap, 
scanning a mass range between 350 and 1500 m/z. Peptide fragmentation was performed 
using collision induced dissociation (CID/CAD) and fragment ions were detected in the linear 
ion trap. The normalized collision energy was set to 35%, the Q value to 0.25 and the 
activation time to 10 ms. The maximum ion injection times for the survey scan and the 
MS/MS scans were 500 ms and 100 ms respectively and the ion target values were set to 
1E6 and 5000, respectively for each scan mode. Samples were run in duplicates. 
 
(III) Data analysis 
Raw files were analyzed by Proteome Discoverer (version 1.4.1.14) against a forward-
reverse concatenated human database (UniProtKB/Swiss-Prot, 88354 sequences, 
26/03/2013 release). Oxidation of methionines was set as variable modification whereas 
carbamidomethylation of cysteines was considered as fixed modification in the SequestHT 
search engine. Minimal peptide length was set to 6 amino acids, a maximum of two missed-
cleavages were allowed. Peptides were filtered at 1% FDR using Percolator. In case that 
identified peptides were shared by two or more proteins (homologs or isoforms), they were 
reported by Proteome Discoverer as one protein group. As stated above, each sample was 
run in triplicate. Label-free analysis was performed with Proteome Discoverer using the 
spectral count values determined by the software. Further analysis was done using Excel 
and MultiExperiment Viewer software (version 4.8.1). The changes in protein abundance 
between the different samples were measured via a direct comparison of the spectral count 
values. Protein classification (molecular function, biological process and protein class) was 
performed by STRING320 software. Raw files from the eluted samples were also analyzed by 
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MaxQuant321 (version 1.4.1.2) (UniProtKB/Swiss-Prot human database, canonical and 
isoform sequences, 39748 sequences, 01/22/2014 release), including phosphorylation on 
serine, threonine and tyrosine residues as variable modification. The rest of search 
parameters were set as above. For protein assessment, at least two unique peptides 
provided by Andromeda search engine322 with a FDR = 1% were required. Results at peptide 
label were exported to excel for further analysis.  
 
5.14 RNA Immunoprecipitation (RIP) followed by qPCR 
p62 infected cells or control cells (non targeting shRNA) at 80% confluence were fixed in 
1% formaldehyde for 10 minutes at room temperature (RT), and fixation was stopped by 
adding 1M Glycine for 5 minutes at room temperature. After washing with ice cold PBS, cells 
were collected by scraping and lysed with in NT2 buffer (50 mM Tris–HCl pH 7.5, 150 mM 
NaCl, 1mM MgCl2, 0.5% Nonidet P-40 and 1 mM EDTA) supplemented with protease and 
RNase inhibitors. For the solubilization of crosslinked complexes, lysates were sonicated for 
10 minutes at medium intensity. The lysates were centrifuged at maximum speed and the 
supernatant was collected. After preclearing by protein A Dynabeads for 30 minutes at 4°C, 
samples were immunoprecipitated using IGF2BP1 antibody (MBL Ribonomics, cat. No. 
RN007P) or rabbit IgG (Sigma, cat. No. I5006) as a negative control coupled to protein A 
Dynabeads for 3h at 4°C. Immunoprecipitates were washed extensively, 4-6 times and 
resuspended in NT2 buffer containing 50µg proteinase K (Roche Applied Science, cat. No. 
03115836001), 1% SDS, 200mM NaCl and 10mM EDTA. Samples were split into two (1:4 
for protein, 3:4 for RNA extraction). The protein fraction was mixed with loading dye, boiled 
at 95°C for 5 minutes and supernatant was collected. RNA elution was done by consecutive 
incubations at 55°C for 30 minutes and at 65°C for 45 minutes. Supernatants were collected 
and digested with DNase I for 10 minutes at RT. RNA was extracted with the TRI Reagent 
(Sigma, cat No. T9424) following manufacturer´s protocol. The total amount of RNA 
immunoprecipitated and 1µg of RNA extracted from inputs were retrotranscribed using 
cDNA reverse transcriptase Superscript III (ThermoScientific, cat No. 18080044) and qPCR 
were performed as described before. Fold binding enrichment of target mRNAs in the 
immunoprecipitated fraction was calculated after normalization with the gene expression 
from the inputs or with the negative controls. All the experiments were performed in three 
biological replicates. The primers used for RIP-qPCR are listed in Table 7. 
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5.15 Immunofluorescence in fixed cells 
Cells were cultured on cover slips and were fixed with 4% paraformaldehyde in PBS at 
room temperature or with ice cold methanol for 20 min. Cells were then washed twice with 
0.1M glycine in PBS for 10min each, permeabilized with 0.2% Triton X‐100 in PBS for 5 min, 
washed twice with PBS and incubated with 1% BSA in PBS at room temperature for 30 min. 
Fixed cells were incubated with primary antibody diluted in blocking buffer (1% BSA in PBS) 
at room temperature for 1 h. Cells were then washed three times with PBS and incubated 
with Invitrogen´s Alexa‐conjugated secondary antibodies at room temperature for 1h. Cells 
were washed 3 times with PBS and counterstaining of nuclei with 4,6-diamidino-2-
phenylindole (DAPI) and mounting of the cover slips were done with Prolong Gold 
(Invitrogen, cat. No. P36930) 20 minutes before imaging. Negative controls were obtained by 
omitting the primary antibody. The following primary antibodies were used: p62 (Novus 
Biosciences, cat No. 610832); IGF2BP1 (Cell Signaling Technology, cat. No. 8482); LC3B 
(Cell Signaling Technology, cat. No. 2775). Alexa Fluor 555 anti‐rabbit IgG (Invitrogen, cat. 
No. A-31572) and Alexa Fluor 488 anti‐mouse IgG (Invitrogen, cat. No. A-21202) were used 
as secondary antibodies.  
 
5.16 Tissue Immunostaining  
(I) Immunofluorescence 
 Paraffin-embedded tumor samples were stained for p62 (Novus Biologicals, cat. No. 
NBP1-49956), LC3B (Cell Signaling Technology, cat. No. 2775d), phospho-p65 (Cell 
Signaling Technology, cat. No. 3037).  After deparaffinization and antigen retrieval (10 
mmol/L sodium citrate buffer at pH 6) the samples were incubated overnight with primary 
antibodies at 4 °C in a humidified chamber. Mouse IgG (M.O.M.) Blocking Reagent (Vector 
Laboratories; MKB-2213); and Image‐iT FX signal enhancer (Invitrogen; cat. No. I36933) 
were used before the primary antibody incubation according to manufacturer’s protocols for 
mouse saples. Then rinsed and incubated with fluorescent secondary antibodies for 1 hour 
at room temperature. For detection, Alexa Fluor 555 anti‐rabbit IgG (Invitrogen, cat. No. A-
31572) and Alexa Fluor 488 anti‐mouse IgG (Invitrogen, cat. No. A-21202) were used. 
Nuclei were counterstained with DAPI and mounted with Prolong Gold (Invitrogen, cat. No. 
P36930) 20 minutes before imaging. The fluorescence emission was acquired using a 
confocal TCSSP5‐WLL (AOBS‐UV) spectral microscope (Leica Mycrosystems, Wetzlar, 
Germany).  
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(II) Immunohistochemistry in human and mouse biopsies 
 
a. Tissue microarrays (TMAs) and immunohistochemistry (human samples) 
 For p62, melanocytic tumors including dermal nevi (n=31), dysplastic nevi (n=29), primary 
radial growth phase (RGP) malignant melanoma (n=16), primary vertical growth phase 
(VGP) melanoma (n=105), cutaneous metastasis (n=30), lymph node (n=28) and visceral 
(n=22) melanoma metastases were used for immunohistochemistry (IHC) and TMAs 
construction as previously described323. FERMT2 staining was performed using anti-
FERMT2 antibody, clone 3A3 (Merck Millipore). For FERMT2, melanocytic tumors including 
dermal nevi (n=34), primary vertical growth phase (VGP) melanoma (n=82), cutaneous 
(n=33), lymph node (n=28) and visceral (n=22) melanoma metastases were used. p62-
specific staining was scored blinded and considered positive for p62 taking into account both 
the percentage of positive cells and the intensity of its expression. It was blinded scored as 
follows: negative (no expression), low (weak intensity or <50% of the cells with strong 
intensity of expression) and high (≥50% of the cells with strong intensity of expression). For 
FERMT2 the scoring system was as follows: negative (no expression), low (weak intensity or 
<50% of the cells with strong intensity of expression) and high (≥50% of the cells with strong 
intensity of expression).  
 IHC was performed on 4-µm-thick sections of formalin-fixed, paraffin-embedded samples. 
p62 (anti-p62 Ick ligand BD Biosystem) and FERMT2 (anti-Kindlin-2 antibody, clone 3A3 
Merck Millipore) staining were performed on a BondTM
 
Automated System (Leica 
Microsystems)323. The IHCs were performed in the Dermatology and Pathology Department 
at the Hospital 12 de Octubre Medical School and the scoring was blinded by the Drs. Erica 
Riveiro-Falkenback, Pablo Ortiz-Romero and Jose L Rodríguez-Peralto. 
 
b. Immunohistochemistry (mouse samples) 
 Tissue samples were fixed in 10% neutral buffered formalin (4% formaldehyde in 
solution), paraffin-embedded and cut at 3 µm, mounted in superfrost® plus slides and dried 
overnight. For different staining methods slides were deparaffinized in xylene and and re-
hydrated through a series of graded ethanol until water. Consecutive sections were stained 
with hematoxylin and eosin (H&E) and for immunohistochemistry an automated 
immunostaining platform was used (Ventana Discovery XT, Roche). Antigen retrieval was 
first performed with high or low pH buffer,  depending on the primary antibody (CC1m, 
Roche or RiboCC, Roche); endogenous peroxidase was blocked (peroxide hydrogen at 3%) 
and slides were then incubated with the appropriate primary antibody as detailed:  rabbit 
monoclonal anti-ATG5 (EPR1755 (2); 1:600; Abcam ab108327), rabbit polyclonal anti-p62 
(SQSTM1; 1:150; Novus Biologicals NBP1-49956), rabbit polyclonal anti-S100  (1:500; 
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Dako, Z0311), and  goat polyclonal anti-Sox10 (1/300; Santa Cruz sc-17342. After the 
primary antibody, for Sox10, slides were incubated with the corresponding secondary 
antibodies (rabbit anti goat biotinylated, Dako) and visualization systems when needed 
(OmniRabbit, Ventana, Roche) conjugated with horseradish peroxidase. The rest of the 
antibodies were incubated with UltraMap Rabbit (Ventana, Roche) conjugated with alkaline 
phosphatase.  Immunohistochemical reaction was developed using 3,30-diaminobenzidine 
tetrahydrochloride (DAB) (Chromomap DAB, Ventana, Roche) and Naphtol with Fast Red 
(FR) (Chromomap RED, Ventana, Roche) as a chromogen . Nuclei were counter stained 
with Carazzi’s hematoxylin. Finally, the slides was dehydrated, cleared and mounted with a 
permanent mounting medium for microscopic evaluation.  
 
5.17 Mitochondrial Respiration 
 5x103cells of p62 deficient SK-Mel-103 and UACC-62 cells with the corresponding shcon 
cells were plated per well in XF 96-well microplates and incubated for 24 hr at 37 °C in 5% 
CO2. Respiration was measured under basal conditions, and in response to Oligomycin 
(ATP synthase inhibitor; 0.5 μM; Sigma Aldrich, cat. no. 75351) and the electron transport 
chain accelerator ionophore FCCP (Trifluorocarbonylcyanide Phenylhydrazone; 0.5 μM; 
Quimigen S.L., cat. no. SC-203578). Finally, respiration was stopped by adding the electron 
transport chain inhibitors Rotenone and Antimycin A (1 μM each; Sigma Aldrich, cat. no. 
R8875 and A8674, respectively). Oxygen consumption rate (OCR) and extra-cellular 
acidification rate (ECAR) were measured with a XF96 Extracellular Flux Analyzer (Seahorse 
Biosciences) as per the manufacturer’s recommended protocol. OCR and ECAR values 
were normalized to cell number. Four technical replicates were used per condition in three 
independent experiments.  
 
5.18 Mice breedings and activation of Tyr::CreER transgene 
The following strains were used in this study: Tyr::CreERT2/1Lru 324, p62-deficient mice325, 
Atg5tm1Myok 326, Braftm1Mmcm (BrafCA/CA)327, Ptentm2Mak 328. For simplicity these lines are herein 
referred as to Tyr:CreERT2, p62KO, Atg5flox/flox, BrafCA/CA, and Ptenflox/flox, respectively. For 
the analysis of melanomas, breedings were set to generate Tyr:CreERT2; BrafCA/CA 
Ptenflox/flox background with different p62 or/and Atg5 copy number (herein referred to as 
Atg5+/+, Atg5-/+, Atg5-/- or p62+/+, p62-/+, p62-/-, respectively).  
Topical administration was performed by applying 2μl (2mg/ml) of (Z)-4-Hydroxytamoxifen 
(Sigma Aldrich, cat. No.H7904) in ethanol on the skin back at postnatal days 2, 3 and 4. For 
systemic administration, 8 week-old mice were induced by 100 ml intraperitoneal injection of 
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tamoxifen (Sigma, T5648; stock 8 mg/ml) for 3 consecutive days. Tumor growth was 
measured every 5 days blinded to the experimental conditions at the indicated time intervals 
after post-mortem depilation. Tumor volume was estimated using a calliper and calculated 
as V= axb2xπ/6, where “a” stand for the bigger and “b” for the smaller diameter of the tumor. 
Studies for tumor growth and survival were performed. Mice were sacrificed 8 weeks upon 4-
hydroxytamoxifen administration or when total tumor volume was exceed 2cm3. Necropsy 
was performed collecting tumor samples and mouse tissues for histopathological and protein 
detection studies.  
 
5.19 Subcutaneous inoculation of B16-F10 cells into p62 deficient mice 
5x105 B16-F10 (ATCC), resuspended in PBS, mouse melanoma cells were inoculated 
subcutaneously in the back of 8 week old mice expressing different copies of p62. 
Development of subcutaneous tumor was monitored every week, blinded to the experimental 
conditions at the indicated time intervals, and measured by caliper, as described above. The 
mice were sacrificed 3 weeks after injection and tumors were collected for histopathological 
and protein detection studies. All experiments with mice met the Animal Welfare guidelines 
and were performed in accordance with protocols approved by the Institutional Ethics 
Committee of CNIO. 
 
5.20 Genotyping 
Genotyping of every strain was obtained by DNA extraction from the tails of each mouse 
after the weaning. Briefly, mouse tails were digested overnight with DNA digestion buffer 
(50mM Tris-HCl with ph 8, 100mM EDTA with pH 8, 100mM NACl, 1% SDS and 20mg/ml 
proteinase K (Roche, cat. No. 03115852001) at 55oC. Then, saturated NaCl was added and 
after full speed centrifugation the supernatant was collected equal volume of ice cold 
isopropanol was added. Precipitated DNA was washed with 70% ethanol and then 
resuspended in TE buffer (10mM Tris, ph 8 and 1mM EDTA). PCRs were performed for 
target gene amplification. The samples were loaded into agarose gels. Primers that were 
used for genotyping are indicated in the Table 7. 
 
Table 7: Primers for genotyping used in this PhD thesis. 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) °C 
p62-WT CTTACGGGTCCTTTTCCCAAC TCCTCCTTGCCCAGAAGATAG 57 
p62-KO CTGCATGTCTTCTCCCATGAC TAGATACCTAGGTGAGCTCTG 57 
Pten CTCCTCTACTCCATTCTTCCC ACTCCCACCAATGAACAAAC 57 
Cre GGCTGGACCAATGTAAATATTG CATCATCGAAGCTTCACTG 55 
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Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) °C 
m-Actin TCATCAGGTAGTCAGTGAGGTCGC CACCACACCTTCTACAATGAGCTG 55 
Braf TGAGTATTTTTGTGGCAACTGC CTCTGCTGGGAAAGCGGC 55 
Atg5-WT ACAACGTCGAGCACAGCTGCGCAAGG GAATATGAAGGCACACCCCTGAAATG 60 
Atg5-KO CAGGGAATGGTGTCTCCCAC GTACTGCATAATGGTTTAACTCTTGC 60 
 
5.21 GO terms, Networks, Heatmaps and Venn Diagrams 
GSEA was applied to previously reported data sets from the Cancer Cell Line Encyclopedia 
evaluating gene lists as described before329. Gene sets showing FDR<0.25 after 
Kolmogorov-Smirnoff testing were considered enriched between classes under comparison. 
Significantly enriched (p≤0.05) GO biological processes and functions for differentially 
expressed proteins upon p62 genetic inactivation and p62 interactome were identified by 
using Ingenuity Pathway Analysis (IPA) software and String database330. Heatmap and 
correlation graphs for RNA and protein levels were created by Perseus v1.5.1.6. Venn 
diagrams were created by using online tools Venny v2.0331 and jvenn332. 
 
5.22 Statistical Analyses  
 Unless otherwise indicated, statistical analyses were performed using Graphpad Prism 
software with unpaired two-tailed t-test. p62 and FERMT2 in vivo correlation was analyzed 
by Chi-square test. For microarray hybridization and gene expression analyses, gene sets 
showing FDR<0.25 after Kolmogorov-Smirnoff testing were considered enriched between 
classes under comparison. For survival analysis, clinical data and immunohistochemical 
scoring were performed blind, and data were compiled only after all analyses were 
completed. p62 and FERMT2 IHC stainings were quantified by two independent 
investigators. The distribution of the patients according to p62 and FERMT2 expression was 
analyzed by Chi-square test (sex, ulceration and clinical staging) and Student´s t test (age 
and Breslow). Disease Free Survival (DFS) curves were estimated with Kaplan-Meier 
product-limit method and survival curves were compared using logrank test. DFS was 
defined as the time interval between diagnosis (made by histopathological study of primary 
melanoma) and the development of the first metastasis. It was considered censored for 
patients who did not present metastasis at last follow-up. The hazard ratio was calculated 
using Cox regression and adjusted with univariate and multivariate models adjusting by 
Breslow, Clinical Stage and T3 category.   
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6.1 Expression and prognostic studies support pro-metastatic roles of p62 in 
 human melanomas 
 
Databases such as The 
Cancer Genome Atlas 
(TCGA) are being 
consolidated as a versatile 
platform to screen for 
oncogenic drivers and 
tumor suppressors across 
large cohorts of clinically-
annotated biopsies333. For 
example, TCGA served as 
the starting point of 
selective dose-dependent 
downregulation of ATG5 
and multiple lysosomal-
associated factors we have 
reported in aggressive 
melanomas142,220. 
Therefore, we interrogated 
the TCGA for genomic 
alterations and expression 
changes that could guide 
in subsequent functional 
studies of p62 in this 
disease. Interestingly, allelic losses of the p62 locus were notably less frequent than for 
ATG5 in the TCGA melanomas (<28% vs 56%; Figure 12A) indicating distinct roles of these 
two proteins in melanoma. Additionally, TCGA revealed a significant upregulation of p62 
protein expression at metastatic sites (skin in transit, regional lymph nodes and distal 
visceral organs), when compared to primary melanomas (see number of specimens 
analyzed and the corresponding p-values in Figure 12B). Of note, the relatively high 
expression of p62 in melanoma was supported by Cancer Cell Line Encyclopedia database 
(Figure 12C; CCLE, encompassing over 700 cell lines of 25 different cancer types).  
Figure 12: p62 is overexpressed in human melanoma biopsies and 
melanoma cell lines. A. Graphical representation of the percentage of cases 
with the indicated alterations in specimens with clinical annotations in the 
TCGA melanoma database (n=367), in the p62 and ATG5 genes, 
respectively. B. Vertical scatter plot of p62 protein expression in the TCGA 
skin cutaneous melanoma from primary and metastatic melanoma. C. Box 
plots showing the relative expression of p62 mRNA across the different 
tumor types in the CCLE dataset (http://www.broadinstitute.org/ccle/home).  
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 The above data were independently validated by immunohistochemical staining of p62 in 
high density tissue microarrays (TMAs; n=213 samples) covering  a broad spectrum of 
melanocytic lesions at different stages of progression (provided by E. Riveiro-
Falkenbach)334. These included common and dysplastic nevi, primary melanomas at radial 
and vertical growth phase of expansion (RGP and VGP, respectively), as well as metastases 
from skin, lymph node and visceral sites. All acquired human dermal nevi analyzed were 
found with a largely undetectable p62 staining (see representative examples in Figure 13A 
and quantification in Figure 13B). These data therefore, support the concept that this protein 
is not involved in suppressor mechanisms that maintain common nevi in a benign state285. 
Interestingly, a retrospective 5-year follow-up study in an independent cohort of 101 
clinically-annotated melanoma specimens showed that patients with positive p62 expression 
presented an increased risk for the development of metastasis with respect to negative 
cases (hazard ratio 2.96 and p=0.022; Figure 13C).  
 Altogether, these data suggest that p62 may be involved not only in cutaneous 
melanomas285, but also, at advanced and metastatic stages of this disease. 
 
Figure 13: p62 is progressively increased in human melanoma biopsies. A. Representative histological images 
of p62 immunohistochemistry in tissue microarrays containing the indicated human benign and malignant 
melanocytic tumors. B. p62 quantification for 213 melanocytic tumors. The staining was classified into negative, 
low and high p62-expressing tumors (p≤0.0001). C. Kaplan–Meier plot of Disease Free Survival (DFS) curves 
subgrouped by p62 expression (p62 negative and p62 positive with the indicated number of cases in each 
group). Analysis time represents years of follow-up. Data provided by E. Riveiro-Falkenbach, ref.
334
.  
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6.2 Tumor-, but not stromal-driven p62 favors melanoma progression in   
  GEMM 
 
 p62 has been found overexpressed in multiple neoplasias189,258-263,265-267. However, high 
p62 levels are not an unequivocal indicator of functional requirement, as pro- and 
antitumoral roles of this protein have been reported depending on the system analyzed. In 
particular, genetically-engineered mouse models (GEMM) reported in the context of cancer 
for prostate and hepatocellular carcinomas260,282 have revealed distinct roles of p62 in tumor 
and stromal cells; in the latter with suppressive function278,308. Therefore, we generated new 
GEMM to dissect the contribution of p62 to melanoma progression. To mimic benign nevi, 
p62-deficient mice325 were crossed into the Tyr::CreERT2;BrafV600E strain, where 
constitutively active Braf (BrafV660E) is induced by means of a tamoxifen-inducible Cre-
recombinase restricted to the melanocytic compartment327. In turn, crosses into 
Tyr::CreERT2;BrafV600E;Pten-/- animals were used to assess the impact of p62 in the context 
of the characteristic BRAFV600E and PTEN loss of human cutaneous melanomas327. 
Pigmented lesions were optically and histopathologically monitored at different time points 
after topical application of 4-hydroxytamoxifen (4-HT).  
 In the normal (uninduced) skin, histological analyses revealed p62 mostly confined to the 
hair bulge expressing low levels (Figure 14A, pink staining). Consistent with dysplastic 
human nevi shown in Figure 13A, hyperplastic lesions in Tyr::CreERT2;BrafV600E animals 
(herein referred to as BrafV600E for simplicity) showed a modest induction of p62 staining 
(pink signal in pigmented-brown-melanocytic cells in middle panels of Figure 14A).  
Figure 14: p62 is highly 
induced in Braf
V600E
;Pten
-/-
 
mouse model. A. Histological 
images (p62 staining upper and 
H&E lower) upon topical 
administration of 4-HT on the 
back skin of Braf
V600E
 and 
Braf
V600E
;Pten
-/-
 mice. B. 
Histological images for p62 
(upper) and S100 (lower)  of 
different tumor sizes developed 
on the back skin of 
Braf
V600E
;Pten
-/-
 mice upon 
topical administration of 4-HT.  
 
 
 
 
 
A
BrafV600E;Pten-/-
100 μm
BrafV600E BrafV600E;Pten-/-Non induced
H
&
E
p
6
2
 
B
p62+/+;BrafV600E;Pten-/-
1 mm 2 mm
S
1
0
0
p
6
2
 
500 μm
500 μm
0.5< mm
100 μm
VI.RESULTS   
 
78 
 
 In contrast, BrafV600E;Pten-/- melanomas showed a marked increased p62 staining in 
histological sections (Figure 14A, right panel). Interestingly, p62 accumulation was 
particularly evident as melanomas progressed and became invasive (Figure 14B). 
 To determine the contribution of p62 in benign nevi, mice with monoallelic and biallelic 
loss of p62 were crossed into Tyr::CreERT2;BrafV600E strain. Nevus formation was followed 
by visual inspection after 4-HT administration (Figure 15A). As summarized in Figures 15B-
C p62 was largely dispensable for the generation of benign melanocytic lesions, as neither 
their onset, number nor progression were significantly affected by heterozygous or 
homozygous loss of this gene (see the corresponding quantifications in Figure 15D). In this 
Tyr::CreERT2;BrafV600E background, melanomas were not developed, independently on the 
presence or absence of p62.  
  
 We then questioned the effect of allelic loss of p62 in melanoma, with particular emphasis 
in the transition from radial to vertical/metastatic growth (e.g. under similar settings that have 
revealed protumorigenic roles of Atg5 heterozygous loss220). This was performed by topical 
administration of 4-HT on the back of the skin of BrafV600E;Pten-/- strains with different allelic 
status of p62 (Figure 16A). In these animals, heterozygous p62 deletion led to a visibly 
compromised melanoma development, which was further inhibited in p62-/- background (see 
representative macrographs of Figure 16B). The relevance of p62 in the BrafV600E;Pten-/- 
melanomas was confirmed histologically (IHC or IF) by staining for the melanocytic markers 
S100 or TRP2 (Figures 16C-D, respectively). Quantitative analyses of tumor volume 
Figure 15: p62 is dispensable 
for nevi formation in Braf
V600E
 
mice. A. Graphical illustration 
of post-natal administration of 
4-ΗΤ on the back skin of 
newborn Braf
V600E
 mice. B. 
Representative images 
acquired 8 months after 
topical administration of 4-ΗΤ 
on the back of inducible 
Braf
V600E
 mice in different p62 
genotypes. C. Histological 
images of H&E and p62 
stainings from (A). D. 
Distribution of lesions after 
topical administration of 4-ΗΤ 
on the back of inducible 
Braf
V600E
 mice in different p62 
genotypes. Light blue 
corresponds to number of 
lesions range from 0-50, blue 
from 50-100 and dark blue 
>100.  
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emphasized deleterious effects of mono and bi-allelic deletions of p62 in the BrafV600E;Pten-/- 
background (Figures 16E-F) ; p≤0.0001).  
 
  p62 loss not only reduced tumor growth of cutaneous melanomas (Figures 16E-F), but 
also led to a markedly decreased metastatic efficiency to proximal (inguinal) and distal 
(axilar) lymph nodes (Figures 17A-B). To address the relevance of p62 in the metastatic 
potential a to distal organs (i.e. lungs), BrafV600E;Pten-/- adult mice were induced systemically 
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Figure 16: p62 loss abrogates tumor growth and diminishes the metastatic capacity of melanoma cells in 
Braf
V600E
;Pten
-/-
 mice. A. Graphical illustration of post-natal administration of 4-HT on the back skin of newborn 
Braf
V600E
;Pten
-/-
 mice mice. B. Representative images acquired 6 weeks after topical administration of 4-HT on 
the back of inducible Braf
V600E
;Pten
-/-
 mice in different p62 genotypes. C. Upper panel, representative images 
of p62 immunofluorescence (red) in the 3 different genotypes for p62. Lower panel, histology slides of back 
skin showing representative examples of p62 and S100 expression in the 3 different genotypes of p62. D. 
Representative images of double-immunofluorescence for p62 (red) and TRP2 (green) of inducible 
Braf
V600E
;Pten
-/-
 mice in the 3 different genotypes of p62. E. Tumor outgrowth of Braf
V600E
;Pten
-/-
 mice in 
different p62 genotypes shown at 40 days after 4-HT topical administration (mm
3
). Results are mean ± SEM. 
F. Tumor outgrowth follow-up of Braf
V600E
;Pten
-/-
 mice in different p62 genotypes shown at mm
3
. Results are 
mean ± SEM.  
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by 4-HT (intraperitoneal injections, see Materials and methods, 5.18). The enhanced lung 
(micro)metastases that were observed in p62+/+ background were diminished in mice with bi-
allelic deletion of p62, four weeks upon induction (Figures 17C-D). Consequently, follow-up 
studies revealed a dose-dependent impact of p62 loss on the survival of melanoma-bearing 
BrafV600E;Pten-/- mice (Figure 17E). The results above support a key role of melanoma-
expressed p62 in tumor progression and metastasis.  
 To rule out possible effects on the stroma278, a separate set of p62+/+, p62+/- and p62+/- 
mice were used as hosts for implantation of syngenic B16 melanoma cells. Interestingly, the 
allelic status of p62 in this system had no significant impact on these B16-tumors (Figures 
17F).  
Figure 17: p62 loss inhibits melanoma metastasis and prolongs the  lifespan of Braf
V600E
;Pten
-/-
 mice. A. 
Histology stainings in lymph nodes for p62 and S100 of Braf
V600E
;Pten
-/-
 mice in different genotypes of p62. B. 
Metastases count in lymph nodes 8 weeks after 4-HT administration on the back of the skin of Braf
V600E
;Pten
-/-
;p62
(+/+)
 (n=9), Braf
V600E
;Pten
-/-
;p62
(-/+) 
(n=7) and  Braf
V600E
;Pten
-/-
;p62
(-/-)
(n=4) mice, respectively. C. H&E 
staining (highlighting pigmented-brown-melanocytic cells) of isolated lungs from Braf
V600E
;Pten
-/-
;p62
(+/+) 
and 
Braf
V600E
;Pten
-/-
;p62
(-/-)
 mice, 4 weeks upon intraperitoneal injection with 4-HT.  D. Quantification of pigmented-
brown-melanocytic cells of (C.). Lung metastases were quantified as area per lung section. In a section, single 
cells and aggregated cells (3 and 5) were counted in every area and were considered as (micro)metastases. 
Results are mean ± SEM. E. Kaplan–Meier survival curve of the 3 different groups: Braf
V600E
;Pten
-/-
;p62
(+/+)
 
with mean time to death of 45 days (n=6), Braf
V600E
;Pten
-/-
;p62
(-/+)
 66 days (n=12) and Braf
V600E
;Pten
-/-
;p62
(-/-)
 
88 days (n=18). F. Tumor growth (mm
3
) upon subcutaneous implantation of B16-F10 cells in C57BL/6J mice 
expressing different alleles of p62 (n=6 for p62
+/+
, n=5 for p62
-/+
 and n=6 for p62
-/-
). Results are mean ± SEM.  
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 Together, these data: (i) provide physiological relevance of dose-dependent roles of p62 
in melanoma progression; and importantly, (ii) separate melanomas from other tumor types 
where p62 has a more dominant suppressive role in the stromal compartments. 
 
6.3 p62 controls key proliferative and metastatic signatures in melanoma  
  cells  
 
 As indicated above, the roles of p62 
in cancer cells are highly dependent on 
the tumor type. Ultimately, these can 
range from proper entry and exit 
through mitosis309,335 to dispensable 
effects on cell cycle, but a key role in 
the control of cell viability253.  
 Previous studies in our laboratory 
have demonstrated the functional role 
of p62 in human melanoma cells by 
means of lentiviral-driven transduction 
of short hairpin interfering RNAs 
(shRNAs)334. In short, sustained p62 
depletion (Figure 18A) resulted in 
phenotypic changes visualized by cell 
flattening and reduced growth capacity 
in human melanoma cell lines (Figure 
18B). This effect is independent of the 
main genetic alterations in melanoma 
such as BRAF and NRAS mutations. 
p62 shRNA effectively reduced p62 
protein expression in all the cell lines 
tested (Figure 18A), with the 
concomitant inhibition of their 
proliferative capacity in cell monolayers 
(see quantifications in Figure 18C). 
The inhibited proliferative capacity was found translated into a marked decreased 
tumorigenic growth in mouse xenograft models334. Moreover, p62 depleted cells revealed 
that the compromised proliferation was associated to reduced entry in S-phase334. Finally, 
transcriptomic profiles at early time points after p62 depletion in SK-Mel-103 and UACC-62, 
Figure 18: p62 loss inhibits melanoma proliferation in vitro. 
A. Immunoblot analysis for p62 upon p62 knockdown in 
different melanoma cell lines. B. Bright field images of 
different melanoma cell lines upon p62 knockdown. C. Bar 
graph representing the percentage of cells upon p62 
knockdown relative to control cells. Results are mean ± 
SEM.  (A) and (B) were provided by E Riveiro-Falkenback 
ref.
334
. 
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as representative examples of NRAS and BRAF-mutated melanomas, identified cellular 
pathways (Table S5, appendix) related to vesicular trafficking (upregulated) and to cell cycle 
(downregulated)334. These results provide therefore, a mechanistic explanation for the 
association between p62 and proliferation that we had found in aggressive human 
melanomas and the inhibited tumor development in genetically engineered melanoma 
mouse models.  
Functions of p62 in metastasis, as indicated above, are less understood. To study this 
process in human melanoma cells, matrigel-based assays were used upon p62 depletion in 
different metastatic cell lines. As shown in Figures 19A, melanoma cells showed a 
decreased invasive capacity upon p62 depletion compared with the control cells. Together, 
these results reinforce the concept of p62 as modulator of poor prognosis in melanoma 
patients and  the aggressive and metastatic potential of the newly generated p62-GEMM. By 
text mining and guided searches via the Molecular Signatures Database (MSigDB) from 
GSEA platform we identified 3 comprehensive transcriptomic molecular signatures to be 
selectively upregulated in metastatic melanomas336-338. Interestingly, these melanoma-
metastasis signatures were significantly downregulated in the transcriptome of p62-depleted 
SK-Mel-103 and UACC-62 cells (Figures 19B-C). 
Therefore, these data support a coordinated effect of p62 on multiple signaling cascades, 
with new insight on signatures specifically linked to metastasis.  
Figure 19: p62 loss decreases invasive capacity of melanoma cells. A. Invasiveness of indicated melanoma 
cell lines upon p62 knockdown, evaluated by matrigel invasion assay. Results are mean ± SEM. (lower part, 
immublots for p62 knockdown). B. Molecular signatures of metastatic melanoma downregulated in the 
transcriptome of p62 depleted cells obtained from GSEA. C. Representative enrichment plot obtained from (B).  
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6.4 p62-deficient melanoma cells support new protumorigenic activities of  
  this protein  
 
 Next, we set to study the molecular basis underlying the dependency of melanoma cells 
on p62. To this end, we tested main known roles of this protein (e.g., modulation of 
autophagy, mTOR, NF-κB, MYC signaling, oxidative stress and mitochondrial function) that 
have been described in other systems253,260,282,339,340. It is likely that these functions may be 
differentially regulated under endogenous or exogenous stress inducers (i.e. nutrient 
deprivation or therapeutic agents). However, here we selected to study basal conditions, 
where p62 was found essential to maintain malignant features of melanoma cells as 
described above. First, to define whether p62 is a substrate of autophagy, histological 
stainings were performed in generated autophagy-deficient melanomas, using GEMM 
models we have reported before for conditional depletion of Atg5 
(TyrCre::ERT2;BrafV600E;Pten-/-;Atg5fl/fl)220. As shown in Figure 20A, Atg5 deficiency lead to 
the accumulation of p62 foci, reminiscent of autophagosome defects in these cells. 
Accumulation of p62 was also observed in human melanoma cells (UACC-62) blocking 
lysosomal degradation with chloroquine (Figure 20B). Interestingly, in p62 depleted cells, 
activation (Rapamycin) or inhibition (Chloroquine) of autophagy did nοt affect the levels of 
the autophagosomal marker LC3 (Figure 20C). However, only a fraction of p62 foci 
colocalized with the LC3 in CQ-treated cells (Figure 20B) suggesting the participation of p62 
in additional complexes. In fact, no obvious differences were found in the focal staining of 
LC3, and in the amount of the autophagosome-lipidated LC3-II form when p62 was depleted 
in vivo -murine BrafV600E;Pten-/- melanomas (see immunomicrographs in Figure 20D; and 
representative immunoblots for LC3-II and ATG5 in Figure 20E). Similarly, neither p62 
overexpression nor p62 depletion in human cultured melanoma cells significantly altered 
basal LC3-II and ATG5 levels (Figure 20F).  
 To further characterize the p62 dependency in autophagy, newly generated GEMM 
TyrCre::ERT2;BrafV600E;Pten-/-;Atg5fl/fl;p62KO were induced by topical administration of 4-HT 
and were followed for 8 weeks. From the Figure 20G (results in double compound mice) it 
was observed that the inhibitory effect of p62 allelic loss in the development of 
BrafV600E;Pten-/- melanomas was not affected by the genomic status of Atg5.  
 All together, these data conclusively demonstrate that p62 is a target of autophagy in 
melanoma, but not an essential driver of the process.  
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Figure 20: p62 is dispensable for autophagy in melanoma. A. Immunofluorescence for p62 (red) in 
melanomas from the back of inducible Braf
V600E
;Pten
-/-
 mice in different genotypes of ATG5. B. 
Immunofluorescence for p62 and LC3 in melanoma cells treated chloroquine (25μM) for 6 hours. C. 
Immunoblot for p62 and LC3 in melanoma cells treated with rapamycin (50nM) and chloroquine (25μM) for 6 
hours upon p62 knockdown. D. Representative images of double immunofluorescence for p62 (red) and LC3B 
(green) in melanomas from the back of inducible Braf
V600E
;Pten
-/-
 mice in different p62 genotypes. E. 
Immunoblot analysis for the indicated autophagosome proteins in tumors isolated from the back skin of 
inducible Braf
V600E
;Pten
-/-
 mice in different p62 genotypes F. Immunoblot analysis for autophagy related 
proteins in melanoma cells upon ectopic expression and knockdown of p62, respectively. G. Tumor outgrowth 
of Braf
V600E
;Pten
-/-
 mice in different p62 and ATG5 genotypes shown at 8 weeks after 4-HT topical 
administration (mm
3
). Number of mice per group is indicated in the graph. Results are mean ± SEM.  
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 We then tested the mTOR pathway using three approaches: (i) mining TCGA for a 
correlation between the effector S6K1 and p62 mRNA in clinical biopsies as described 
before282  and performing (ii) gain and loss of function studies in two independent melanoma 
cell lines (i.e. overexpressing and depleting p62). Results from patient specimens revealed 
no correlation of S6K1 with p62 expression (Figure 21A). Consistent with these negative 
results, neither upregulation nor depletion of p62 had detectable effects on the 
phosphorylation of S6, another classical reporter of mTOR function (Figure 21B). Similar 
studies failed to reveal significant correlations between p62 and the cytoprotector NRF2 and 
its downstream target NQO1 (Figures 21A-B). This was also the case for MYC, an 
oncogene that may be regulated by p62 under oxidative stress (Figures 21A-B). Regarding 
NF-κB, p62-IKKβ levels were not correlated in TCGA, and no changes in the 
phosphorylation of p65 were observed upon p62 loss (Figure 21C). Finally, the 
mitochondrial function of melanoma cells was not impaired by p62 loss as defined by 
monitoring oxygen consumption rate (OCR) in two melanoma cell lines (Figure 21D, left 
panels). This study revealed also that the ratio of oxidative phosphorylation and the 
glycolysis was not altered suggesting that the mitochondrial respiration of p62 depleted cells 
was functional (Figure 21D, right panels).  Altogether, these results separate melanomas 
from other tumor types, suggesting yet additional roles of p62 in malignancy. 
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Figure 21: p62 described functions in other systems are not altered in melanoma. A. Correlation of p62 with 
its downstream targets (S6K1 and MYC) and direct targets (KEAP1 and IKKβ) in skin cutaneous melanoma 
obtained from TCGA database (n=472). B. Immunoblot analysis for known p62 targets (mTOR pathway, 
KEAP1/NRF2 pathway and MYC) upon ectopic expression and knockdown of p62, respectively, in 
melanoma cells. C. Immunoblot analysis for phospho-p65 and total levels of p65 upon ectopic expression 
and knockdown of p62, respectively. D. Left panels indicate the mitochondrial respiration/function of 
melanoma cells upon p62 knockdown determined by oxygen consumption rate (OCR) utilizing the Seahorse 
XF96 Extracellular Flux Analyzer (Seahorse Bioscience). OCR was measured as pmol/min/cells (5x10
3
) in 
four technical replicates at basal conditions and after the administration of the indicated compounds (n=3). 
Right panels indicate the ratio of basal oxygen consumption rate (OCR, indicative of mitochondrial oxidative 
phosphorylation) with basal extracellular acidification rate (ECAR, representing glycolysis) ratio upon p62 
knockdown of melanoma cell lines. Results are mean ± SEM.  
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6.5 Quantitative proteomics (iTRAQ) for the identification of downstream  
  effectors of p62 
 
 While high throughput proteomics have been reported to identify interactor networks in 
autophagy pathways341no similar studies have been described for p62 in cancer cells. 
Therefore, multiplexed isobaric Tags for Relative and Absolute Quantification (iTRAQ) and 
subsequent LC-MS/MS (liquid chromatography tandem-mass spectrometry) were performed 
for parallel comparisons of control and p62-shRNA melanoma cells (SK-Mel-103 and UACC-
62, in triplicates). In addition, proteomic analyses were run in both cell lines for ATG5 
depletion as a reference for autophagy-associated changes in gene expression. Filters and 
cut off parameters for the identification of significantly deregulated proteins followed 
standards in the field317 (as indicated in the Materials and Methods, 5.12). Interestingly, the 
fraction of significantly downregulated proteins after depletion of p62 and ATG5 was 
surprisingly low in both, SK-Mel-103 and UACC-62 cells (6.4 and 6.6% affected proteins for 
p62 shRNA cells, respectively; and 3.2% and 2.5% for ATG5 siRNA cells; respectively), as 
summarized in scatter plots of Figures 22A-B (see legends for the specific number of 
affected proteins per cell line and Tables S6-9 in the appendix). Therefore, we concluded 
that although p62 and ATG5 (autophagy) may have pleiotropic roles; these ultimately affect 
a rather restricted sets of proteins. However, the p62- and ATG5-associated iTRAQ changes 
were unexpectedly divergent (i.e. proteins upregulated upon p62 depletion, were 
downregulated for the ATG5 counterparts; see venn diagram and the specific list of affected 
proteins in Figure 22C). Furthermore, we found the p62-iTRAQ data in melanoma displaying 
also a minor overlap with proteins annotated in the Human Autophagy Database (Figure 
22D). These results confirm p62 acting primarily beyond autophagy in melanoma cells.  
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  Ingenuity Pathway Analysis (IPA) was then performed on iTRAQ-p62 data, aggregating 
proteomic data from SK-Mel-103 and UACC-62 cells. For this study, we focused on 
downregulated factors after p62 depletion (adjusted p-values<0.05), under the hypothesis 
that those may reflect tumor drivers controlled by p62. Enriched signaling cascades found in 
this IPA analysis corresponded to (i) Cell Morphology, (ii) Cellular Assembly and 
Organization, (iii) Cellular Development, (iv) Cellular Function and Maintenance, and (v) 
Cellular Growth and Proliferation (Figure 23A). These 5 functional categories shared 30 
proteins (Figure 23A), which were then ranked using two criteria: (i) novelty, namely, no 
reported links to melanoma, and (ii) annotated roles in invasion and metastasis -as these are 
the least understood functions of p62. To further narrow down these candidates to those with 
a higher likelihood of physiologically relevance, we mined the TCGA database for differential 
expression in metastatic vs primary melanomas.   
Figure 22: p62 proteomic analysis (iTRAQ) identifies 
downstream targets in melanoma. A. Scatter plots of expression 
levels of identified proteins from two melanoma cell lines (left 
panel, SK-Mel-103 and right panel, UACC-62) upon p62 shRNA 
transduction estimated with respect to shRNA controls, obtained 
from iTRAQ LC-MS/MS analysis. Number of up- and down- 
regulated proteins (red and green, respectively) is highlighted. 
B. Scatter plots of expression levels of identified proteins from 
two melanoma cell lines (left panel, SK-Mel-103 and right panel, 
UACC-62) upon ATG5 silencing by siRNA pool estimated with 
respect to siRNA controls, obtained from iTRAQ LC-MS/MS 
analysis.  
 
  
 
 
 
 
 
Number of up- and down- regulated proteins (red and green, respectively) is highlighted.  C. Left panel, venn 
diagram depicting the low overlap of p62 and ATG5 differentially regulated proteins from iTRAQ analysis. 
Right panel, table of common deregulated proteins indicating the fold change. D. Left panel, venn diagram 
showing low overlap of p62 differentially regulated proteins from iTRAQ analysis and autophagy related 
proteins obtained from (Human Autophagy Database). Right panel, table of common detected proteins 
indicating the fold change.  
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 RNA sequencing-based information from TCGA database was mined for our candidates 
in n=101 primary melanomas and in n=364 metastatic cases (see p-values in Figure 23B). 
From this analysis and the applied selection criteria, we identified 6 proteins (FERMT2, 
NEFL, LAMA2, UBA6, SPTBN1, GALNS) not previously annotated in melanoma and no 
direct links with p62. Two of the identified proteins (FERMT2, NEFL) have been linked with 
roles in metastasis (Figures 23B). However, FERMT2 was the putative target that was 
significantly enriched in metastatic biopsies compared with primary in TCGA database and 
downregulated in both melanoma cell lines (Figures 23C). FERMT2 (Fermitin Family 
Member 2/KINDLIN-2) is a scaffold protein involved in cell adhesion and migration342, with 
well-reported links to metastasis in different cancer types, although regulatory mechanisms 
are not well understood343-345. Together, these results pointed to FERMT2 as a key driver of 
malignant features of melanoma cells, acting downstream of p62. 
Figure 23
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Figure 23: Proteome analyses and data mining identify FERMT2 as a 
downstream target of p62 in melanoma. A. Molecular and cellular functions of 
downregulated proteins upon p62 knockdown in two melanoma cell lines (SK-
Mel-103 and UACC-62). B. Table list of common downregulated proteins 
implicated in molecular and cellular functions upon p62 knockdown that are 
mined to be novel in melanoma, with described roles in invasion and enriched 
in metastatic melanoma compared with primary (TCGA, skin cutaneous 
melanoma). Bold indicates the significantly enriched in metastatic melanoma 
versus primary melanoma. C. Vertical scatter plot of FERMT2 expression in 
TCGA (skin cutaneous melanoma) in primary and metastatic melanoma.  
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6.6 FERMT2 is a novel risk factor for poor prognosis in melanoma acting  
  downstream of p62 
 
 Before proceeding to functional analyses, histological analyses were performed to 
confirm a melanoma-associated accumulation of FERMT2 at the protein level. These were 
performed on TMAs containing melanocytic benign and malignant lesions at different stages 
of the disease (see Table S10 in the appendix for detail on the specimens analyzed, n=199 
in total). Interestingly, and as the case for p62, FERMT2 was undetectable (or very low) in 
the dermal nevi studied. Vertically invading melanomas (VGPs) and metastases (particularly 
at the skin) were found highly positive by immunohistochemistry (Figures 24A-B). In an 
independent validation cohort of 82 VGPs with annotated 10-year follow up, high FERMT2 
expression showed a significant correlation to poor disease free survival (Figure 24C, 
Tables S10-12 in the appendix; double analyses for p62 and FERMT2 expression are 
discussed below). 
 To demonstrate the relevance of FERMT2 as a downstream effector of p62, loss and gain 
of function studies were performed. Specifically, p62 was depleted (shRNA or siRNA pool) or 
Figure 24: FERMT2 is a novel risk factor for poor prognosis in melanoma acting downstream of p62. A. 
Representative histological images of FERMT2 immunohistochemistry in tissue microarrays containing the 
indicated human benign and malignant melanocytic tumors. B. FERMT2 quantification for 199 melanocytic 
tumors. The staining was classified into negative, low and high FERMT2-expressing tumors. C. Kaplan–Meier 
plot of Disease Free Survival (DFS) curves subgrouped by FERMT2 expression (FERMT2 low in blue and 
FERMT2 highin red with the indicated number of cases in each group). Analysis time represents years of 
follow-up.  
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overexpressed by means of lentiviral transfer. The effect on FERMT2 protein expression by 
these strategies was consistent: downregulation upon p62 depletion, and increase through 
ectopic p62 expression (Figures 25A-C). To independently validate FERMT2 as bona fide 
target of p62, two short guide RNAs (sgp62_1 and sgp62_2) were generated for 
CRISPR/Cas9-mediated gene depletion. As shown in Figure 25D, sgRNAs effectively 
eliminated p62 expression and consequently the levels of FERMT2 (versus scrambled 
sgRNA). In vivo, FERMT2 levels were decreased in BrafV600E;Pten-/- GEMM melanomas as a 
function of p62 allelic loss (see the differential staining in p62+/+ with respect to p62+/- and 
p62-/- in Figure 25E). Similar results were found for xenografts of human melanoma cells 
(SK-Mel-103) expressing p62 shRNA and implanted in mice compared to the corresponding 
control (Figure 25F). 
  
 Next, we determined whether depletion of FERMT2 phenocopied p62 loss. Two 
independent shRNAs were identified to provide a sustained and efficient downregulation of 
FERMT2 (see immunoblots in Figure 26A for three melanoma cell lines). FERMT2-deficient 
melanoma cells showed a markedly reduced proliferative capacity in long term colony 
formation assays (Figure 26B-C). Moreover, depletion of FERMT2 (as the case for p62) 
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Figure 25: p62 regulates FERMT2 in vitro and in vivo in melanoma. A. Immunoblot analysis for p62 and 
FERMT2 upon p62 knockdown in the indicated melanoma cell lines. B. Immunoblot analysis for FERMT2 
upon p62 knockdown by siRNA pool in melanoma cells. C. Immunoblot analysis for p62 and FERMT2 upon 
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resulted in a significant reduction in invasive potential of otherwise aggressive melanoma 
cells (Figure 26D).  
 To determine if FERMT2 levels are regulated by p62 through degradation (main function 
of p62), melanoma cells were treated with inhibitors of the proteasome (Bortezomib) and 
lysosome (Chloroquine). While p62 was accumulated (especially in CQ-treated cells), 
FERMT2 levels were not affected. Additionally, another main cargo receptor protein, NBR1, 
was depleted in melanoma cells. NBR1 exhibits similar domain architecture to p62 and it has 
been reported that these two proteins cooperate in autophagy294. NBR1 depletion did not 
affect the expression levels of FERMT2 (Figure 26F), strengthening the concept that p62 
acts on FERMT2 expression in a manner beyond autophagy.  
Figure 26: FERMT2 loss leads to inhibition of proliferation and invasion in melanoma. A. Immunoblot analysis 
for FERMT2 upon FERMT2 knockdown in different melanoma cell lines using two different shRNAs. B. 
Crystal violet staining of colonies formed in the indicated cell populations upon FERMT2 genetic inactivation 
by shRNAs C. Relative quantification of crystal violet staining of colonies formed in the indicated cell lines 
upon FERMT2 genetic inactivation. Results are mean ± SEM D. Invasiveness of SK-Mel-103 upon p62 and 
FERMT2 knockdown evaluated by matrigel invasion assay. Results are mean ± SEM. E. Representative 
immunoblot analysis of p62 and FERMT2 upon proteasomal (Bortezomib) and lysosomal (Chloroquine) 
degradation in melanoma cell lines. G. Representative immunoblot analysis for the indicated proteins upon 
NBR1 knockdown in melanoma cells. 
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 Importantly, to demonstrate that FERMT2 is indeed a physiologically-relevant p62 target, 
rescue experiments were performed. To this end, melanoma cells were infected with 
lentiviruses expressing ectopic FERMT2, or an empty vector control. Each of these 
subpopulations was then depleted for p62 (Figure 27A). As shown in Figures 27B-D, this 
ectopic FERMT2 expression diminished the effect of p62 depletion in the proliferative and 
invasive features of melanoma cells. Therefore, while p62 may certainly impinge on multiple 
signaling cascades (Figure 23A), main roles in proliferation and invasion largely depend on 
FERMT2. 
 The corollary of the data above is that FERMT2 and p62 expression should be correlated 
in patient biopsies. To this end, we constructed a TMA containing 111 melanocytic lesions, 
and stainings for p62 and FERMT2 were performed in consecutive sections. As illustrated in 
Figure 27E, 20% of p62 negative melanomas still expressed high FERMT2, but overall, Chi-
squared test indicated a positive correlation between the two proteins (p=0.001; see 
representative examples in Figure 27F). 
 Altogether, these results identify FERMT2 as a physiologically-relevant novel indicator of 
poor prognosis in melanoma, acting downstream of p62. 
Figure 27: p62 and FERMT2 positively correlate in vitro and in human melanoma biopsies. A. Immunoblot 
analysis of FERMT2 ectopically expressed in melanoma cells followed by p62 knockdown. B. Crystal violet 
staining of colonies formed in FERMT2 ectopically expressed cells upon p62 knockdown. C. Relative 
quantification of (B). Results are mean ± SEM.  D. Invasive capacity of FERMT2 ectopically expressed SK-
Mel-103 cells followed by p62 knockdown, evaluated by matrigel invasion assay. Results are mean ± SEM. E. 
p62 and FERMT2 quantification showing the positive correlation between p62 and FERMT2 expression in 
tissue microarrays containing 111 melanocytic lesions. F. Representative histological images of p62 and 
FERMT2 negative and positive tissues from (E).  
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6.7 The p62 interactome identifies RNA binding proteins as novel binding  
  partners in melanoma 
 
 Next, we investigated the mechanism by which p62 regulates FERMT2. As p62 has been 
reported to act as a hub to define the localization and stability of other proteins, we 
questioned whether this was the case for FERMT2. However, no interaction between these 
two proteins was found by immunoprecipitation assays (data not shown). Interestingly, 
quantitative RT-PCR revealed a 50% reduction FERMT2 RNA in p62 depleted melanoma 
cells (Figure 28A). Therefore, we set to study roles of p62 in RNA regulation. As p62 does 
not have RNA binding domains277, we hypothesized that the regulation of FERMT2 could be 
indirect, perhaps via transcription factors or RNA binding proteins.  
  
 No genome-wide proteomic information is available for p62 interactors in cancer which 
we could use as a guideline. However, mining the Biological General Repository for 
Interaction Datasets (BioGRID)346 256 unique p62 interactors were identified (extracted from 
low and high throughput analyses in various systems). A global inspection of these known 
p62 interactors did not reveal reported regulators of FERMT2. Therefore, affinity purification 
followed by LC-MS/MS were performed to dissect interactors of endogenous p62 in 
melanoma cells. More specifically, these analyses were performed on UACC-62 cells using 
a highly efficient p62-immunoprecipitating antibody upon subcellular fractionation of the 
cytoplasm and the nucleus (Figure 28B; see Materials and methods, 5.13). The eluted 
samples were analyzed with MaxQuant bioinformatic tools, using Andromeda as a peptide 
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Figure 28: p62 interactome in melanoma cells. A. qPCR for p62 and 
FERMT2 upon p62 knockdown in melanoma cells. Results are mean ± 
SEM. B. Immunoblot analysis for the indicated proteins upon cellular 
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immunoprecipitation against p62. C. Cellular localization of the 
identified p62 interactors. D. Left panel, venn diagram highlighting the 
low overlap of common p62 interactors identified in melanoma cells 
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search engine for probabilistic scoring321,322. Using an FDR = 1%, this strategy identified 153 
proteins as putative interactors of p62 in melanoma cells (Table S13, appendix). 54.5% of 
p62 interactors were found to localize in the cytoplasm; 18.8% in the nucleus; and 26.6% in 
both compartments (Figure 28C) supporting the dynamic role of p62 mainly in the 
cytoplasm, but also as a shuttling protein from the cytoplasm to the nucleus232,308.  
Surprisingly, the overlap between p62-melanoma interactome and the p62-BioGRID data 
was rather low, with only 12 proteins in common (Figure 28D). These results therefore, 
suggest a melanoma-specific nature of the p62 bound proteins. This hypothesis was indeed 
confirmed by GSEA using as a reference the Cancer Cell Line Encyclopedia (CCLE), which 
contains information from 752 cell lines, 54 of which are from melanomas (see heatmap 
plots of this comparative analysis in Figures 29A-B; FDR=0.0047).  
 STRING330 (Search Tool for the Retrieval of Interacting Genes/Proteins) was then used to 
explore the molecular functions of the p62-affinity precipitated proteins in melanoma cells. 
Surprisingly, the most enriched GO terms found were related to a particular enrichment in 
RNA binding processes (see highly significant FDR values in Figure 28C). Therefore, these 
results support the attractive scenario of p62 having new cellular roles as a hub for RNA 
binding proteins (RBPs).  
Figure 29: p62 interactors are enriched in melanoma cell lines among other cancer cell lines. A. Heatmap 
summarizing a comparative analysis of p62 interactors (in vertical) across 24 tumor types of the CCLE (n=54 
and n=752 cell lines from melanoma and other cancers, respectively). Note the differential expression profile of 
melanoma vs the rest of tumors. B. Enrichment plot of p62 interactors from (A). C. Gene ontology terms of 
molecular functions (obtained from String database) of p62 interactors (p≤ 0.05).  
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 The data above open new avenues of research in the p62 and RBP fields that could be 
explored in future studies. Here, we focused on the possibility of a “p62-RBP axis” as a 
modulator of FERMT2. From the interacome analyses of Figures 28-29, we found 44 RBPs 
as putative p62 interactors. It was not practical to assess in detail each of these proteins. 
Therefore, candidates for functional characterization were selected in two steps: first, the 44 
p62-interactors were screened through the CLIPdb 2:POSTAR347 database for binding to 
FERMT2 mRNA. Specifically, CLIPdb 2:POSTAR was selected as it represents the largest 
collection of experimentally probed and computationally predicted RBP binding sites in the 
human and mouse transcriptomes347. Secondly, for a more guided analyses, text mining was 
performed on the 44 p62-precipitated RBPs for functions related with cancer cell proliferation 
and invasion. As summarized in Figures 30A, this approach yielded 2 RBPs (IGF2BP1 and 
IGF2BP3) that fitted the three criteria: (i) p62 interaction, (ii) binding to FERMT2 mRNA in 
other settings, (iii) and functions that could account for roles of p62 in tumor progression and 
metastasis. 
 IGF2BP1 and IGF2BP3 are homologues of the insulin-like growth factor 2 (IGF2) 
messenger RNA (mRNA)-binding proteins348,349. Both are highly conserved oncofetal RBPs 
that regulate RNA processing at several levels, including localization, translation, and 
stability349. Importantly, IGF2BP1 and IGF2BP3 have been previously shown to be 
upregulated during melanoma progression, with key roles in tumor cell invasion350,351, 
although with no links to p62. The overexpression of IGF2BP1 and IGF2BP3 was validated 
by immunoblot analysis in freshly isolated normal skin cells and in a panel of melanoma cells 
(Figure 30B). Using double immunofluorescence analyses we found a visible colocalization 
of p62 with IGF2BP1 but not with IGF2BP3 (Figures 30C and data not shown). Therefore, 
we centered on IGF2BP1 for further characterization. This selection was further reinforced 
by finding that large scale analyses of IGF2BP1 binding sites in human pluripotent stem cells 
included FERMT2 as a direct target352. 
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 From the results above, the hypothesis we set to demonstrate is that p62 by binding 
IGF2BP1 may favor the ability of this RBP to bind and stabilize FERMT2 mRNA. First, p62-
IGF2BP1 interaction was confirmed in different melanoma cell lines by reciprocal co-
immunoprecipitations assays (see immunoblots in Figures 31A). Secondly, data obtained 
from enhanced UV crosslinking and immunoprecipitation fort IGF2BP1352 to analyze the 
binding to FERMT2 mRNA. From the data analyzed it was observed that IGF2BP1 binds to 
the 3’UTR of FERMT2 (Figure 31B). Independent RNA Immunoprecipitation (RIP) with anti-
IGFBP1 antibodies followed by qPCR proved that IGF2BP1 indeed binds FERMT2 mRNA 
(immunoblot for IGF2BP1 immunoprecipitation in Figure 31C; see 25-fold difference in 
binding with respect to IgG control in Figure 31D). Thirdly, RIP-qPCR was performed in 
melanoma cells depleted for p62, finding a reduced IGF2BP1 binding to FERMT2 by 50% 
(Figures 31E). 
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Figure 30: p62 and IGF2BP1 colocalize in 
melanoma cells. A. Left panel, pie chart indicating 
the enriched binding of RBPs with p62 in 
melanoma cells. Right panel, table of RBPs that 
interact with p62. Purple boxes indicates the RBPs 
reported to bind mRNA FERMT2, orange the 
RBPs implicated to proliferation and grey the RBPs 
related with invasion. B. Immunoblot for the 
indicated proteins in freshly isolated skin cells and 
melanoma cell lines. C. Representative images of 
double-immunofluorescence for p62 (red) and 
IGF2BP1 (green) in melanoma cells.  
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 Finally, FERMT2 mRNA half life was assessed in the presence or absence of p62 
(through actinomycin D treatments to prevent new transcription). Melanoma cells depleted 
for p62 exhibited a significant acceleration of FERMT2 mRNA decay (Figures 31F, p= 
0.006).  
Figure 31: p62 regulates the stability of FERMT2 mRNA in melanoma via the interaction with IGF2BP1. A. 
Melanoma cell lysates were subjected to co-immunoprecipitation against p62, IGF2BP1 and rabbit IgG 
(negative control). Indicated proteins were detected by immunoblot analysis. Data are representative 
Immunoblot of three independent assays. Left panel indicates the cell line SK-Mel-103 and right panel the cell 
line UACC-62. B. Read density tracks show read density for IGF2BP1 (red), RBFOX2 (as a non related RBP), 
and paired SMInputs (black) across the 3-UTR of FERMT2 (blue). C. Immuprecipitation against IGF2BP1 in 
melanoma cells followed by immunoblot for IGF2BP1. D. RNA Immunoprecipitation (RIP) followed by qPCR 
analysis for FERMT2 in melanoma cells (n=3). Results are mean ± SEM. E. RIP followed by qPCR analysis 
for FERMT2 in melanoma cells upon p62 knockdown in melanoma cells (n=3). Results are mean ± SEM. F. 
mRNA levels of FERMT2 prior and after actinomycin D treatment upon p62 knockdown in melanoma cells. 
Results are mean ± SEM.  
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 In conclusion, this comprehensive -omic approach (trascriptomic, proteomic and 
interactomic analyses) revealed a p62>IGF2BP1>FERMT2 axis embedded within a newly-
identified function of p62 as binding partner for RBPs. 
 
6.8 p62-IGF2BP1 interaction controls the mRNA stability of multiple pro-  
  metastatic factors 
 
 IGF2BP family members are highly pleiotropic RBPs348,349,353. Therefore, we considered 
unlikely that FERMT2 would be the only pro-metastatic factor regulated by the p62-IGF2BP1 
interaction. In particular, we questioned whether indeed IGF2BP1 could contribute to a 
broader impact of p62-related functions. The transcriptomic and proteomic analyses of p62 
showed mild positive correlation in the detected genes (Figure 32A) and we therefore 
focused on genes positively controlled by p62 where changes at RNA levels had a 
significant im  pact on protein expression.  
Figure 32: p62 regulates pro-metastatic factors via IGF2BP1 in melanoma. A. Scatter plots for commonly 
differentially expressed genes at RNA and protein level in SK-Mel-103 (left panel) and UACC-62 (right panel) 
obtained from iTRAQ LC-MS/MS and transcriptomic arrays upon p62 knockdown. B. Venn diagram of 
downregulated genes upon p62 knockdown depicting a high fraction (28%) of them as targets of IGF2BP1. C. 
Heatmap of downregulated genes (at least in one cell line) obtained from transcriptomic and proteomic analysis 
upon p62 knockdown that are targets of IGF2BP1, mined for roles in melanoma and metastasis (red indicates 
upregulation; green, dowregulation; black, no changes; grey, no detected). D. Venn diagram depicting the low 
overlap of IGF2BP1 targets regulated by p62 compared with ATG5 downregulated proteins.  
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 This gene set, found to include 146 genes, was obtained by merging aggregated 
transcriptomic and proteomic data in SK-Mel-103 and UACC-62 (Figure 32B). These 146 
p62-regulated genes were crossed with IGF2BP1-binding targets described by eCLIP 
(enhanced UV CrossLinking and Immunoprecipitation) in other cell types (human stem 
cells)352. This approach revealed a highly significant set of p62-modulated genes (40/146; 
i.e. 27%) with the potential to be under the control of IGF2BP1 in melanoma (Figure 32C). 
Of note, these identified genes were not overlapping in ATG5-regulated genes from iTRAQ 
analysis gene list (Figure 32D) suggesting that these factors are not regulated by p62 via 
the autophagy machinery. These results therefore, further support a key role of this RBP in 
melanoma progression. For validation, representative genes considered attractive for not 
being linked to melanoma, but reported with pro-metastatic functions  were selected (Figure 
32C). We thus chose different gene categories: (i) EHMT2 and TOP2A as examples for 
transcriptional regulators354,355; (ii) modulators of vesicular trafficking (FLOT1 and CD2AP), 
that favored progression in different types of cancer356-358; (iii) and  pro-metastatic genes with 
roles in metabolism (NCEH1 and OGFOD1)359,360. Intriguingly, the selected factors neither 
exhibit high mutational status nor copy number alterations (deletions or amplifications) in 
human melanoma biopsies (Figure 33A; data extracted from TCGA, n=470 specimens). 
However, the levels of expression are increased in metastatic compared with primary 
melanoma biopsies (Figure 33B). 
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Figure 33: p62-IGF2BP1 targets are upregulated 
in metastatic melanoma. A. Frequency (%) of 
melanoma patients with mutations and/or copy 
number alterations (deletions or amplifications) in 
the indicated genes. Data were retrieved from the 
melanoma TCGA database (n=470 specimens) 
using cBioPortal. BRAF and NRAS are included 
as references for classical melanoma-associated 
oncogenes. B. Gene expression of primary versus 
metastastic human melanoma patients for the 
indicated genes obtained from TCGA database.  
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 As IGF2BP1 was found to bind the 3’ UTR of these factors in other systems352 we set to 
determine whether these candidates were also IGF2BP1 targets in melanoma. RIP followed 
by qPCR demonstrated that this was the case (see the differential binding of the IGF2BP1 
antibody with respect to IgG control in Figure 34A). Moreover, this binding was significantly 
decreased in p62 deficient cells (Figure 34B), ultimately resulting in reduced mRNA 
expression of all the candidates studied (Figure 34C). 
Figure 34: p62 regulates the stability of pro-metastatic factors via IGF2BP1.  A. RNA immunoprecipitation 
followed by qPCR analysis for the selected targets in melanoma cells (n=3). B. RNA immunoprecipitation 
followed by qPCR analysis for the selected targets in melanoma cells upon p62 knockdown by shRNA in 
melanoma cells (n=3). C. Expression levels of indicated targets by qPCR analysis upon p62 knockdown by 
shRNA (n=5). D. mRNA levels of pro-metastatic targets prior and after actinomycin D treatment upon p62 
knockdown by shRNA in melanoma cells (n=3).  
Results are mean ± SEM.  
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 To determine whether this inhibited mRNA levels were a consequence of accelerated 
degradation, cells were treated with actinomycin D to blunt new mRNA synthesis and thus 
define the half-life of these transcripts. Results showing the requirement of p62 to sustain the 
stability of all these factors (EHMT2, TOP2A, FLOT1, CD2AP, NCEH1 and OGFOD1) are 
summarized in Figure 34D.  
 Collectively, these results strongly illustrate that p62 regulates the stability of a broad 
range of pro-metastatic factors, and described the RNA binding factor IGF2BP1 as a key 
mediator in this newly identified function. 
  
 
 
 
 
 
 
 
 
 
   
 
 
 
VII.DISCUSSION 
  VII.DISCUSSION 
 
107 
 
 Melanomas are prime examples of aggressive tumors that proceed with a plethora of 
changes in the transcriptome and proteome95,361-364. Characterization and identification of 
oncogenes provides new features and traits in melanoma progression, especially at the 
metastatic stages of the disease. However, the oncogenic factors rarely act via single 
targets. This complexity is particularly notorious for proteins such as Sequestosome 1/p62, 
which function by pleiotropic protein-protein interactions. 
 In this PhD thesis we performed a global analysis of p62 expression and mechanism of 
action in melanoma cells, clinical biopsies and newly-generated mouse models. The 
selection of p62 as a putative new modulator of selective gene sets enriched in melanoma 
was prompted by previously described roles of this protein in lysosomal-associated 
functions, primarily autophagy186,298, which we had found with a distinct lineage-selective 
regulation in this disease220. Therefore, we questioned whether p62 (like the autophagy 
effector ATG5) may be tuned down in invasive or metastatic stages of melanoma 
progression. In parallel, we also set to define to which extent p62 was required for 
autophagosome formation. These studies were combined with a comprehensive 
characterization of the p62-modulated transcriptome, proteome and interactome. Briefly, it 
was found that (i) the p62 locus does not suffer frequent heterozygous loses we had 
reported for ATG5220; moreover, p62 protein was found overexpressed in TCGA-metastatic 
melanomas, a feature we confirmed by (ii) histological analyses in independent patient 
cohorts (in collaboration with Hospital 12 de Octubre), where positive expression was 
associated with poor prognosis in melanoma patients334. (iii) The new GEMM confirmed that 
p62 is required for the progression and the metastasis of malignant melanoma, and more 
interestingly the loss of p62 prolongs the survival of the mice. (iv) Genetic silencing of p62 
abrogated the proliferation and invasion capabilities of cultured melanoma cells. (v) At 
molecular level, it was found that known roles of p62 in the modulation of mTOR, NF-κB, 
KEAP1-NRF2, MYC and mitochondrial respiration were not affected. (vi) More interestingly, 
it was found that p62 exhibits distinct roles and does not impair the autophagic machinery. 
(viii) Additionally, from a comprehensive –omics analyses in melanoma cells we identified 
metastatic signatures significantly downregulated upon p62 depletion. The downstream 
effector of p62, FERMT2 was identified and proposed as a novel risk factor for poor 
prognosis in melanoma. (ix) Surprisingly, a large set of RBPs was identified to interact with 
p62. Among them, IGF2BP1 (via the interaction with p62) was found to regulate the stability 
of the pro-metastatic factor FERMT2 (and others). Together, these results provide new 
insights in the role of p62 in melanoma and ultimately separate this disease from other 
pathologies, where this protein is also overexpressed.  
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 The Figure 34 illustrates the findings of this PhD thesis highlighting the main steps that 
were followed to characterize and identify the new role of p62 in melanoma progression and 
metastasis. 
 
7.1 Expression and prognostic studies of p62 in human melanomas 
 
 Publicly available databases are being consolidated as a versatile platform to screen for 
oncogenic drivers and tumor suppressors across large cohorts of clinically-annotated 
biopsies (TCGA)333  and cell  lines (CCLE)329. Of high importance, the TCGA platform has 
performed a systematic multi-platform characterization of cutaneous melanomas (~300 
biopsies) at the DNA, RNA, and protein levels to create a catalogue of somatic alterations 
and describe their potential biological and clinical significance. These analyses established a 
genomic/transcriptomic framework of classification that has potential implications for 
prognosis and therapy95. Moreover, it provides evidence for exploring how additional 
molecular alterations may explain observed biological and clinical differences among the 
subtypes. It also provides signposts for identification of druggable targets and predictive 
biomarkers, as well as potentially useful guidance for decisions about therapy. p62 
overexpression has been addressed in various cancers types (see introduction and Table 
S4 in the appendix) but still its expression pattern during tumor progression and metastasis 
is not well characterized. Intriguingly, there is no clear consensus on whether it acts as a 
tumor promoting253,260 or tumor suppressive agent278,308 (i.e. liver cancer). In melanoma, a 
Figure 35: Graphical representation of steps followed to characterize and identify the pleiotropic roles of p62 
in melanoma progression and metastasis.  
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recent study characterized the expression of p62 in primary tumors285; however the 
contribution of the protein at later stages was not addressed.  
 In this PhD thesis, mining TCGA database we found a significant upregulation of p62 
protein expression at metastatic sites (skin in transit, regional lymph nodes and distal 
visceral organs), when compared to primary melanomas. The relatively high expression of 
p62 in melanoma was supported by CCLE (encompassing over 700 cell lines of 25 different 
cancer types). These findings were independently validated by immunohistochemical studies 
for p62 in high density tissue microarrays covering a broad spectrum of melanocytic lesions 
at different stages of progression334. The significant upregulation of the protein at the later 
stages of the disease raise the possibility that during metastasis p62 levels are tune up to 
maintain the tumorigenic features of the cells. Furthermore, from a retrospective 5 
year‐follow up analysis of p62 expression in clinically‐annotated primary melanomas it was 
demonstrated that p62 can be an independent prognostic indicator of patient outcome334. 
 Collectively, results obtained from databases and independent validation support the 
oncogenic roles of p62 in melanoma, especially in metastasis. 
 
7.2 Pathophysiological roles of p62 in vivo  
 
 Genetically-modified mouse models (GEMM) have been instrumental in defining cell-type 
dependent roles of p62 in cancer development. For example, in GEMM of hepatocellular 
carcinoma (HCC), p62 was found to act as a sufficient and necessary oncogene in stressed 
cancer initiating cells (hepatocytes)260, but as a tumor suppressor in hepatic stellate cells308. 
Prostate cancer models have revealed also tumor suppressive functions of p62 exerted by 
rewiring the metabolism of stromal fibroblasts278. In this PhD thesis two GEMM were 
generated to dissect the contribution of p62 to melanoma progression. For the benign nevi, 
the Tyr::CreERT2;BrafV600E strain was crossed with p62 mice (p62+/+, p62 -/+, p62 -/-). From 
these studies it was observed that the allelic loss of p62 (monoallelic and biallelic) was 
dispensable for the generation of benign melanocytic lesions. Moreover, melanomas were 
not developed in the presence or absence of p62. These findings (i) recapitulate our clinical 
data where the different types of nevi exhibit negative or very low levels of p62. (ii) 
Moreover,support that p62 is dispensable for the transformation of the benign nevi to 
melanomas in the context of these individual oncogenic changes in vivo. However, when 
p62 mice (p62+/+, p62-/+, p62-/-) were crossed to Tyr::CreERT2;BrafV600E;Pten-/- strain, to 
recapitulate melanoma progression, the effect was different. Allelic loss of p62 in these mice 
led to a significantly (i) compromised melanoma development, (ii) nodular  and lung 
metastasis were diminished (iii) and the survival was extended. (iv) Interestingly, we 
observed that the p62-deficient microenvironment does not override the requirement for p62 
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in the melanoma tumors. Indeed, the contribution of stroma cells (where p62 levels are low) 
did not result in increased melanomagenesis when B16 melanoma cells were implanted in 
p62 KO mice. This is different as in the case of prostate cancer where the p62 negative 
expression of stromal fibroblasts led to epithelial cell proliferation278. These findings support 
the cell type specific roles of p62 in the contribution of tumor progression and also shed light 
to devising therapeutic strategies depending on the cancer type.  
  Autophagy has been shown to play complex roles in the regulation of cancer 
development and progression where p62 functions as a cargo receptor236. We and other, 
have shown that GEMM with defective autophagy lead to the accumulation of 
p62186,217,220,236. An important finding of this study was that p62 has distinct roles from 
autophagy in melanoma. Using GEMM and functional studies in vitro we found that p62 is 
not essential for autophagosome formation and the autophagic machinery. Classical 
autophagy markers did not change in vitro and in vivo upon p62 loss. Interestingly, Atg5 
defective melanoma mice (TyrCre::ERT2;BrafV600E;Pten-/-;Atg5fl/fl) with accumulated p62 
aggregates display no synergistic effect in tumor progression when the mice were crossed 
with p62 KO mice. Thus p62 may be essential (clearance of ubiquitinated proteins) but it is 
not necessary for autophagy machinery during tumor progression. These results are 
supported from the fact that other cargo receptors including NBR1 (neighbor of BRCA1 gene 
1) and NDP52 (nuclear dot protein 52), OPTN (optineurin), and TAX1BP1 (Tax1-binding 
protein 1)365,366 can compensate the loss of p62 and act in the degradation process of 
autophagy. Of note, ablation of p62 in hepatocytes or pancreatic acinar cells does not result 
in any obvious autophagy defects260,302, suggesting that its function is redundant with that of 
other cargo receptors. Finally, the findings from proteomic studies strengthen our data that 
p62 acts beyond autophagy. 
 
7.3 p62 known functions are not altered in melanoma  
 
 The data obtained from human biopsies and the GEMM reinforced the concept of p62 as 
modulator of aggressive and metastatic potential. These data were supported by the 
significantly decreased melanoma metastatic signatures (obtained from GSEA) from the 
transcriptomic arrays in p62 depleted cells. Considering the pleiotropic effects of p62 in 
different cancer types our studies failed to characterize an active role of the protein to any of 
the known pathways described.  
 One well described role of p62 is the hyperactivation of mTOR pathway by tethering 
proteins to endo/lysosomes (e.g. Raptor and RAGs; TRAF6; MEKK3)282,283,339 in prostate 
cancer. However, (i) through data mining in TCGA (ii) and functional studies in vitro it was 
found no dependency with p62 expression. These data were supported from the 
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transcriptomic and proteomic studies where no enrichment of mTOR pathway was observed. 
Accordingly, the interactome analysis failed to identify mTOR related proteins as interactors 
of p62. The findings that p62 is not involved in mTOR activation, first support the hypothesis 
that p62 acts in a cell type specific manner. Secondly, it raises the possibility that this 
pathway can be regulated by other lysosomal genes where melanoma exploits a lineage-
specific wiring of the endolysosomal pathway142. Thirdly, these studies were performed at 
basal conditions, where p62 was found essential to maintain malignant features of 
melanoma cells. It would be of high interest to explore the possible role of p62 under 
situations of cellular stress and nutrient availability where mTOR has been found to be 
hyperactivated by p62282,339.   
 In the same manner, studies for KEAP1-NRF2 pathway (antioxidant response) failed to 
show positive correlation with p62. Keap1 binds NRF2 and promotes its degradation in a 
p62-dependent manner247,367, whereas Keap1 itself is degraded through autophagy on p62 
binding27. In cancer, NRF2 is stabilized by p62 via degradation of Keap1 resulting in the 
induction of antioxidant response elements199,306. Although p62 was found to interact with 
KEAP1 in the interactome arrays, our studies revealed no changes of both proteins (and 
downstream targets, such as NQO1) in melanoma. Various studies have shown that KEAP1-
NRF2 pathway plays important role in cancer progression260,261,368,369 through p62; however 
there are studies supporting that this pathway can be regulated in a p62 independent 
manner370,371. Thus, this suggests that in melanoma this pathway can be regulated 
independently of p62 or under stress conditions (ROS-inducers or chemotherapeutic agents) 
that need to be addressed in future studies. 
 NF-κΒ is considered to be a central player in linking inflammation and cancer372 where 
previous studies have shown that p62 induces its activation in different 
diseases207,253,304,373,374. Following the same strategy, NF-κΒ downstream targets (phospho-
p65, IKKβ) were not correlated with p62 in melanoma cells. Moreover, NF-κΒ players were 
not found to interact with p62 in the interactome arrays.  
 p62 positively regulates MYC oncogene via (i) mTORC1260, (ii) KEAP1-NRF2260 or by 
repressing the expression of the microRNAs let-7a/b277. In our study, neither correlation was 
observed (TCGA, in vitro) nor the stability of MYC was affected in p62 depleted cells (data 
not shown). A possible explanation comes from the fact that the above pathways were not 
affected by p62, consequently MYC levels remained stable. 
 Finally, the mitochondrial bioenergetics that p62 alters in other systems340 remain stable 
in p62 depleted cells raising the possibility that other mitophagy related proteins (Parkin375, 
Optineurin376) act in a compensatory way in the absence of p62 in melanoma. 
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 Overall, the above data indicated that the basal levels of p62 that are sufficient to 
maintain tumorigenesis in melanoma are not altering described pathways in other systems 
supporting the hypothesis of cell type specific roles of this protein. 
 
7.4 Novel roles of p62 in melanoma progression and metastasis 
  
 Our initial studies to assess mechanistically how p62 maintains tumorigenesis and 
promotes metastasis indicated that this protein with the pleiotropic effects does not alter 
known pathways described in other systems. In the light of the above results, we decided to 
proceed to an unbiased transcriptomic, proteomic and interactome analyses in melanoma 
cells. Gene Set Enrichment Analyses (GSEA) in p62 shRNA-associated transcriptomic 
profiles identified a large variety of pro-tumorigenic factors in melanoma cells that included 
expected modulators of cell cycle and mitosis309,334. However, these studies also revealed 
mRNA-regulated factors not previously assigned to p62. Importantly, these included the 
gene signatures we and others had reported to be enriched in metastatic melanomas, as 
well as a large set of pro-metastatic factors with no reported links to this disease. 
 The proteomic analyses provides a useful platform for downstream targets that p62 
regulates in melanoma. From this study the first observation was that the percentage of the 
affected proteins by p62 depletion was rather low (6.5% for SK-Mel-103 and 7% for UACC-
62) indicating that p62 ultimately affects a rather restricted sets of proteins. Ingenuity 
Pathway Analysis (IPA) in p62 depleted cells identified molecular and cellular functions 
altered that are essential for the oncogenic features of the protein. Setting selection criteria 
to the identified proteins and combining data with RNA sequencing-based information from 
TCGA revealed that 24 of these proteins have been linked to melanoma with roles in 
invasion and metastasis; 9 of these proteins were found enriched in metastatic biopsies 
(Figure 23).  However these proteins have not previously linked with p62 indicating it as an 
upstream regulator in melanoma. It will be interesting in future studies to characterize the 
connection of p62 with these proteins and shed light to new pathways that the protein is 
implicated.   
 Of interest, 6 proteins were identified with no previous link to melanoma (FERMT2, NEFL, 
LAMA2, UBA6, SPTBN1, GALNS) and two of them were found with positive roles in 
metastasis in other systems (FERMT2377,378, NEFL379,380). FERMT2 was more significantly 
enriched in metastatic melanoma (TCGA) and was found to be downregulated in both 
melanoma cell lines. FERMT2 is itself a signaling hub, best known for its roles in the binding 
and recycling of integrins381,382, and the activation of multiple signaling cascades involved in 
cell adhesion, cell motility and invasion342,383. To date, FERMT2 regulation has been 
reported primarily by post-transcriptional mechanisms, involving phosphorylation384,385 and 
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integrin-dependent conformational changes386,387. We demonstrated the positive regulation 
of p62-FERMT2 (i) performing functional studies, (ii) using GEMM and (iii) a large cohort of 
human melanocytic lesions. Our studies identified FERMT2 as a physiologically-relevant 
novel indicator of poor prognosis in melanoma, acting downstream of p62. Although, the 
oncogenic potential of FERMT2 has been reported in other systems344,388-390, this is the first 
study that shows the clinical relevance of the protein in melanoma. In this context, the data 
suggested that these two proteins may have a clinical relevance in melanoma and can be 
used as potential biomarkers.  
 
7.5 p62 interactors in the regulation of mRNA stability 
 
 A relevant finding that stemmed from this PhD thesis was the identification of the 
interactors of p62 in melanoma which they were found to be distinct from other systems 
(BIOGRID) and they were specifically enriched in melanoma among other cancer cell lines 
(GSEA using as a reference the Cancer Cell Line Encyclopedia). This result comes in 
agreement with the above data that p62 is acting in a cell type specific manner controlling 
different signaling pathways. It is tempting to speculate that p62 adapts its activity depending 
on the cell type and the corresponding signals of the upstream regulators in order to act as a 
scaffold. 
 The most unanticipated finding of this study was the interaction of p62 with an increased 
number of RNA Binding Proteins (RBPs). The p62 interactors that corresponded to RBPs 
were almost 30% suggesting a new function of p62 as a hub for RBPs. Although, further 
studies need to be performed to address if the high number of RBPs are protein-protein 
interactions or p62 interacts with complexes of RBPs, these data imply possible roles of p62 
in processes mediated through RBPs such as post-transcriptional gene regulation and RNA 
processing. 
 A fundamental role of RBPs (among others) is the regulation of mRNA stability391,392. The 
mRNAs are packaged into ribonucleoprotein particles (mRNPs). Thus, we investigated if any 
of the precipitated RBPs can directly regulate the stability of FERMT2. Our analyses 
indicated IGF2BP1 as the intermediate player acting in the p62-FERMT2 axis. Moreover, 
previous studies have shown the IGF2BP1 pro-metastatic roles in melanoma393,394. p62 via 
the interaction with IGF2BP1 stabilizes the mRNA of FERMT2 resulting in protein translation. 
p62-mediated regulation linked to the inhibition of mRNA decay, offers therefore an 
additional strategy to sustain FERMT2 levels under situations of high demand for dynamic 
focal adhesions during invasive processes. Loss of p62 (i) prevents IGF2BP1 binding to 
FERMT2, (ii) destabilization and (iii) ultimately decreased invasive capacity of melanoma 
cells.  
VII.DISCUSSION   
 
 
114 
 
 IGF2BP1 acts by preventing miRNA-mediated silencing, especially for the let-7 family395-
399. It is possible that IGF2BP1 by counteracting miRNAs protects the degradation of  
FERMT2 mRNA. Hence, through this mechanism FERMT2 can favor the invasiveness of 
melanoma cells. This is an attractive scenario that needs to be investigated and more 
specifically it would be important to identify the miRNAs that can target FERMT2 and also to 
characterize how FERMT2 promotes invasion. Finally, it was observed that the p62-
IGF2BP1 axis in mRNA decay is broader, as other pro-metastatic factors were regulated 
under similar settings as FERMT2. This implies that FERMT2 and other pro-metastatic 
factors can positively promote invasion under the control of p62-IGF2BP1 axis (Figure 36). 
 Collectively, this PhD thesis underscores the relevance of p62 in melanoma progression 
and metastasis by unraveling a new mechanism of action, where p62 via interaction with 
RBPs can modulate the stability of pro-metastatic factors.  
 
Figure 36: Proposed model of p62 in melanoma progression and metastasis. p62 via interaction with IGF2BP1 
favors the stability of  pro-metastatic factors promoting melanoma invasion. Loss of p62 prevents the binding of 
IGF2BP1 in the mRNA of pro-metastatic factors resulting in their degradation and consequently to inhibition of 
invasion. 
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Conclusions 
 
In the light of the results presented in this PhD thesis we conclude the following: 
 
1. Analyses of publicly available databases (TCGA and the CCLE) demonstrate that p62 is 
not a subject of heterozygous copy number loss in melanoma (as the case for ATG5). 
Instead, p62 was found to be overexpressed in human melanomas, especially at 
metastatic stages of the disease, a feature validated by histopathological analyses. 
 
2. New Genetically Engineered Mouse Models (GEMM) revealed that p62 is dispensable for 
benign nevi, but it ιs required for the  progression and the metastastic potential of 
malignant melanoma. These results distinguish melanoma from other tumor types where 
p62 exerts inhibitory roles via the stroma.  
 
3. Targeted depletion of p62 compromises the proliferation and invasion capabilities of 
cultured melanoma cells, independently on the status of main melanoma-associated 
drivers (BRAF, NRAS, PTEN or p53). 
 
4. Known roles of p62 in the modulation of mTOR, NF-κB, KEAP1-NRF2, MYC and 
mitochondrial respiration were not affected by targeted depletion or overexpression of 
p62 in melanoma cells (also different from other cancer types). 
 
5. In vitro studies and newly generated GEMM revealed that p62 loss or ectopic expression 
does nοt affect autophagosome formation. 
 
6. Transcriptome analyses and subsequent computational studies by GSEA identified 
melanoma-associated metastatic signatures significantly downregulated upon p62 
downregulation. 
 
7. A comprehensive transcriptomic/proteomic/interactomic approach identified downstream 
effectors of p62 implicated in metastasis. In particular, the scaffold protein FERMT2 was 
demonstrated to be a novel risk factor for poor prognosis in melanoma. Accordingly, p62 
and FERMT2 were positively correlated in human melanoma biopsies. 
 
8. Interactome analysis identified a large set of RNA Binding Proteins (RBPs) as new p62 
binding partners. In particular, IGF2BP1 was validated as a p62-interacting factor that 
controls the mRNA half-life of FERMT2.  
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9. p62 was found to oppose mRNA decay of other pro-metastatic factors (i.e. EHMT2, 
CD2AP, TOP2A, FLOT1, OGFOD1, and NCEH1) through the interaction with IGF2BP1.  
 
Collectively, the data presented in this PhD thesis underscore a novel mechanism of p62 
in the stability of pro-metastatic factors via the interaction with RBPs. 
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Conclusiones 
 
 
A la luz de los resultados presentados en esta tesis doctoral, se presentan las siguientes 
conclusiones: 
 
1.  Un detallado análisis mediante bases de datos públicas (TCGA y CCLE) muestra que 
p62, a diferencia de ATG5, no está sujeto a una pérdida parcial del número de copias en 
melanoma. Por el contrario, se encuentra sobre-expresado especialmente en estadíos 
metastásicos.  Este dato se ha podido validar a través de estudios histopatológicos.  . 
2. Los experimentos con nuevos modelos de ratones modificados genéticamente revelan 
que p62 es prescindible en la formación de lesiones melanocíticas benignas (nevi),  y sin 
embargo, es requerido en la iniciación y progresión del melanoma. Esto diferencia al 
melanoma de otros tumores, en los que p62 presenta un efecto inhibidor a través del 
estroma. 
3. La depleción de p62 in vitro compromete la capacidad proliferativa e invasiva de las 
células de melanoma en cultivo, con independencia del estado mutacional en los 
principales oncogenes como BRAF, NRAS, PTEN o p53. 
4. Las funciones ya definidas de p62 en la modulación de factores como mTOR, NF-κB, 
KEAP1-NRF2, y MYC; o de procesos como la respiración mitocondrial,  no se ven 
afectadas tras la supresión o expresión ectópica en células de melanoma. Esto remarca 
nuevamente el papel diferenciador de p62 en melanoma. 
5. Tanto el silenciamiento como la sobreexpresión de p62 (in vitro o in vivo) carecen de 
efecto en la formación de autofagosomas. 
6. Mediante análisis transcripcionales y estudios computacionales GSEA, se han podido 
identificar factores característicos asociados a la metástasis de melanoma cuya 
expresión disminuye al deplecionar p62. 
7. Mediante un análisis global de la transcriptómica, proteómica e interactoma se han 
podido identificar proteínas efectoras de p62 implicadas en metástasis. En particular, 
hemos identificado la proteína de FERMT2 como un nuevo factor de riesgo y prognóstico 
desfavorable en pacientes de melanoma. Además, análisis histopatológicos de biopsias 
humanas confirman una correlación entre los niveles de p62 y FERMT2 . 
8. El análisis del interactoma de p62 permitió identificar un grupo de proteínas de unión a 
RNA (RBPs) como nuevos factores de interacción. Entre ellos, se ha validado cómo 
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IGF2BP1 actua como mediador en la regulación de la vida media del mRNA de FERMT2 
por p62. 
9. Además, la interacción de p62 con IGF2BP1 regula la estabilidad del mRNA de otros 
factores prometastáticos (EHMT2, CD2AP, TOP2A, FLOT1, OGFOD1, y NCEH1).  
 Todos los datos presentados en esta tesis confirman una nueva función de p62 como 
modulador  de los niveles de factores pro-mestastásicos a través de la interacción con 
RBPs. 
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10.1 Supplementary tables and figures  
 
 
Table S1: Systemic therapies approved since 2011 for advanced-stage melanoma.Source:Ref.
35
 
 
 
Table S2: Prominent mechanisms of pathway alterations in BRAF, RAS, NF1 and Triple Wild-Type (WT)   
 subtypes with potential predictive genetic alterations indicated (
1, 2, 3, 4, 5, 6
). Source:Ref.
95
 
 
 
 
 
Mutation Subtypes BRAF RAS NF1 Triple Wild-Type
1MAPK pathway 1BRAFV600,K601
1(N/H/K)RASG12,
G13,Q61
1NF1 LoF mut;(BRAF
non-hot-spot mut)
1KITC OSMIC mut/amp,
PDGFRa amp,KDR
(VEGFR2)amp;rare
COSMIC GNA11 mut,
GNAQ mut
2Cell-cycle pathway
CDKN2Amut/del/h-meth
(60%);2(CDK4
COSMIC mut)
CDKN2A mut/del/h-meth
(70%);CCND1 amp
(10%),2(CDK4
COSMIC mut)
CDKN2A mut/del/h-meth
(70%);RB1 mut
(10%)
CDKN2A mut/del/h-meth
(40%);CCND1 amp
(10%),2CDK4 amp
(15%)
3DNA damage response
and cell death pathways
TP53mut(10%);
3(note:TP53wild-type in
90% of BRAF subtype)
TP53mut(20%) TP53 mut(30%)
3MDM2 amp(15%);
3BCL2 upregulation
4PI3K/Akt pathway
4PTEN mut/del(20%);
4(rareAKT1/3 and
PIK3CA COSMIC mut)
4AKT3 overexpression
(40%);4(rare AKT1/3
and PIK3CA COSMIC
mut)
4AKT3 overexpression
(30%)
4AKT3 overexpression
(20%)
5Epigenetics
5IDH1mut,5(rare EZH2
COSMIC mut);5ARID2
mut (15%)
5IDH1mut,5(rare EZH2
COSMIC mut);5ARID2
mut(15%)
5IDH1mut,5(EZH2 mut);
5ARID2mut(30%)
5IDH1 mut,5(rare EZH2
COSMIC mut)
Telomerase pathway Promoter mut (75%) Promotermut(70%) Promoter mut(85%)
Promoter mut(<10%);
TERT amp(15%)
Other pathways
PD-L1amp, MITF amp,
PPP6C mut(10%)
PPP6C mut(15%)
6High immune infiltration
(pathology)
~30% ~25% ~25% ~40%
Agent Mechanism FDA-approved indications
Targeted therapies
Vemurafenib BRAF inhibitor
As monotherapy and in combination with 
cobimetinib for BRAF
V600E/K
-mutant disease
Dabrafenib BRAF inhibitor
As monotherapy and in combination with 
trametinib for BRAF
V600E/K
-mutant disease
Trametinib MEK inhibitor
As monotherapy and in combination with 
dabrafenib for BRAF
V600E/K
-mutant disease
Cobimetinib MEK inhibitor
In combination with vemurafenib for 
BRAF
V600E/K
-mutant melanoma 
Immunotherapies
Ipilimumab Anti-CTLA-4 antibody
As monotherapy and in combination with 
nivolumab
Pembrolizumab Anti-PD-1 antibody As monotherapy
Nivolumab Anti-PD-1 antibody
In combination with ipilimumab, or as 
monotherapy
Oncolytic viral therapy Talimogene laharparepvec Modified oncolytic herpes virus
Local treatment of unresectable cutaneous, 
subcutaneous, and nodal lesions in patients 
with recurrent melanoma after surgery
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Protein Yeast High eukaryotes Function
Atg1/ULKs + +
Protein kinase involved in the induction of autophagy and possibly in PAS/phagophore 
biogenesis
Atg2 + + Interacts with Atg18/WIPI4; possibly involved in PAS/phagophore biogenesis
Atg3 + +
E2‐like enzyme for the ubiquitin‐like conjugation system that catalyses Atg8/LC3’s l ipidation 
involved in phagophore expansion
Atg4 + +
Cysteine protease processing and delipidating Atg8/LC3, thus involved in phagophore 
expansion
Atg5 + +
Covalently l inked to Atg12, generating the Atg12–Atg5 conjugate involved in phagophore 
expansion
Atg6/beclin 1 + +
Component of various PI(3)K complexes, one of which is involved in induction of autophagy and 
PAS/phagophore biogenesis
Atg7 + +
E1-like enzyme for the two ubiquitin-like conjugation systems, thus involved in phagophore 
expansion
Atg8/LC3s + + Ubiquitin-like protein involved in phagophore expansion
Atg9 + +
Transmembrane protein involved in the induction of autophagy and possibly in 
PAS/phagophore biogenesis
Atg10 + +
E2-like enzyme for the ubiquitin-like conjugation system that mediates the formation of the 
Atg12–Atg5 conjugate involved in phagophore expansion
Atg12 + + Ubiquitin-like protein involved in phagophore expansion
Atg13 + +
Binding partner and regulator of Atg1/ULKs, thus involved in the induction of autophagy and 
possibly PAS/phagophore biogenesis
Atg14 + +
Component of the PI(3)K complex I involved in induction of autophagy and possibly 
PAS/phagophore biogenesis
Atg16 + +
Associates with Atg12–Atg5 to form a large complex, which acts as an E3 ligase to direct LC3 
l ipidation on autophagosomal membranes, and thus involved in phagophore expansion
Atg17/FIP200 + +
Binding partner and regulator of Atg1/ULKs, thus involved in the induction of autophagy and 
possibly PAS/phagophore biogenesis
Atg18/WIPIs + + PtsIns3P-binding proteins possibly involved in PAS/phagophore biogenesis
Atg23 + -
Binding partner and regulator of Atg9, thus involved in the induction of autophagy and possibly 
in PAS/phagophore biogenesis
Atg27 + -
Binding partner and regulator of Atg9, thus involved in the induction of autophagy and possibly 
in PAS/phagophore biogenesis
Atg29 + -
Binding partner and regulator of Atg1, thus involved in the induction of autophagy and possibly 
in PAS/phagophore biogenesis
Atg31 + -
Binding partner and regulator of Atg1, thus involved in the induction of autophagy and possibly 
in PAS/phagophore biogenesis
Atg101 - +
Binding partner and regulator of ULKs, thus involved in the induction of autophagy and possibly 
in PAS/phagophore biogenesis
Ambra1 - +
Regulator of the PI(3)K and Atg1/ULK complexes, and thus involved in the induction of 
autophagy
DFCP1 - +
PtdIns3P-binding proteins concentrating at the omegasome, possibly involved in the induction 
of autophagy
VMP1 - + Transmembrane protein regulating autophagy induction
Vps15/p150 + +
Kinase regulating Vps34/hVps34 activity; component of various PI(3)K complexes, one of which 
is involved in the induction of autophagy and PAS/phagophore biogenesis
Vps34/PtdIns3PKC3 + +
Component of various PI(3)K complexes, one of which is involved in the induction of autophagy 
and PAS/phagophore biogenesis
Table S3: Functions of AuTophaGy (ATG) related proteins during autophagosome formation. Source:Ref.
400
 
 
 
Table S4: p62 main described functions in disease and in different cancer types. 
system Domain 
interaction/ 
Regulation 
cancer/ 
disease 
Functions reference 
HeLa, CD4+ , Jurkat T PB1 p56
lck
 - T cell activation 
228
 
COS ΖΖ PKC-ζ - scaffold 
229
 
HeLa/293 PB1 λ/ι/ζ PKC - endolysosomal trafficking 
230
 
mouse brain TB CYLD - turnover of Lys63-polyubiquitinated proteins 
238
 
patients UBA - 
Paget's 
disease 
mutations in PDB patients 
241
 
HeLa/MEFs LIR LC3 - degradation of polyubiquitinated proteins 
243
 
HeLa/MEFs/HEK293 KIR KEAP1 - activation of NRF2 target genes 
245
 
Atg7::Keap1-Alb double-
mutant mice into p62- and 
Nrf2-null backgrounds 
KIR KEAP1 - oxidative stress 
247
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system Domain 
interaction/ 
Regulation 
cancer/ 
disease 
Functions reference 
HeLa, PC3 and HEK293. 
ATG5 and p62 KO cells 
ZZ R-BiP - ER-residing proteins degradation 
248
 
BMDMs from p62KO mice PB1/TB aPKCs, TRAF6 - osteoclastogenesis 
250
 
p62 KO mice - ERK - obesity 
251
 
HeLa/p62
−/−
, or Atg5
−/−
 MEFs. 
p62
−/−
 mice, and 
Atg7F/F:Mx1:p62
−/−
 mice 
PB1 NBR1 - 
Autophagosomal Degradation of Ubiquitinated 
Substrates 
252
 
HeLa and HEK293/p62 KO 
MEFs 
PB1 STAT5A_ΔE18 - 
autophagic clearance of a non-ubiquitylated 
substrate 
300
 
BMK/TRIM21 KO mice PRYSPRY TRIM2 - redox homeostasis 
401
 
Hela - 
PML 
bodies/ataxin/p
olyUb 
prostate cancer 
Recruitment of Nuclear Polyubiquitinated Proteins to 
PML bodies (Nucleocytoplasmic Shuttling) 
232
 
iBMK ATG5 KO and Beclin1 
KO  cell lines 
- 
defective 
autophagy 
hepatocellular 
carcinomas 
oxidative stress/ DNA damage/ NF-κB/ autophagy 
189
 
Tissue sections of  patients 
with HCC 
- - 
hepatocellular 
carcinomas 
associated with HCC 
258
 
Tissue sections of  patients 
with HCC 
- - 
hepatocellular 
carcinomas 
associated with HCC 
259
 
liver-specific ATG7-deficient 
mice 
KIR KEAP1 
hepatocellular 
carcinomas 
persistent activation of Nrf2 
263
 
Tissue sections of  patients 
with HCC  
- 
hepatocellular 
carcinomas 
In Japanese HCC, NRF2 activation is associated 
with phosphorylation of p62, but not with KEAP1 
status 
402
 
HCC cell lines/Atg7 and NRf2 
liver deficient mice. Human 
biopsies 
KIR KEAP1 
hepatocellular 
carcinomas 
Phosphorylation of p62 and metabolism 
261
 
Tissue sections of  patients - - 
cholangiocarcin
oma with 
chronic liver 
Hyaline Inclusions 
264
 
Tissue sections of  patients - - 
Gastrointestinal 
Carcinomas 
p62 and ubiquitin are highly expressed in gastric, 
colonic, and pancreatic carcinomas 
265
 
Tissue sections of  patients - - 
lung 
adenocarcinom
a 
RF2 and p62 are independent prognostic factors for 
NSCLC 
266
 
Tissue sections of  patients - - 
lung 
adenocarcinom
a 
LC3 and p62 are differentially expressed in NSCLC 
267
 
cell lines/tissue samples - - 
Squamous Cell 
Carcinoma of 
Head and Neck 
resistance to PI3Ki 
268
 
cell lines/tissue samples - - 
oral squamous 
cell carcinomas 
p62 accumulation and resistance to radiation or 
chemotherapy 
269
 
cell lines/tissue samples - - 
Esophageal 
adenocarcinom
as 
Tumors with low LC3B and p62 expression show 
the most aggressive behavior 
270
 
Tissue sections of  patients - - gastric cacner 
Autophagy determined by LC3, Beclin 1, and p62 
significantly correlated with lymph node metastasis, 
vessel invasion, and hepatic metastasis 
271
 
 
Tissue sections of  patients - - colon cancer p62 is overexpressed in 85% of the samples 
272
 
cell lines/Tissue sections of  
patients 
- - breast cancer PDEF stimulates the p62 promoter 
273
 
Tissue sections of  patients - - 
breast cancer 
(TNB) 
p62 in TNBC is associated with a higher risk of 
distant metastases 
274
 
Tissue sections of  patients - - breast cancer 
p62 expression correlated with grade and distant 
metastasis and EGFR, HER2, HER3 and HER4 
275
 
cell lines/Tissue sections of  
patients 
- - prostate cancer high-grade prostatic intraepithelial neoplasia 
279
 
Tissue sections of  patients - - prostate cancer 
p62 expression was related with LC3A and B 
reactivity and also with extraprostatic invasion 
280
 
Tissue sections of  patients - - melanoma 
p62 expression was related with melanoma 
progression 
285
 
cell lines/Tissue sections of  
patients 
- - 
endometrial 
cancer 
High expression of cytoplasmic p62 correlates with 
endometrial cancer 
286
 
Tissue sections of  patients - - ovarian cancer 
p62 expression epithelial ovarian cancer and 
platinum resistance during chemotherapy 
287
 
A498, A704, Caki-2, HK-2, 
RCC4, 769-P, 786-O,UMRC-
2, UMRC-6, and UOK101 
- 
NRF2, NF-kB 
and mTOR 
kidney cancer 
selection pressure to amplify 5q in ccRCC is driven, 
at least partly, by p62 
289
 
Tissue sections of  patients - - 
hepatocellular 
carcinomas 
p62 in Mallory bodies (MBs) and intracellular hyaline 
bodies (IHBs) 
291
 
Tissue sections of  patients - - 
non-alcoholic 
fatty liver 
disease 
suppression of autophagic proteolysis by hepatic 
steatosis is involved in the pathogenesis of NAFLD 
292
 
Tissue sections of  
patients/mouse models  
increased ER 
stress 
non-alcoholic 
fatty liver 
disease 
autophagic flux is impaired in NAFLD human mouse 
NAFLD due to elevated ER stress leading to 
apoptosis 
293
 
Human GSC - - glioblastoma DRAM1 and p62 regulate cell motility and invasion 
288
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system Domain 
interaction/ 
Regulation 
cancer/ 
disease 
Functions reference 
multiforme in GSCs 
Pca - - prostate cancer 
IL-1β can drive Pca progression in an inflammatory 
microenvironment through AR repression and p62 
induction to promote the development and survival 
of androgen independent Pca 
281
 
 
Tissue sections of  
patients/mice xenografts 
- raptor prostate cancer critical mediator for mTOR activation 
282
 
Tissue sections of  
patients/mouse models 
LIR/UBA TRB3 
HCC, colon 
cancer and 
lung cancer 
TRB3 interacts with p62, which causes p62 
deposition and suppresses autophagic/proteasomal 
degradation 
262
 
mouse prostate epithelial cells 
floxed or Cre-deleted Map3k7 
- - prostate cancer 
p62 Regulates the Switch between Apoptotic and 
Necroptotic Cell Death 
284
 
cell lines/p62 KO, PTEN
+/-
 , 
and TRAMP
+
 
- 
mTORC1/c-
Myc 
prostate and 
breast cancer 
p62 levels were reduced in the stroma of several 
tumors and that its loss in the tumor 
microenvironment or stromal fibroblasts resulted in 
increased tumorigenesis of epithelial prostate 
cancer cells 
260
 
HEK 293T/Liver-specific 
TRAF6 KO mice 
TB TRAF6 - 
TRAF6, through its interaction with p62 and 
activation of mTORC1, modulates autophagy and is 
an important mediator in cancer cell proliferation 
339
 
cell lines and PTEN
+/− 
 and 
PTEN
fl/fl
-PBcre mice 
PB1 MEKK3 prostate cancer 
p62 is phosphorylated via a cascade that includes 
MEK3/6 and p38δ and is driven by the PB1-
containing kinase MEKK3 
283
 
cell lines/Ikkα
Δpan
 - - pancreatitis p62 accumulation through IKKα and ATG12L2 
305
 
Atg5,Atg3,Atg7,Atg9,Atg12,At
g14,p62 KO MEFs, 
HaCaT,HEK-
293T,A431,A375. 
UBA Twist1 
MEFs/melanom
a cells 
p62 promotes loss of Ecadherin, cell proliferation 
and migration in vitro, and tumor growth and 
metastasis in vivo through stabilizing Twist1 (EMT 
modulation) 
299
 
Mel624,A375,A431,p62 KO 
MEFs 
- - 
squamous cell 
carcinoma 
cells/melanoma 
cells 
CQ induced NF-kB activation and the expression of 
its target genes HIF-1a, IL-8, Bcl-2 and Bcl-XL 
through the accumulation of autophagosomes, p62, 
and JNK signaling. 
403
 
COS-7 and HeLa cells - - - 
Mammalian cells use a common pathway involving 
ubiquitin and p62 for targeting diverse types of 
substrates for autophagy 
295
 
Atg7
F/F
:Mx1:GFP-LC3 
miceAtg7
F/F
:Mx1:p62
−/−
, 
Atg7
F/F
:Mx1:p62
−/−
:GFP-LC3, 
and Atg7
F/F
:Nes:p62
−/−
 mice 
LIR LC3 
liver injury and 
neurodegenera
tion 
role of homeostatic level of p62, which is regulated 
by autophagy, in controlling intracellular inclusion 
body formation 
298
 
FIP200f/f;MMTV-PyMT and 
p62 KO mice/HEK293, MEFs, 
and MDA-MB-231 cells 
- - 
mammary 
tumor cells 
p62 synergizes with autophagy for tumor growth in 
vivo 
207
 
Flp-in Neuro2a/Atg5-KO mice 
and MEF cells 
- - mefs 
phosphorylation of p62 at S403 regulates 
autophagic clearance of ubiquitinated proteins and 
protein aggregates that are poorly degraded by 
proteasomes 
240
 
Rpt2f/f;Alb-Cre mice/ p62 KO 
MEFs 
KIR KEAP1 
hepatocellular 
carcinomas 
p62 phosphorylation induces expression of 
cytoprotective Nrf2 targets through interaction with 
KEAP1 
404
 
PDAC mouse models based 
on KRAS
G12D
 
- - 
Pancreatic 
Ductal 
Adenocarcinom
a 
Dual feed forward loops of IL-1α/p62 through which 
IKK2/β/NF-κB is activated by Kras
G12D
 in PDAC 
304
 
p62KO, CCSP-rtTA, and 
KRASG12D mice/ p62KO 
MEFs 
- - 
lung 
adenocarcinom
a 
p62 is induced by Ras, activates IKK through 
TRAF6 polyubiquitination, is overexpressed in 
human tumors, and is necessary for survival of 
human lung adenocarcinoma cells 
253
 
Atg7
F/F
:Mx1:Nrf2
−/−
 
/Keap
F/F
:Atg7
F/F
:Alb mice 
KIR KEAP1 MEFs 
p62 accumulation results in hyperactivation of Nrf2 
and delineates unexpected roles of selective 
autophagy in controlling the transcription of cellular 
defence enzyme genes 
199
 
HEK293/A549/p62 KO MEFs - - MEFs K-Ras
V12
 
lack of p62 phosphorylation by cdk1 leads to 
enhanced cell proliferation and tumorigenesis in 
Ras-transformed cells. 
309
 
DA-MB-231, BT-549, MCF-7 
and SKBR-3 
- - 
breast cancer 
stem cells 
p62 promotes MYC mRNA stabilization at the post-
transcriptional level in breast cancer cells 
277
 
p62 KO mice/ hepatic stellate 
cells 
several 
domains 
VDR:RXRα 
dimer  
Loss of p62 in hepatic stellate cells results in 
increased fibrosis, inflammation, and HCC 
308
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Table S5: Common enriched pathways from GSEA ( using KEGG and Reactome) upon p62 knockdown in two 
   melanoma cell lines (SK-Mel-103 and UACC-62) and two different time points (day 3 and day 6). 
 
CELLULAR PATHWAYS 
SK-Mel-103 UACC-62 
 
day 3 day 6 day 3 day 6 
FDR-q 
value 
FDR-q 
value 
FDR-q 
value 
FDR-q 
value 
REACTOME__EGFR DOWNREGULATION 0.0049 0.0408 0.0438 0.0749 
trafficking REACTOME__MEMBRANE TRAFFICKING 0.0565 0.0605 0.2141 0.0870 
KEGG_ENDOCYTOSIS 0.0124 0.0817 0.0608 0.0633 
REACTOME__CELL CYCLE, MITOTIC <0.0001 <0.0001 0.0706 <0.0001 
Cell cycle 
REACTOME__G2_M CHECKPOINTS <0.0001 <0.0001 0.0639 <0.0001 
REACTOME__G1_S TRANSITION <0.0001 <0.0001 0.0685 <0.0001 
REACTOME__CELL CYCLE CHECKPOINTS <0.0001 <0.0001 0.0567 <0.0001 
REACTOME__E2F MEDIATED REGULATION OF DNA 
REPLICATION 
<0.0001 <0.0001 0.0704 <0.0001 
REACTOME__M_G1 TRANSITION 0.0003 <0.0001 0.0621 0.0001 
REACTOME__CYCLIN E ASSOCIATED EVENTS DURING G1_S 
TRANSITION 
0.0134 0.0009 0.0842 0.0492 
REACTOME__DNA REPAIR 0.0036 0.0040 0.2150 0.0012 
DNA damage REACTOME__ACTIVATION OF ATR IN RESPONSE TO 
REPLICATION STRESS 
<0.0001 <0.0001 0.0603 <0.0001 
KEGG_DNA REPLICATION <0.0001 0.0044 0.1642 <0.0001 
DNA 
replication 
REACTOME__ACTIVATION OF THE PRE-REPLICATIVE 
COMPLEX 
<0.0001 <0.0001 0.0962 <0.0001 
REACTOME__DNA REPLICATION <0.0001 <0.0001 0.0691 <0.0001 
REACTOME__DNA REPLICATION PRE-INITIATION <0.0001 <0.0001 0.0626 <0.0001 
REACTOME__ASSEMBLY OF THE PRE-REPLICATIVE COMPLEX 0.0004 <0.0001 0.0649 0.0002 
REACTOME__CHOLESTEROL BIOSYNTHESIS 0.0029 <0.0001 0.0475 0.0029 
Metabolism 
REACTOME__METABOLISM OF CARBOHYDRATES 0.0118 0.0039 0.0768 0.0017 
REACTOME__ORNITHINE METABOLISM 0.0331 0.0084 0.0495 0.1479 
REACTOME__GLUCONEOGENESIS 0.1432 0.0139 0.1369 0.0109 
REACTOME__CITRIC ACID CYCLE (TCA CYCLE) 0.1627 0.0093 0.1833 0.0064 
KEGG_STEROID BIOSYNTHESIS 0.0123 0.0511 0.1142 0.0653 
KEGG_PENTOSE PHOSPHATE PATHWAY 0.0227 0.0589 0.1087 0.0115 
KEGG_CARBON METABOLISM 0.0481 0.0456 0.0877 0.0063 
KEGG_BIOSYNTHESIS OF AMINO ACIDS 0.0830 0.0653 0.1419 0.0320 
KEGG_CITRATE CYCLE (TCA CYCLE) 0.2296 0.0408 0.1633 0.0012 
KEGG_BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 0.2362 0.0679 0.2280 0.0854 
 
*Red indicates upregulation and green downregulation, respectively. Intensity of colours indicates the degree of 
significance (dark: FDR < 0.01; light: 0.01 < FDR < 0.25) 
 
 
 
Table S6: Upregulated proteins detected by iTRAQ analysis upon p62 knockdown in melanoma cell lines. 
 
SK-Mel-103 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
P52926 HMGA2 2.380 Q9Y277 VDAC3 1.383 
Q99856 ARID3A 1.907 Q5U3C3 TMEM164 1.382 
Q8WUH1 CHURC1 1.831 P55786 NPPS 1.381 
P00414 MT-CO3 1.810 Q9BWS9 CHID1 1.380 
A6NKG5 RTL1 1.771 O15156 ZBTB7B 1.380 
Q9HCG8 CWC22 1.745 Q9C0H2 TTYH3 1.377 
Q14643 ITPR1 1.739 P09486 SPARC 1.376 
P15954 COX7C 1.704 P27540 ARNT 1.372 
P33947 KDELR2 1.700 Q5BJD5 TMEM41B 1.370 
Q9NPH3 IL1RAP 1.668 Q5NDL2 EOGT 1.369 
O75909 CCNK 1.657 Q9NRX4 PHPT1 1.368 
O00622 CYR61 1.627 Q8N5L8 RPP25L 1.364 
P43355 MAGEA1 1.624 Q9NW08 POLR3B 1.364 
Q9NUD5 ZCCHC3 1.616 Q8WWI5 SLC44A1 1.363 
P09669 COX6C 1.612 P48060 GLIPR1 1.361 
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SK-Mel-103 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
O75152 ZC3H11A 1.610 Q86TP1 PRUNE 1.359 
P52823 STC1 1.604 P35555 FBN1 1.359 
Q14978 NOLC1 1.596 Q9Y6B6 SAR1B 1.359 
P11047 LAMC1 1.583 Q9BSV6 TSEN34 1.355 
Q92521 PIGB 1.576 O14817 TSPAN4 1.355 
Q96DC9 OTUB2 1.573 Q9UPT9 USP22 1.354 
O14686 MLL2 1.567 P15923 TCF3 1.354 
O60331 PIP5K1C 1.567 Q5T9L3 WLS 1.349 
Q9NWT6 HIF1AN 1.557 Q17RY0 CB4 1.349 
Q13542 EIF4EBP2 1.527 O14802 POLR3A 1.349 
P98153 DGCR2 1.513 P49356 FNTB 1.348 
P24311 COX7B 1.512 O75340 PDCD6 1.347 
Q9H7F0 ATP13A3 1.511 O94887 FARP2 1.347 
P35908 KRT2 1.511 P43251 BTD 1.347 
Q9UI42 CPA4 1.503 O00592 PODXL 1.347 
Q15047 SETDB1 1.501 Q8NDZ6 TMEM161B 1.346 
P05120 SERPINB2 1.485 Q3YEC7 RABL6 1.345 
Q9UBU8 MORF4L1 1.469 Q00534 CDK6 1.345 
P19021 PAM 1.465 O75143 ATG13 1.344 
O95470 SGPL1 1.464 A6NLU0 RFPL4A 1.342 
Q9BPZ3 PAIP2 1.450 P51161 FABP6 1.340 
Q9UPY3 DICER1 1.449 Q7LBR1 CHMP1B 1.338 
O00507 USP9Y 1.447 P32121 ARRB2 1.338 
P04264 KRT1 1.439 P05496 ATP5G1 1.337 
Q7Z3C6 ATG9A 1.437 P10606 COX5B 1.331 
Q5XKK7 FAM219B 1.431 Q9Y2K7 KDM2A 1.331 
Q13277 STX3 1.430 P01583 IL1A 1.330 
O75794 CDC123 1.430 Q9Y2V2 CARHSP1 1.328 
Q8WU17 RNF139 1.428 Q9UMX5 NENF 1.328 
Q9BW60 ELOVL1 1.427 Q9NUM3 SLC39A9 1.327 
O95182 NDUFA7 1.425 Q9H300 PARL 1.327 
Q9BY49 CR 1.421 O95857 TSPAN13 1.323 
O14672 ADAM10 1.420 P20933 AGA 1.323 
P00403 MT-CO2 1.418 O96011 X11B 1.321 
P60520 GABARAPL2 1.416 P17612 PRKACA 1.321 
O95168 NDUFB4 1.411 O14880 MGST3 1.319 
O95835 LATS1 1.405 Q14696 MESDC2 1.316 
P15407 FOSL1 1.405 Q3SXM5 HSDL1 1.315 
Q14980 NUMA1 1.402 Q9H3K6 BOLA2 1.313 
A5PLL7 TMEM189 1.398 Q8N954 CCDC75 1.310 
Q9ULU4 ZMYND8 1.394 P11171 EPB41 1.309 
Q99985 SEMA3C 1.393 Q9H5X1 FAM96A 1.306 
Q5TCZ1 SH3PXD2A 1.392 Q92833 JARID2 1.306 
Q8IVP5 FUNDC1 1.391 Q01432 AMPD3 1.304 
O43731 KDELR3 1.388 Q9NRR4 DROSHA 1.303 
Q5HYI8 RABL3 1.384 P13645 KRT10 1.301 
P20674 COX5A 1.384 Q96AQ6 PBXIP1 1.300 
 
 
 
UACC-62 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
O60315 ZEB2  4.375 Q9NYB0 TERF2IP  1.425 
P30508 HLA-C  3.020 Q6NXE6 ARMC6  1.424 
Q9NUM3 SLC39A9  2.902 Q9UKN8 GTF3C4  1.422 
Q6N063 OGFOD2  2.708 Q9NVV4 MTPAP  1.422 
O14646 CHD1  2.699 Q86XA9 HEATR5A  1.420 
P35908 KRT2  2.662 Q2TAL8 QRICH1  1.408 
Q9H9Q2 COPS7B  2.635 P19022 CDH2  1.407 
P00533 EGFR  2.348 O14734 ACOT8  1.407 
P61244 MAX  2.327 Q6PKG0 LARP1  1.406 
Q7Z5J4 RAI1  2.222 Q69YN2 CWF19L1  1.406 
P04264 KRT1  2.186 Q7Z3J2 C16orf62  1.403 
Q9UII2 ATPIF1  2.163 Q15004 PAF  1.403 
P14136 GFAP  2.147 P05026 ATP1B1  1.400 
P11908 PRPS2  1.943 O14521 SDHD  1.397 
Q7Z569 BRAP  1.917 Q14738 PPP2R5D  1.385 
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SK-Mel-103 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q13131 PRKAA1  1.889 Q16890 TPD52L1  1.383 
Q9Y3D8 TAF9  1.813 O15259 NPHP1  1.381 
Q7Z4Q2 HEATR3  1.801 P23497 SP100  1.379 
Q8NEB9 PIK3C3  1.734 Q9C0C9 UBE2O  1.373 
Q9BRS2 RIOK1  1.723 Q96ME7 ZNF512  1.372 
P52926 HMGA2  1.700 Q8WVJ2 NUDCD2  1.371 
P13645 KRT10  1.698 Q9UNX4 WDR3  1.366 
Q9H5K3 SGK196  1.687 P40937 RFC5  1.366 
Q9BTZ2 DHRS4  1.663 Q96QU8 XPO6  1.366 
P08651 NFIC  1.656 Q92922 SMARCC1  1.359 
P53667 LIMK1  1.637 O75030 MITF  1.359 
Q9NR12 PDLIM7  1.618 Q9Y3A6 TMED5  1.358 
Q9UKJ3 GPATCH8  1.617 P35227 PCGF2  1.358 
Q12933 TRAF2  1.614 Q5T9L3 WLS  1.358 
O00141 SGK1  1.607 Q9NZ32 ACTR10  1.349 
O43264 ZW10  1.597 Q00653 NFKB2  1.348 
O75506 HSBP1  1.596 P49356 FNTB  1.348 
Q6DKK2 TTC19  1.596 Q9Y294 ASF1A  1.348 
Q8NEZ5 FBXO22  1.593 Q15003 NCAPH  1.347 
Q9H074 PAIP1  1.590 Q9NRF9 POLE3  1.345 
Q12986 NFX1  1.580 Q15334 LLGL1  1.345 
P31323 PRKAR2B  1.562 Q9BT09 CNPY3  1.345 
Q9HCG8 CWC22  1.558 Q9UQN3 CHMP2B  1.345 
Q9UJY4 GGA2  1.556 Q5NDL2 EOGT  1.342 
Q9BWE0 REPIN1  1.550 Q04721 NOTCH2  1.342 
Q6ZT12 UBR3  1.537 O75122 CLASP2  1.341 
P57076 C21orf59  1.535 Q9NR50 EIF2B3  1.338 
Q14653 IRF3  1.519 P61421 ATP6V0D1  1.337 
Q9NPH3 IL1RAP  1.513 Q8TAE8 GADD45GIP1  1.335 
P07992 ERCC1  1.512 O00139 KIF2A  1.332 
Q86WA6 BPHL  1.506 O14545 TRAFD1  1.329 
Q9NPH0 ACP6  1.498 Q9BUL8 PDCD10  1.328 
Q7Z4S6 KIF21A  1.489 P15927 RPA2  1.328 
O75439 PMPCB  1.484 P19387 POLR2C  1.325 
Q9Y3T9 NOC2L  1.484 Q15796 SMAD2  1.322 
Q9Y383 LUC7L2  1.482 Q86UU1 PHLDB1  1.321 
Q6BCY4 CYB5R2  1.481 P05121 SERPINE1  1.319 
P49366 DHPS  1.481 Q8TBQ9 TMEM167A  1.319 
Q15843 NEDD8  1.473 Q6ZNE5 ATG14  1.318 
Q5MNZ6 WDR45L  1.471 Q96GC9 VMP1  1.317 
Q6WCQ1 MPRIP  1.469 P62714 PPP2CB  1.312 
Q96AX1 VPS33A  1.466 Q9ULV0 MYO5B  1.309 
Q96GQ7 DDX27  1.464 Q6ZSR9 1 SV 1.309 
P51116 FXR2  1.464 Q92878 RAD50  1.305 
O00499 BIN1  1.464 Q9UKM9 RALY  1.305 
Q8WW12 PCNP  1.455 Q9P253 VPS18  1.304 
P14923 JUP  1.455 Q8N128 FAM177A1  1.303 
P78362 SRPK2  1.452 Q9UHQ4 BCAP29  1.303 
O14976 GAK  1.452 O43765 SGTA  1.303 
O14524 TMEM194A  1.445 O75152 ZC3H11A  1.302 
 
 
 
Table S7: Downregulated proteins detected by iTRAQ analysis upon p62 knockdown in melanoma cell lines. 
 
SK-Mel-103 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q9P2R3 ANKFY1 0.767 Q13287 NMI 0.693 
Q9BQE5 APOL2 0.767 Q9UPN7 PPP6R1 0.689 
Q6ZTR7 FAM92B 0.766 Q9HC78 ZBTB20 0.687 
O43741 PRKAB2 0.766 Q00587 CDC42EP1 0.687 
Q7Z7A4 PXK 0.766 Q9Y3Z3 SAMHD1 0.686 
Q8N8A2 ANKRD44 0.766 Q8IWA0 WDR75 0.685 
P43121 MCAM 0.766 Q14592 ZNF460 0.683 
O94919 ENDOD1 0.766 Q06787 FMR1 0.683 
Q96RT1 ERBB2IP 0.765 Q9UIQ6 LNP 0.682 
Q15050 RRS1 0.764 Q96KB5 PBK 0.682 
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SK-Mel-103 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q31612 HLA-B 0.764 Q9Y2H2 INPP5F 0.682 
Q86VI3 IQGAP3 0.763 Q9NUQ6 SPATS2L 0.681 
Q14534 SQLE 0.763 Q5SSJ5 HP1BP3 0.680 
Q15345 LRRC41 0.762 P23381 WARS 0.680 
Q9Y2U8 LEMD3 0.761 P16298 PPP3CB 0.679 
Q01082 SPTBN1 0.761 P06280 GLA 0.677 
Q9BV79 MECR 0.761 O14519 CDK2AP1 0.677 
Q13393 PLD1 0.760 O95864 FADS2 0.673 
Q8N6L1 KRTCAP2 0.760 P51788 CLCN2 0.673 
Q96IV0 NGLY1 0.759 Q6ICB0 DESI1 0.672 
Q63HN8 RNF213 0.759 P49247 RPIA 0.669 
Q9BRJ6 C7orf50 0.759 Q8IYM9 TRIM22 0.667 
Q99598 TSNAX 0.759 O00562 PITPNM1 0.665 
Q9BXS9 SLC26A6 0.759 Q6PIJ6 FBXO38 0.661 
P12931 SRC 0.759 Q92736 RYR2 0.660 
P07196 NEFL 0.759 P0CW20 LIMS3L 0.658 
A3KMH1 VWA8 0.758 Q9Y653 GPR56 0.658 
Q8TCS8 PNPT1 0.758 P80217 IFI35 0.653 
Q8IWS0 PHF6 0.758 Q53GL7 PARP10 0.653 
Q96EU7 C1GALT1C1 0.758 Q9Y5Q0 FADS3 0.652 
Q9UKL6 PCTP 0.757 O95249 GOSR1 0.651 
Q15025 TNIP1 0.757 Q14202 ZMYM3 0.651 
Q12929 EPS8 0.756 O15554 KCNN4 0.650 
Q12765 SCRN1 0.756 O43493 TGOLN2 0.649 
Q8N543 OGFOD1 0.756 O60307 MAST3 0.648 
O00442 RTCA 0.756 Q5D862 FLG2 0.647 
Q14693 LPIN1 0.756 Q8NHU6 TDRD7 0.645 
Q92743 HTRA1 0.755 Q9NYZ1 FAM18B1 0.643 
P06396 GSN 0.755 Q13438 OS9 0.643 
P43360 MAGEA6 0.755 P30281 CCND3 0.642 
Q9ULT8 HECTD1 0.755 Q9Y5A7 NUB1 0.640 
P46976 GYG1 0.754 P40306 PSMB10 0.640 
P07996 THBS1 0.754 Q9NUG6 PDRG1 0.640 
Q16666 IFI16 0.754 P19474 TRIM21 0.638 
Q8TEL6 TRPC4AP 0.753 P36954 POLR2I 0.634 
P53985 SLC16A1 0.752 Q9H5Z1 DHX35 0.634 
O15234 CASC3 0.751 Q15417 CNN3 0.632 
Q5T3I0 GPATCH4 0.751 P19525 EIF2AK2 0.631 
A0AVT1 UBA6 0.751 Q16222 UAP1 0.630 
Q68D91 MBLAC2 0.751 P32004 L1CAM 0.629 
Q05193 DNM1 0.750 Q5K651 SAMD9 0.628 
Q99538 LGMN 0.749 P11137 MAP2 0.628 
Q9UBV2 SEL1L 0.749 Q9Y3R5 DOY2 0.628 
P51884 LUM 0.748 Q9UBT7 CTNNAL1 0.625 
O00767 SCD 0.747 Q9Y6K5 OAS3 0.625 
Q9BRP1 PDCD2L 0.746 Q9BRQ6 CHCHD6 0.622 
Q9H7E9 C8orf33 0.746 Q96AC1 FERMT2 0.618 
Q03135 CAV1 0.744 Q92624 APPBP2 0.617 
P60602 ROMO1 0.743 P05121 SERPINE1 0.613 
P30460 HLA-B 0.740 O75955 FLOT1 0.610 
Q9BSU1 C16orf70 0.739 Q9Y2Z2 MTO1 0.607 
Q9BTE7 DCUN1D5 0.738 Q9C0D9 EPT1 0.604 
Q8TB03 CXorf38 0.737 Q8IXQ6 PARP9 0.604 
Q8NBM8 PCYOX1L 0.737 Q460N5 PARP14 0.601 
Q9H814 PHAX 0.737 O00418 EEF2K 0.598 
Q9NWS0 PIH1D1 0.735 O75886 STAM2 0.596 
O43592 XPOT 0.735 Q9NQ25 SLAMF7 0.594 
P69905 HBA1 0.734 Q9NY97 B3GNT2 0.589 
Q9NZR1 TMOD2 0.733 Q96EN8 MOCOS 0.588 
A1X283 SH3PXD2B 0.733 P06899 HIST1H2BJ 0.587 
Q9H6X4 TMEM134 0.733 Q8TDB6 DTX3L 0.582 
O00472 ELL2 0.732 P08138 NGFR 0.582 
Q8NC69 KCTD6 0.732 Q15800 MSMO1 0.578 
Q15631 TSN 0.730 Q99541 PLIN2 0.578 
Q9Y5K6 CD2AP 0.729 O60814 HIST1H2BK 0.576 
P09455 RBP1 0.729 Q9HCJ6 VAT1L 0.575 
P28838 LAP3 0.729 P30508 HLA-C 0.569 
Q96S19 C16orf13 0.728 Q14699 RFTN1 0.562 
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SK-Mel-103 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q96EP0 RNF31 0.728 P42574 CASP3 0.562 
P38159 RBMX 0.728 Q8IYT2 FTSJD1 0.560 
Q96D46 NMD3 0.728 Q8N9M5 TMEM102 0.560 
Q9H6R7 C2orf44 0.725 P48723 HSPA13 0.559 
Q8WWB7 C1orf85 0.724 Q6PIU2 NCEH1 0.551 
Q96BN2 TADA1 0.723 Q9BYK8 PRIC285 0.541 
A0JNW5 UHRF1BP1L 0.721 Q9UMR5 PPT2 0.541 
O14763 TNFRSF10B 0.721 Q9Y2V0 C15orf41 0.535 
Q49A26 GLYR1 0.719 Q9NUL5 C19orf66 0.531 
Q7L5N7 LPCAT2 0.719 Q13501 SQSTM1 0.525 
Q9P0R6 GSKIP 0.719 O94856 NFASC 0.521 
Q6P996 PDXDC1 0.719 O95786 DDX58 0.519 
P55265 ADAR 0.717 O14933 UBE2L6 0.519 
P23229 ITGA6 0.716 P61960 UFM1 0.506 
Q03518 TAP1 0.716 Q5QJ74 TBCEL 0.501 
Q9UDT6 CLIP2 0.716 P42224 STAT1 0.492 
Q13938 CAPS 0.714 P05161 ISG15 0.486 
Q8N2F6 ARMC10 0.713 P41226 UBA7 0.485 
O95365 ZBTB7A 0.713 Q9BPU6 DPYSL5 0.481 
Q96JQ2 CLMN 0.711 P52630 STAT2 0.474 
O00635 TRIM38 0.710 P35610 SOAT1 0.474 
Q9H330 TMEM245 0.710 Q7Z417 NUFIP2 0.463 
Q15785 TOMM34 0.708 Q9P2E3 ZNFX1 0.460 
Q2VPB7 AP5B1 0.708 P32455 GBP1 0.456 
Q08AF3 SLFN5 0.706 Q13325 IFIT5 0.446 
Q9H0P0 NT5C3 0.705 P62805 HIST1H4A 0.424 
Q96JG6 CCDC132 0.704 Q8TCB0 IFI44 0.383 
Q9Y3C0 CCDC53 0.704 Q8N4J0 C9orf41 0.382 
Q96MU7 YTHDC1 0.702 P61587 RND3 0.374 
P00750 PLAT 0.701 O15162 PLSCR1 0.318 
P61769 B2M 0.700 O14879 IFIT3 0.267 
O95210 STBD1 0.700 Q9NQC7 CYLD 0.258 
Q9BZQ8 FAM129A 0.698 P09914 IFIT1 0.217 
Q9BTE3 MCMBP 0.697 Q86UL8 MAGI2 0.210 
P16190 HLA-A 0.696 P09913 IFIT2 0.118 
P09884 POLA1 0.694 
   
 
UACC-62 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q86U38 NOP9  0.768 P82914 MRPS15  0.714 
P53634 CTSC  0.767 Q7Z417 NUFIP2  0.712 
P04271 S100B  0.767 O43592 XPOT  0.712 
P33897 ABCD1  0.767 Q9Y653 GPR56  0.710 
P01011 SERPINA3  0.765 O43719 HTATSF1  0.709 
O15541 RNF113A  0.764 P27338 MAOB  0.709 
P61604 HS1  0.764 P37840 SNCA  0.703 
Q8NHU6 TDRD7  0.764 P16403 HIST1H1C  0.703 
Q9BX68 HINT2  0.764 Q9UBD5 ORC3  0.701 
P05556 ITGB1  0.763 Q15050 RRS1  0.700 
P34059 GALNS  0.763 P20338 RAB4A  0.699 
Q9UBB9 TFIP11  0.762 Q96RF0 SNX18  0.699 
Q8N511 TMEM199  0.762 Q8WTV0 SCARB1  0.697 
Q9NZJ4 SACS  0.761 Q9Y250 LZTS1  0.691 
O95070 YIF1A  0.761 O95249 GOSR1  0.691 
Q9Y5U9 IER3IP1  0.761 O00762 UBE2C  0.689 
Q969X5 ERGIC1  0.759 Q9H2J7 SLC6A15  0.686 
P57088 TMEM33  0.759 Q03154 ACY1  0.683 
P41240 CSK  0.757 Q9BW72 HIGD2A  0.683 
O95149 SNUPN  0.757 Q6PIU2 NCEH1  0.683 
Q9UJW0 DCTN4  0.757 Q96PU8 QKI  0.681 
Q8WUA2 PPIL4  0.756 Q9NVR2 INTS10  0.681 
Q9NW82 WDR70  0.756 P53675 CLTCL1  0.679 
Q8WW59 SPRYD4  0.755 P46976 GYG1  0.677 
Q7Z333 SETX  0.755 Q9Y6W5 WASF2  0.675 
Q96D46 NMD3  0.754 P23229 ITGA6  0.672 
Q96J42 TXNDC15  0.754 Q99538 LGMN  0.670 
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UACC-62 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (shp62/shcon) Accession Gene name log2FC  (shp62/shcon) 
Q9Y606 PUS1  0.754 Q14146 URB2  0.663 
Q15005 SPCS2  0.753 Q6P996 PDXDC1  0.663 
Q969E4 TCEAL3  0.753 O60443 DFNA5  0.661 
O14773 TPP1  0.753 Q9Y5B9 SUPT16H  0.655 
Q86WB0 ZC3HC1  0.752 Q9BV36 MLPH  0.654 
Q6RW13 AGTRAP  0.751 Q6P2C8 MED27  0.650 
P61513 RPL37A  0.750 Q9H4A3 WNK1  0.649 
Q15785 TOMM34  0.749 Q9UBM4 OPTC  0.644 
Q7Z739 YTHDF3  0.749 Q9C0D9 EPT1  0.641 
O43847 NRD1  0.747 Q9NRL2 BAZ1A  0.641 
Q92743 HTRA1  0.747 Q9NVN8 GNL3L  0.640 
Q9BY43 CHMP4A  0.747 Q16222 UAP1  0.636 
Q15631 TSN  0.746 Q6ICB0 DESI1  0.631 
Q86VU5 COMTD1  0.746 P55795 HNRNPH2  0.630 
Q6L8Q7 PDE12  0.745 P49247 RPIA  0.630 
Q9H6W3 NO66  0.743 Q9H0W9 C11orf54  0.629 
Q8N131 TMEM123  0.742 Q9H814 PHAX  0.627 
Q9Y3A2 UTP11L  0.742 Q8WU79 SMAP2  0.623 
P15586 GNS  0.741 P49711 CTCF  0.623 
O43776 NARS  0.740 Q96AC1 FERMT2  0.616 
P62341 SELT  0.740 P11388 TOP2A  0.615 
Q8N6V9 TEX9  0.739 Q96E52 OMA1  0.610 
O14497 ARID1A  0.737 Q8NB46 ANKRD52  0.603 
Q12765 SCRN1  0.736 P27694 RPA1  0.594 
Q9P2Q2 FRMD4A  0.735 P33552 CKS2  0.592 
P43360 MAGEA6  0.729 Q9BUP3 HTATIP2  0.588 
Q9P1U0 ZNRD1  0.727 Q9UDW1 UQCR10  0.585 
Q96SZ5 ADO  0.726 Q96KQ7 EHMT2  0.583 
Q96GQ5 C16orf58  0.726 P51692 STAT5B  0.583 
Q9BRX2 LO  0.726 Q5TAQ9 DCAF8  0.567 
P53367 ARFIP1  0.726 Q330K2 NDUFAF6  0.563 
Q5J8M3 EMC4  0.725 Q9UNN8 PROCR  0.555 
O60518 RANBP6  0.725 Q9Y5Q0 FADS3  0.527 
Q99598 TSNAX  0.724 Q14739 LBR  0.519 
Q9BU61 NDUFAF3  0.723 P42574 CASP3  0.498 
O60671 RAD1  0.723 Q13510 ASAH1  0.492 
Q9H8Y8 GORASP2  0.723 Q8N2G6 ZCCHC24  0.476 
P61163 ACTR1A  0.722 P48426 PIP4K2A  0.470 
Q86YV9 HPS6  0.720 Q8TDX7 NEK7  0.459 
O43172 PRPF4  0.719 P48723 HSPA13  0.456 
P02794 FTH1  0.718 Q8N4J0 C9orf41  0.451 
Q9Y6Y0 IVNS1ABP  0.717 P24043 LAMA2  0.450 
P82675 MRPS5  0.717 Q6GQQ9 OTUD7B  0.424 
Q5VWP3 MLIP  0.717 P50443 SLC26A2  0.397 
P51608 MECP2  0.714 Q13501 SQSTM1  0.284 
 
 
 
Table S8: Upregulated proteins detected by iTRAQ analysis upon ATG5 knockdown in melanoma cell lines. 
 
SK-Mel-103 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
Q92581-3 SLC9A6 3.006 H3BPR7 TYRO3 1.410 
Q8TD22 SFXN5 2.028 A6NM62 LRRC53 1.407 
G3V0H6 NARG2 2.003 B4DGV4 RYR2 1.403 
Q6ZTA4-2 TRIM67 1.996 Q8NI37 PPTC7 1.397 
Q9UBN7-2 HDAC6 1.901 O15504 NUPL2 1.390 
A8MZ59 LEUTX 1.859 O00429-4 DNM1L 1.382 
Q9BV19 C1orf50 1.745 B4E3L6 D2HGDH 1.381 
Q92871 PMM1 1.693 Q9NUH8-2 TMEM14B 1.374 
P35527 KRT9 1.689 P53675-2 CLTCL1 1.371 
Q8WXG9-3 GPR98 1.651 C9JZR9 SLC30A6 1.370 
Q8NBP0-2 TTC13 1.641 P02533 KRT14 1.367 
F8WEM9 ZNF655 1.592 Q9Y248 GINS2 1.364 
D6RJA4 AMOTL2 1.586 P60660 MYL6 1.364 
Q9NZ71-5 RTEL1 1.584 E9PPF2 TYK2 1.363 
F8W036 2 1.583 P20749 BCL3 1.361 
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SK-Mel-103 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
Q9H2H9 SLC38A1 1.570 Q9Y3Y2-4 CHTOP 1.361 
Q68DH5 LMBRD2 1.541 Q9BYC5-3 FUT8 1.354 
Q9BWW5 SSDP4 1.528 P10412 HIST1H1E 1.350 
C9J9V6 NME6 1.501 H3BTL1 MAP1LC3B 1.348 
Q8WWB7-2 C1orf85 1.498 Q96BR1-2 SGK3 1.347 
Q9NS91 RAD18 1.493 Q9NVN3-3 RIC8B 1.342 
Q16384 SSX1 1.491 E7ET89 DTX2 1.341 
P33552 CKS2 1.488 Q8NB46 ANKRD52 1.336 
O15069 NACAD 1.488 B4DJJ3 TAPT1 1.334 
D3DWC4 TMEM23 1.488 Q05D32-2 CTDSPL2 1.331 
Q71DI3 HIST2H3A 1.487 O43854-2 EDIL3 1.331 
A6NDU8 C5orf51 1.480 Q9NSY1 BMP2K 1.324 
Q7L0J3-2 SV2A 1.474 Q9BZM4 ULBP3 1.324 
Q86SX6 GLRX5 1.460 Q9Y233 PDE10A 1.322 
A8MUN2 APOB 1.439 Q9NZD2 GLTP 1.321 
P07585 DCN 1.438 Q96HY7 DHTKD1 1.316 
Q9NQG6 SMCR7L 1.433 E9PP15 LRP8 1.312 
C9JEZ4 CDC42EP3 1.433 O60725 ICMT 1.311 
C9J5B3 KCTD20 1.432 Q9NP73-2 ALG13 1.311 
Q8IWT0 ZBTB8OS 1.427 H3BVI5 RHOT2 1.311 
Q96IV0-3 NGLY1 1.425 Q9NR31 SAR1A 1.308 
H7C0U0 PARL 1.423 Q12913 PTPRJ 1.306 
P12259 F5 1.419 Q9BV23 ABHD6 1.304 
Q96S97 MYADM 1.414 Q96DX7 TRIM44 1.302 
Q86UT6-2 NLRX1 1.411 P62745 RHOB 1.300 
 
UACC-62 
UPREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
P35527 KRT9 5.091 P51397 DAP 1.403 
Q9UQL6 HDAC5 2.742 P51512 MMP16 1.402 
P02533 KRT14 2.333 P08582-2 MFI2 1.398 
P14859-3 POU2F1 2.283 F8VUA5 RAB5B 1.397 
Q15366-6 PCBP2 2.001 H0YL93 FMN1 1.392 
Q95IE3 HLA-DRB1 1.922 E9PPF2 TYK2 1.391 
P59542 TAS2R19 1.915 P16402 HIST1H1D 1.385 
P04264 KRT1 1.895 A5A3E0 POTEF 1.380 
Q4G0P3-2 HYDIN 1.838 Q9HCE3 ZNF532 1.375 
B1AZU4 HLA-F 1.815 Q08AT0 SGCZ 1.372 
E7ENQ1 MAP4K4 1.805 Q9BWW5 SSDP4 1.370 
Q4VC05 BCL7A 1.794 Q12769-3 NUP160 1.368 
O14893-2 GEMIN2 1.787 Q9NQS3 PVRL3 1.367 
Q76I76 SSH2 1.744 A8MXF6 RABL2B 1.360 
Q9BQQ3 GORASP1 1.690 Q9NRF2-2 SH2B1 1.359 
Q13015 MLLT11 1.655 H7C1Q1 2 1.357 
Q9Y248 GINS2 1.650 P17535 JUND 1.354 
Q9UPN3 MACF1 1.631 P25440 BRD2 1.341 
F8WEM9 ZNF655 1.614 P17066 HSPA6 1.339 
K7EJS5 MFSD12 1.564 Q9UMN6 WBP7 1.337 
P61601 NCALD 1.549 E9PDF6 MYO1B 1.336 
Q6T4R5-4 NHS 1.547 Q9NTU7 CBLN4 1.333 
O00329 PIK3CD 1.542 Q7L7V1-2 DHX32 1.332 
P13284 IFI30 1.536 Q8TD30 GPT2 1.329 
D6RGY8 YIPF3 1.524 H0Y853 WDR52 1.327 
H7C4F8 CD86 1.518 Q9BVS4-2 RIOK2 1.325 
C4AMC7 WASH3P 1.492 O43854-2 EDIL3 1.324 
O76061 STC2 1.468 Q6NTF9 RHBDD2 1.322 
M0QX48 EPHX3 1.464 E9PSI1 TM9SF1 1.313 
Q9Y2S2-2 CRYL1 1.451 P12074 COX6A1 1.312 
Q9HCJ6 VAT1L 1.448 Q9NVH2-4 INTS7 1.311 
C9J9D7 SIAH2 1.445 O60218 AKR1B10 1.308 
Q2MD36 MBD4 1.442 P17028 ZNF24 1.307 
P58107 EPPK1 1.437 Q7Z7G8-2 VPS13B 1.303 
G3V217 CCDC63 1.405 Q9UGU5 HMGXB4 1.302 
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Table S9: Downregulated proteins detected by iTRAQ analysis upon ATG5 knockdown in melanoma cell lines. 
 
SK-Mel-103 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
Q5JTQ6 CTNNAL1 0.457 E9PSH3 TSPAN4 0.703 
B4E0J7 RRN3 0.466 O43194 GPR39 0.714 
C9J473 MPV17 0.485 Q8TBN0-2 RAB3IL1 0.714 
E5RFF3 TRPS1 0.525 O14556 GAPDHS 0.717 
E7ER97 ASMTL 0.537 Q96AC1 FERMT2 0.717 
Q9H1Y0-2 ATG5 0.554 Q9NZJ4 SACS 0.718 
Q13495-4 MAMLD1 0.565 P05120 SERPINB2 0.720 
B7ZKP8 UBXN2A 0.568 Q14676-3 MDC1 0.720 
O94817 ATG12 0.577 Q16739 UGCG 0.722 
E7ENQ1 MAP4K4 0.579 H0Y9R9 IDUA 0.723 
Q9H469 FBXL15 0.594 E7EMN6 PPP1R2 0.728 
Q8N3X1 FNBP4 0.607 P15104 GLUL 0.728 
Q8IYT2 FTSJD1 0.608 Q9P0S9 TMEM14C 0.729 
Q8IYQ7 THNSL1 0.609 D3DR31 IFIT1 0.731 
Q58FG1 HSP90AA4P 0.623 E5RG63 PSEN2 0.735 
Q15173-2 PPP2R5B 0.628 P12532 CKMT1A 0.736 
Q8TCZ2-3 CD99L2 0.632 Q9Y2I1 NISCH 0.737 
Q8NHU2-4 C20orf26 0.635 Q15366-6 PCBP2 0.740 
P09913 IFIT2 0.637 Q5SW96 LDLRAP1 0.740 
Q99675 CGRRF1 0.639 Q5T0D9 TPRG1L 0.743 
O14578-3 CIT 0.640 P53985 SLC16A1 0.743 
P12074 COX6A1 0.641 C9J0J0 CCDC126 0.748 
P38432 COIL 0.641 Q9H7E2-2 TDRD3 0.749 
A8MX49 PPM1F 0.641 B3KRF7 ZKSCAN1 0.749 
O95785 WIZ 0.642 P58511 SMIM11 0.749 
I3L196 ARL16 0.644 D6RC69 CEP120 0.749 
Q01518-2 CAP1 0.645 Q9BYT5 KRTAP2-2 0.750 
E9PCV0 GUSB 0.649 O75600 GCAT 0.750 
J3KN27 FBRSL1 0.650 H7C2M2 POLM 0.750 
B4E2D5 SUPT20H 0.652 P25445-6 FAS 0.750 
Q9UI10-3 EIF2B4 0.653 Q9UPS8-2 ANKRD26 0.750 
P58107 EPPK1 0.653 Q9UNW1 MINPP1 0.751 
Q9UJU3-2 ZNF112 0.654 B8ZZR0 CLK1 0.753 
F5GYA1 CAPRIN2 0.658 P02790 HPX 0.754 
Q96SI9-2 STRBP 0.661 K7EIN1 WBP2 0.754 
K7ERE1 4 0.662 Q8IYM9-2 TRIM22 0.755 
Q9P1Y5 CAMSAP3 0.667 Q3MIP1 ITPRIPL2 0.755 
Q58FF3 HSP90B2P 0.669 Q6UWH4-3 FAM198B 0.755 
H3BRL3 UBFD1 0.670 Q02156 PRKCE 0.758 
Q08345 DDR1 0.672 O60502 MGEA5 0.759 
Q676U5-3 ATG16L1 0.675 C9JKF1 SAMD9 0.759 
F5H4R4 DCP1B 0.677 G3V1U5 GOLT1B 0.759 
Q8WWQ0 PHIP 0.679 C9JMQ9 KLHL24 0.759 
Q8N1W1-4 ARHGEF28 0.679 B4DN24 FANCL 0.760 
Q8NDV7-2 TNRC6A 0.679 Q6GYQ0-4 RALGAPA1 0.760 
K7EJS5 MFSD12 0.680 Q12959-4 DLG1 0.760 
P43356 MAGEA2 0.681 O14933 UBE2L6 0.760 
G3V1V8 MYL2 0.681 Q9NQL2 RRAGD 0.760 
H7BXR5 SNX29 0.681 Q9Y2F5 KIAA0947 0.762 
Q8IVT1 PGPEP1 0.685 Q9NR16-2 CD163L1 0.764 
Q9Y6V0-2 PCLO 0.688 Q9H2G4 TSPYL2 0.764 
Q5EBL4-2 RILPL1 0.688 P82909 MRPS36 0.764 
P54646 PRKAA2 0.694 Q15434 RBMS2 0.764 
Q15651 HMGN3 0.694 Q9Y3Q8 TSC22D4 0.765 
Q9Y6R7 FCGBP 0.696 Q6P1X5 TAF2 0.766 
Q9Y289 SLC5A6 0.700 Q96EH3 MALSU1 0.769 
Q96DX8 RTP4 0.702 
   
 
UACC-62 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
Q330K2-2 NDUFAF6 0.413 Q9Y3R5-2 DOPEY2 0.715 
E9PBG7 CAMK2D 0.415 Q9NQN1 OR2S2 0.715 
Q0VDD8-3 DNAH14 0.433 Q9NQA3 WASH6P 0.718 
C9J9V6 NME6 0.475 Q8N1W1-4 ARHGEF28 0.719 
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UACC-62 
DOWNREGULATED PROTEINS 
Accession Gene name log2FC  (siATG5/shcon) Accession Gene name log2FC  (siATG5/shcon) 
O94817 ATG12 0.496 F5H5W6 DDX58 0.720 
Q8TD22 SFXN5 0.497 Q9H4E5-2 RHOJ 0.721 
Q13495-4 MAMLD1 0.532 Q5XG87 PAPD7 0.724 
Q9UGJ0-2 PRKAG2 0.535 O14578-3 CIT 0.724 
K7EQ93 UNK 0.540 A8MU44 HOOK1 0.725 
K7ES52 TK1 0.596 P57088 TMEM33 0.725 
Q5T0D9 TPRG1L 0.599 P07108 DBI 0.727 
Q9ULP9-2 TBC1D24 0.615 Q9Y5N5-2 N6AMT1 0.728 
Q9H1Y0-2 ATG5 0.615 Q14676-3 MDC1 0.729 
Q676U5-3 ATG16L1 0.616 D6RD42 MLIP 0.730 
B3KU92 LOC90826 0.617 P78358-2 CTAG1A 0.731 
Q8N9M5 TMEM102 0.626 Q08345 DDR1 0.731 
Q9Y289 SLC5A6 0.627 Q9UBX3 SLC25A10 0.731 
K7EIN1 WBP2 0.631 Q9NY84-3 VNN3 0.732 
P07602-2 PSAP 0.639 O43194 GPR39 0.737 
Q6N069 NAA16 0.640 Q8NHU2-4 C20orf26 0.739 
Q13424 SNTA1 0.648 Q6N075 MFSD5 0.740 
Q6EEV4-2 POLR2M 0.654 Q8IYQ7 THNSL1 0.741 
A0JNW5 UHRF1BP1L 0.656 Q9H334-2 FOXP1 0.743 
Q8IYT2 FTSJD1 0.658 Q07020 RPL18 0.743 
H0Y7G7 HLA-DPB1 0.660 O75487 GPC4 0.745 
Q13433 SLC39A6 0.664 Q9P086 MED11 0.746 
Q86V85 GPR180 0.670 Q9UIL1-3 SCOC 0.748 
Q9NPG3-2 UBN1 0.679 A6NN40 SHROOM1 0.750 
Q96SI9-2 STRBP 0.685 H0YLN8 TRPM7 0.750 
Q92994 BRF1 0.686 F5H050 DYNC1I1 0.752 
K7ENR6 PSMG2 0.689 Q96T88 UHRF1 0.754 
Q9BZG9-3 LYNX1 0.689 B4DWK3 TFAP2C 0.758 
Q9NQ34 TMEM9B 0.692 K7ENE2 GID4 0.758 
O14879 IFIT3 0.695 F5H5D4 PAAF1 0.758 
Q8N2Y8 RUSC2 0.696 B1AHG3 PRR5 0.759 
Q69YL0 4 0.698 Q9H617 TMEM164 0.759 
Q9ULX9-2 MAFF 0.700 J3KST3 GLTPD1 0.760 
H3BRL3 UBFD1 0.701 F8W036 2 0.760 
Q9H0F6-2 SHARPIN 0.703 E7EMN6 PPP1R2 0.761 
B7ZKP8 UBXN2A 0.704 D3DWC4 TMEM23 0.762 
Q99808 SLC29A1 0.708 Q86X10-2 RALGAPB 0.763 
E9PB91 TIMM23 0.709 B4DXS1 NMT2 0.763 
Q8NDV7-2 TNRC6A 0.709 C9JSE3 FANCG 0.764 
Q6PID8-2 KLHDC10 0.710 K7EK07 H3F3B 0.764 
J3KPS2 FAM83H 0.710 K7ERE1 4 0.767 
Q96HN2-3 AHCYL2 0.712 Q9Y385 UBE2J1 0.768 
E9PCV0 GUSB 0.713 P05161 ISG15 0.769 
F6RY50 SIPA1 0.713 H3BPT0 CMC2 0.769 
P53794 SLC5A3 0.714 
   
 
 
 
 
Table S10. Quantification of FERMT2 immunostaining in tissue microarrays of melanocytic tumors. 
 
Melanocytic tumors 
FERMT2 negative 
n (%) 
FERMT2 low 
n (%) 
FERMT2 high 
n (%) 
Total 
n 
Dermal nevi 28 (82.4%) 5 (14.7%) 1 (2.9%) 34 
VGP melanomas 20 (24.4%) 24 (29.3%) 31 (37.8%) 82 
Cutaneous metastases 9 (27.3%) 8 (24.2%) 16 (48.5%) 33 
Lymph node metastases 7 (25.0%) 14 (50.0%) 7 (25.0%) 28 
Visceral metastases 4 (18.2%) 13 (59.1%) 5 (22.7%) 22 
Total 68 (34.2%) 64 (32.2%) 60 (30.2%) 199 
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Table S11. Clinical and histological data of melanoma cases included in the study of FERMT2 immunostaining 
(total n=82). 
 
Age (years) 25–89 (mean 58.88) 
Gender n (%) 
Female 43 (52.44%) 
Male 39 (47.56%) 
Region of primary melanoma n (%) 
Trunk 24 (29.27%) 
Limbs 27 (32.93 %) 
Hands and feet 16 (19.51%) 
Head and neck 12 (14.63%) 
NA 3 (3.66%) 
Histological type of melanoma n (%) 
Superficial spreading 40 (48.78%) 
Nodular 17 (20.73%) 
Acral 19 (23.17%) 
Lentigo maligna 4 (4.88%) 
NA 2 (2.44%) 
Breslow thickness (mm) 0.4–19 (mean 3.68) 
Clark level n (%) 
I 0 (0%) 
II 3 (3.66%) 
III 32 (39.02%) 
IV 33 (40.24%) 
V 10 (12.20%) 
NA 4 (4.88%) 
Ulceration status n (%) 
Not ulcerated 44 (53.66%) 
Ulcerated 37 (45.12%) 
NA 1 (1.22%) 
                         (Abbreviation; NA=not available)  
 
 
 
 
Table S12. Univariate and multivariate survival analyses using the Cox proportional hazards model in patients 
with melanoma according to FERMT2 immunostaining. 
 
Characteristics Univariate analysis Multivariate analysis 
Disease free survival HR 95% CI p value HR 95% CI p-value 
FERMT2 high expression 1.945 1.107-3.417 0.021* 1.845 1.040-3.272 0.036* 
Breslow - - - 1.085 0.992-1.187 0.073 
Distant metastasis free survival HR 95% CI p value HR 95% CI p-value 
FERMT2 high expression 2.541 1.260-5.126 0.009* 2.357 1.163-4.774 0.017* 
Breslow - - - 1.102 0.981-1.238 0.100 
Overall survival HR 95% CI p value HR 95% CI p-value 
FERMT2 high expression 1.882 0.986-3.593 0.055 1.716 0.895-3.288 0.104 
Breslow - - - 1.157 1.043-1.283 0.006* 
                            (HR, hazard ratio. CI, confidence interval. *Significantly different) 
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Table S13: p62 interactors with the corresponding number of peptides identified by co-IP followed by Mass 
spectrometry in melanoma cell lines. 
 
Gene Name p62_CytoREP_01 p62_CytoREP_02 p62_CytoREP_03 p62_NucREP_01 p62_NucREP_02 p62_NucREP_03 
SQSTM1 175 176 169 45 52 46 
DARS2 175 171 157 63 58 63 
UTRN 84 80 79 
   
ZC3H4 76 65 67 19 18 20 
AZI1 73 70 67 
   
RBM12B 62 58 59 53 50 54 
ATAD3A 62 58 57 42 40 38 
ARHGEF18 57 60 48 
   
BCKDK 52 49 45 4 3 5 
TUBB 50 55 50 8 6 4 
GBAS 45 48 45 1 2 2 
TUBB4B 43 42 42 6 4 3 
RAPGEF2 42 41 39 
   
TAOK1 41 45 41 
   
NIPSNAP1 40 35 39 
   
FN1 39 47 42 12 11 10 
TUBB2A 38 41 39 6 5 4 
CEP350 34 29 29 
   
AHNAK 33 36 34 18 21 22 
ATAD3B 32 31 31 22 22 19 
PCNT 30 23 29 
   
TUBA1B 30 34 30 4 5 3 
HADHB 26 28 26 3 4 3 
SOD3 25 26 24 1 
  
TUBA1C 25 31 29 4 5 3 
CDK5RAP2 24 21 30 
   
SLC25A4 24 28 25 57 59 57 
GOLGB1 22 19 20 
   
ROBO1 22 26 27 
   
MYO1B 22 24 27 23 26 25 
WDR82 20 22 19 10 9 12 
SMG1 18 12 15 
   
RAI14 18 11 17 1 
 
1 
TNC 16 19 19 
  
1 
GAPVD1 15 12 14 
   
PRRC2A 15 12 14 
   
OFD1 15 18 12 
   
SLC25A3 15 17 15 30 29 29 
TJP1 14 16 11 
 
1 1 
RRBP1 14 20 15 24 18 20 
HNRNPUL1 14 10 11 12 14 15 
MIB1 14 14 16 
   
MYO5A 13 14 12 
   
PRKCI 12 12 11 
   
MTDH 12 15 12 18 15 15 
FGFR1OP 12 10 12 
   
CD44 12 10 9 
   
AIFM1 12 13 12 14 16 16 
PIBF1 12 11 12 
   
POLRMT 11 7 10 
   
SPATA20 11 11 10 
   
PGAM5 11 9 12 6 6 6 
CEP290 11 10 12 
   
CCDC77 11 14 15 
   
SNTB1 10 10 10 
   
GLG1 10 8 10 
   
CHCHD3 10 8 9 2 3 3 
ATP5B 10 11 7 22 16 16 
PARD3 9 7 9 
   
MOGS 9 10 8 7 7 6 
EPDR1 9 9 10 
   
CNST 9 9 9 
   
IQGAP1 8 9 7 1 
 
1 
MAGI1 8 8 6 
   
CTHRC1 8 8 7 
   
ATP5A1 8 8 8 26 24 22 
SNTB2 7 7 6 
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Gene Name p62_CytoREP_01 p62_CytoREP_02 p62_CytoREP_03 p62_NucREP_01 p62_NucREP_02 p62_NucREP_03 
IGF2BP3 7 4 7 
   
LLGL1 7 6 6 
   
MPRIP 7 7 5 1 1 2 
OSBPL8 7 6 7 
   
FRYL 7 6 8 
   
IQSEC1 6 3 3 
   
TPX2 6 4 3 7 8 7 
CKAP4 6 6 6 20 13 11 
RPS16 6 5 5 10 10 9 
RPS24 6 6 5 7 5 5 
GDF15 6 5 6 1 2 1 
EIF5B 5 3 5 1 1 1 
SERPINE2 5 5 6 
   
RPS5 5 6 5 12 11 11 
EPRS 5 4 5 
   
CT45A2 5 6 5 11 12 13 
RPS15 5 3 3 5 5 6 
ACTR1A 5 4 6 
   
CCDC61 5 5 3 
   
SLC25A11 5 4 5 17 21 19 
ITIH5 5 6 5 
   
SLC25A1 5 6 6 16 15 15 
KEAP1 4 4 4 
   
SMG8 4 4 4 
   
PRPF38A 4 2 4 1 2 
 
CEP170 4 4 4 
   
PAFAH1B1 4 2 3 
   
PPP2R1A 4 4 4 1 
  
MRPS28 4 2 4 
   
CNP 4 5 5 12 10 15 
GNB1 4 5 3 
   
CD59 4 4 5 
   
SMU1 3 1 1 13 12 11 
TAOK2 3 3 2 
   
AP2B1 3 4 2 2 1 
 
MRPS22 3 3 4 
   
ERAL1 3 3 3 
   
MRPS26 3 4 2 
   
SRPR 3 4 3 3 3 2 
MRPS18B 3 4 3 
   
UQCRH 3 2 2 3 4 4 
HSD17B12 3 2 2 
   
CEP250 3 4 3 
   
GNAI2 3 7 3 
   
NBR1 2 6 3 
   
DYNC1LI2 2 3 3 
   
IGF2BP1 2 2 4 
   
DAP3 2 2 3 
   
MRPS34 2 2 3 
   
SRPK2 2 4 5 
   
DYNC1LI1 2 2 4 
   
MRPS9 2 3 3 
   
HS2ST1 2 2 2 
   
BICD1 2 2 2 
   
FARP1 2 2 3 
   
MTX2 2 3 3 
 
1 
 
GOLGA2 2 2 4 
   
SNAP23 2 3 3 
   
TBC1D31 2 4 4 
   
IK 1 
  
7 6 4 
SRP14 1 2 1 2 2 2 
CETN2 1 2 2 2 2 2 
EIF4B 
   
2 3 2 
NOL8 
   
6 10 8 
NOL9 
   
6 8 4 
CHAMP1 
   
5 3 3 
PWP1 
   
4 4 3 
SMPD4 
   
4 2 4 
AP2A2 
   
3 3 3 
UTP23 
   
3 4 2 
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Gene Name p62_CytoREP_01 p62_CytoREP_02 p62_CytoREP_03 p62_NucREP_01 p62_NucREP_02 p62_NucREP_03 
RFC4 
   
2 2 4 
NFIX 
   
2 2 3 
DHX33 
   
2 3 2 
SCO1 
   
3 2 3 
ZNF384 
   
2 2 2 
ATP5H 
   
2 2 2 
SMARCD1 
   
2 2 2 
CAPZA2 
   
2 2 2 
SLC25A10 
   
2 2 2 
S100A9 
   
4 4 4 
SSR3 
   
2 2 2 
CSTF3 
   
2 2 2 
PTRH2 
   
4 4 2 
FKBP11 
   
2 2 2 
ACSL3 
   
4 3 4 
PNKP 
   
4 4 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X.APPENDIX   
 
 
166 
 
10.2 Publications 
 p62 sustains a protumorigenic gene signature  in melanoma opposing mRNA-dependent  
  decay                           (manuscript in preparation) 
P. Karras, E. Riveiro-Falkenbach, E. Cañón, T. G. Calvo, R. Martinez, E. Pérez-Guijarro, C. Tejedo, M. Cifdaloz, P. Ximenez-
Embun, J. Muñoz, D. Megías,  P. Ortiz-Romero, JL. Rodríguez-Peralto and María S. Soengas. 
 Cross-tumor differences in the landscape of RNA binding proteins identify a protumorigenic 
 regulon controlled by CELF1 in melanoma                             (under revision) 
M. Cifdaloz, L. Osterloh, O. Graña, E. Riverio-Falkenbach, J. Muñoz, T. G. Calvo, P. Karras, D. Olmeda, B. Miñana. G. Gómez-
López, E. Perez-Guijarro, E. Cañon, E. Eyras, P L. Ortiz-Romero, J L. Rodríguez-Peralto, J. Valcárcel, and MS. Soengas  
 Lineage-specific control of melanoma cell proliferation by the cytoplasmic                             
  polydenylation factor CPEB4.                          Nature Communications, 2016 
E. Pérez-Guijarro, P. Karras, M. Cifdaloz, R. Martínez-Herranz, E. Cañón, O. Graña, C. Horcajada, D. Alonso Curbelo, T. G. 
Calvo, G. Gomez, N. Bellora, E. Riveiro-Falkenbach, P. Ortiz-Romero, JL. Rodríguez-Peralto, L. Maestre,    G. Roncador, JC. 
Agustín Asensio, C. Goding, D. Megías, E. Eyras, R. Méndez
 
and María S. Soengas. 
 Metastatic risk and resistance to BRAF inhibitors in melanoma defined by  selective allelic 
 loss of ATG5.                                                      Autophagy, 2016   
M. García-Fernández, P. Karras, A. Checinska, E. Cañón, G. Gómez-López, T. Guadalupe Calvo, G. Gomez-Lopez, M. 
Cifdaloz, A. Colmenar, L. Espinosa, D. Olmeda and M. Soengas. 
 Vascular endothelial cadherin downregulation as a feature of endothelial                    
 transdifferentiation in monocrotaline- induced pulmonary hypertension.   A.J.P.-Lung, 2016       
Nikitopoulou I, Orfanos SE, Kotanidou A, Maltabe V, Manitsopoulos N, Karras P, Kouklis P, Armaganidis A, Maniatis NA. 
 RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of                        
  melanoma development.                                                                          Oncotarget, 2015 
Alonso-Curbelo D, Osterloh L, Cañón E, Calvo TG, Martínez-Herranz R, Karras P, Martínez S, Riveiro-Falkenbach E, Romero 
PO, Rodríguez-Peralto JL, Pastor J, Soengas MS                  
 RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the 
 endolysosomal pathway.                                                                           Cancer Cell, 2014    
D. Alonso-Curbelo, E. Riveiro-Falkenbach, E. Perez-Guijarro, M. Cifdaloz, P. Karras, L. Osterloh, D. Megías, E. Cañón, TG. 
Calvo, D. Olmeda, G. Gómez-Lopez, O. Graña, VJ. Sánchez-Arévalo, DG. Pisano, H-W. Wang, P. Ortiz-Romero, D. Tormo, K. 
Hoeck, JL. Rodríguez-Peralto, JA. Joyce, MS. Soengas. 
 
 
10.3 Presentations 
Oral  
 Hallmarks of Cancer                                                                       
 Title: Fine tuning of pro-metastatic factors by RNA complexes controlled by p62/Sequestosome-1 in 
melanoma                                                                                  Ghent, Belgium, December 2016 
 CNIO Lab day               
      Title: p62/SQSTM-1, more than a scavenger in melanoma progression and metastasis                                                                    
                        Madrid, Spain, December 2015  
 
  X.APPENDIX 
 
 
167 
 
 Posters 
 13th International Congress of the Society for Melanoma Research     Boston, Massachusetts  
 P. Karras, E. Riveiro-Falkenbach, D. Megias, J. Muñoz, P.Ortiz-Romero, JL. Rodríguez-Peralto and Maria S. Soengas.  
Fine tuning of pro-metastatic factors by RNA complexes controlled by p62/Sequestosome-1 in 
melanoma                                      06-09/11/2016 
 12th International Congress of the Society for Melanoma Research    San Francisco, California 
 P. Karras, E. Riveiro-Falkenbach, D. Megias, J. Muñoz, P.Ortiz-Romero, JL. Rodríguez-Peralto and M.S. Soengas.  
Global control of the melanoma transcriptome by the p62/Sequestosome-1 autophagy modulator.                                                                  
                                        8-21/11/2015 
 6
th
 European Melanoma Workshop                           Las Palmas, Canary islands,Spain                    
P. Karras, E. Riveiro Falkenbach, J. Munoz, P. Embun, I. Ruppen, O. Grana; P. Ortiz Romero; JL. Rodríguez-Peralto, M. 
Soengas.  
p62/Sequestosome-1, more than a scavenger protein in melanoma progression.            27-29/06/2014 
 10
th
 International Meeting of the Society for Melanoma Research    Philadelphia, Pennsylvania 
P.Karras, E. Riveiro-Falkenbach, P. Ximénez-Embún, I.l Ruppen, P. Ortiz-Romero, JL. Rodríguez-Peralto
 
and M.S. Soengas.  
p62/Sequestosome-1, more than a scavenger protein in melanoma progression.            17-20/11/2013    
 
10.4 Fellowships/Awards 
 Travel Award, Hallmarks of Cancer                                                 Ghent, Belgium, December 2016 
 Best poster at CNIO Lab day                                                      Madrid, Spain, December 2013 
 Best poster at 10th International Meeting of the Society for Melanoma Research                                                                
                                     Philadelphia, November 2013 
 La Caixa"/CNIO International PhD Programme Scholarship                           Nov. 2011 – Nov. 2015 
 
10.5 Certificates 
 Course of Flow Cytometry                    Spanish National Cancer Research Center (CNIO) ,  2013                                                        
 Course of Laboratory Animal Sciences for Researchers: Categories B and C                 
 Spanish National Cancer Research Center (CNIO) and Animalaria, Formación y Gestion S.L.,  
                                Madrid, Spain, 2013 
 Course on "Functional Analysis of gene Expression Experiments"    
 Spanish National Cancer Research Center (CNIO). Madrid, Spain.                                           2012 
